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Abstract 
 
The pathology and mechanisms underlying allergic conjunctivitis are still poorly 
understood. Even though most studies focusing on the mechanisms of allergic 
diseases, only few have focused on the mechanisms of allergic conjunctivitis. 
Basic and clinical research have been done in order to understand the cells and 
mediators that involved in the immunologic events of ocular allergy. 
Immunologic mediators, including cytokines are important in mediating 
intracellular communication networks during allergy, and they play important 
roles in the contribution of disease pathology.    
 
IL-9 is a well-established growth factor, mediating mast cell and T cell 
production of proinflammatory cytokines. IL-9 has recently been associated in 
the development of allergic diseases including allergic asthma and allergic 
rhinitis, however, its contribution in allergic conjunctivitis is still unknown. IL-9 is 
one of the initially thought Th2 cytokine, but recent studies showed that there 
are many different cell types that also secretes IL-9, including mast cells and 
Th9 cells. (more details) 
 
The data obtained from this thesis is the first to demonstrate the upregulation of 
IL-9 expression by mast cells in the conjunctiva of experimental allergic 
conjunctivitis mice and allergen challenged allergic conjunctivitis donors. 
Further in vitro studies using has revealed that IL-9R blockade resulting in the 
downregulation of mast cell secretion products including histamine and Th2 
cytokines, IL-4, IL-5 and IL-13. 
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In this chapter, I will describe various allergic diseases and their subtypes 
including allergic conjunctivitis (AC), what is currently known about the immune 
cells and immune pathways involved in AC and the relevance and significance 
of current treatment for AC.  
 
1.1. Allergic Diseases 
 
1.1.1. Asthma 
 
Asthma is a chronic inflammatory disease of the airways which involves 
bronchial hyper-reactivity (BHR), mucus overproduction, airway wall 
remodelling and airway narrowing. It is a very common disease that affects up 
to 300 million people worldwide and results in substantial morbidity and is a 
huge burden to healthcare expenditure. 
 
There are two forms of asthma which have been identified in the clinic; allergic 
and non-allergic (intrinsic asthma). Asthma, which coincides mostly with allergic 
sensitization, affects children and about 15% of adults.  Allergic asthma is 
caused by commonly inhaled or ingested allergens such as house dust mite 
(HDM), grass and tree pollen, animal dander and fungal spores. In children, 
asthma initially develops through sensitization, and is often accompanied by 
eczema in the first year of life and, in later years, these children can develop 
allergic rhinitis and allergic asthma. The progression of these symptoms has 
been recognised as the ‘atopic march’. Based on population-based birth cohort 
studies, children with multiple allergies are likely to develop asthma (1,2) and 
approximately half of children with eczema will develop asthma later in life (3).   
Intrinsic asthma often develops later in life and has neither any allergen 
involvement nor any obvious adaptive immune system markers such as Th2 
cells. This form of asthma is normally more difficult to treat and requires long-
term systemic steroids.  
 
Therapy for asthma includes managing symptoms usually by a combination of 
short or long-acting β agonists with inhaled corticosteroids and some patients 
with chronic asthma require systemic corticosteroids. Leukotriene antagonists 
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(such as montelukast) as an add-on therapy have been shown to have a 
positive effect in patients with mild to moderate asthma (4). Omalizumab, a 
monoclonal antibody directed against IgE, has also been used to treat patients 
with severe asthma (5).   
 
Some patients, however, are more difficult to treat and are resistant to 
corticosteroids. With current advances and the availability of genome-wide 
expression studies in asthma, clinicians realised that there are different asthma 
phenotypes, each having a different pathophysiology. The differences in 
asthma phenotypes are now being recognised as asthma endotypes, which 
differ in terms of genetic susceptibility, environmental risk factor, age of asthma 
onset and molecular basis of the disease (6–8).  
 
Besides improving and modifying currently available treatments, through current 
understanding of asthma, newly developed biologic agents targeting specific 
pathways are now in trials. Biologic compounds directed against transcription 
factors and small molecule inhibitors for chemokines and cytokines, include 
blocking chemokine receptors on eosinophils (CCR3), and Th2 cells (CCR4, 
CCR8 and CXCR4), and cytokines IL-4, IL-5, IL-13 and IL-17, are potentially 
promising for asthma treatment (9) of which, anti-IgE and anti-IL-5 have been 
licensed for asthma treatments (10). Specific immunotherapy (SIT) to inhibit 
allergic responses has been shown to be successful in treating individuals with 
allergic rhinitis where the allergens were identified and can be effective in 
reducing symptom scores and medication used in asthma patients (11). SIT 
decreases the development of sensitization to new allergens and decreases the 
risk of asthma developing in rhinitis patients (12,13). 
1.1.2. Allergic Rhinitis 
 
 
Allergic rhinitis (AR) is a common condition, which is an IgE-mediated 
inflammatory response in the nose caused by the interactions of specific 
airborne allergens binding to IgE antibodies on the surface of nasal mast cells. 
It affects nearly 400 million people around the world, a large proportion of which 
are still under-diagnosed and under-treated (2). In the United States, although 
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10-30% of the adult population and 40% of children are affected by AR, the 
health and economic impact of AR are hugely underestimated (14). Only 
recently AR has been recognised as a serious issue of epidemic proportion 
involving enormous medical costs. Typical symptoms of AR include rhinorrhoea, 
sneezing, nasal itching, and nasal congestion.  
 
A significant percentage of rhinitis patients, about one third, suffer from non-
allergic rhinitis, (15). These patients have rhinitis symptoms, but not as a result 
of IgE-mediated events. Compared to non-allergic rhinitis, AR typically presents 
at younger age in which symptoms can be seasonal, episodic or all year round 
(perennial), depending on the type of allergen to which they are sensitized. 
Since seasons do not exist in many areas of the world, this classification does 
not represent a true AR classification. The Allergic Rhinitis and its Impact on 
Asthma (ARIA) guidelines for classifications have led to the definition of AR 
based on the severity of the symptoms ranging from intermittent or persistent 
and mild to moderate or severe (2,16,17). AR is often associated with asthma 
and other allergic diseases which can contribute to asthma exacerbations, 
making asthma more difficult to control and requiring hospitalizations and 
physician visits (18). 
 
Successful treatments involve allergen avoidance and medication with oral and 
intranasal antihistamines, nasal and systemic corticosteroids, intranasal 
cromolyn sodium and more recently anti-leukotriene, which has recently been 
approved in the United States for the treatment of AR. Non-pharmacologic 
measures for AR treatment includes SIT, which has been demonstrated to be 
extremely beneficial to selected AR patients. Immunotherapy could represent a 
cure for AR. Subcutaneous immunotherapy has been shown to be effective in 
AR, with significantly long lasting symptom reduction, reducing the use of other 
medications and preventing new sensitisations and the onset of asthma (19–
22). Sublingual immunotherapy is a safer alternative than subcutaneous 
immunotherapy with side effects  restricted to the upper airways and 
gastrointestinal tract with rare episodes of anaphylaxis (20). 
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1.1.3. Food Allergy 
 
 
Food allergy (FA) is a pathological reaction of the immune system in response 
to the ingestion of a food protein antigen. In food allergic individuals who are 
sensitised to a specific food protein, exposure to even trace amounts of food 
allergens can trigger clinical symptoms such as gastrointestinal disorders, 
urticaria and airway inflammation. These symptoms can range from mild to 
severe which can lead to life-threatening anaphylaxis. FA is common globally 
especially in younger children. It is estimated that about 6-8% of children suffer 
from FA (23–25). Sensitivity to some allergens (cow’s milk, egg, wheat) are 
outgrown, but allergy to peanut, tree nut and seafood normally persists into 
adulthood (26,27). FA is highly prevalent in atopic individuals; approximately 
35% of children with severe persistent eczema also suffer from FA (28).  
 
Food allergies can be classified into three different groups; those which are IgE-
mediated, those which are both IgE-dependent and IgE-independent (mixed), 
and those which are not IgE-mediated (26). IgE-mediated FA is normally 
associated with the risk of severe, and possibly fatal, anaphylactic responses. 
Individuals with IgE-mediated FA are normally sensitized to food allergen (those 
who have had initial exposure to food allergen and caused initial immune 
reaction) and IgE-mediated immune cells triggered by subsequent exposure to 
specific food allergen. Oral allergy syndrome (OAS) is a variant of FA in which 
individuals with rhinitis have specific IgE towards fruits and vegetables as a 
result of cross-reactivity between pollen and plant-derived food (29). OAS 
results in less severe symptoms like oral pruritus, mucosa angioedema and/or 
abdominal pain but these symptoms will not lead to anaphylaxis. Mixed food 
allergy is characterized by both IgE-dependent and IgE-independent pathways. 
IgE-independent pathways cause delayed food-allergy-associated atopic 
dermatitis which happens around 6-48 hours post exposure, due to Th2 cells 
(30,31). Eosinophilic gastrointestinal disorders, such as eosinophilic 
esophagitis, are caused by eosinophil infiltration of the tissues after exposure to 
milk allergen (32) but can also be due to IgE-independent pathways. The 
difference between IgE-mediated FA and mixed FA with non-IgE mediated FA 
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is that the symptoms of non-IgE mediated FA normally affect the 
gastrointestinal tract, rather than the skin and respiratory tract.  
 
Besides food allergen avoidance and treating anaphylactic responses with 
adrenalin as the standard of care, there is currently no definitive treatment for 
FA. Antihistamines are used to treat FA symptoms like itching, pruritus and 
oedema. Currently, immunotherapy against specific food allergen that can be 
delivered sublingually, orally or through the skin has been seen to have some 
potential as the treatment for FA (33–35). A monoclonal antibody against IgE 
has been tested in combination with oral immunotherapy in order to reduce 
allergic responses (36,37). Other examples that use monoclonal antibody to 
target upstream mediators in allergic pathways, such as IL-5, have also been 
used successfully in clinical trials as a treatment for eosinophilic esophagitis 
(38,39). An anti-IL-33 antibody is also currently being evaluated in late phase 2 
clinical trial for treating food allergy (40) 
 
 
 
1.1.4. Atopic Dermatitis 
 
 
Atopic dermatitis (AD), also known as atopic eczema, is the most common 
chronic inflammatory skin disease which affects up to 7% of adults and over 
20% of children (41–43). AD was thought to be the first manifestation of atopy 
and the first step in the atopic march, leading to asthma and allergic rhinitis. The 
disease manifests from the first year of life, but it can start at any age. In 
individuals with AD, the earliest observed clinical signs are rough and dry skin 
and the eczematous lesions only start later on and can continue for long 
periods or become relapsing-remitting in nature with repeated flare-ups (44). A 
birth cohort study suggested that the prognosis of AD depends on the severity, 
the presence of early onset of atopic sensitisation and a family history of AD, 
which are the risk factors for a long disease course (45).  
 
Rather than an IgE-mediated disease, AD has been associated with activation 
of T cell subsets. Several different subtypes have been described and these are 
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based on IgE levels (intrinsic and extrinsic AD) and FLG (fillagrin gene) 
mutation. Extrinsic AD, also known as allergic AD, is associated with high total 
serum IgE levels towards environmental and food allergens and this is the most 
common form of disease with high prevalence (46,47). Intrinsic AD, or non-
allergic AD, normally exhibit normal serum IgE levels and an absence of 
specific IgE. This type of disease normally affects about 10-45% of the 
population, predominantly females (47,48). Fillagrin, an important skin barrier 
protein has shown to be important in individuals with AD. FLG gene mutations 
that lead to FLG deficiency have been associated with a higher risk and a more 
persistent and severe form of the disease (49,50).  
 
At present, only the symptoms of AD can be managed to achieve long-term 
disease control. Continuous repairing of the epidermal barrier with emollients, 
allergen avoidance and application of topical corticosteroids or calcineurin 
inhibitors have been used for managing the symptoms. Short term phototherapy 
treatment can be considered if the disease cannot be controlled by topical 
application of corticosteroids or calcineurin inhibitors (51). Systemic 
immunosuppressive therapies can be considered in cases where both topical 
measures and photo treatment fail. Targeting acute phase inflammation or Th2-
driven immunity has been the aim for developing new therapeutic strategies for 
AD. Dupilumab, an antibody targeting IL-4 receptor alpha chain has shown to 
have marked and rapid improvement in the disease symptoms (52). Other 
newly developed monoclonal antibodies are already in trials and could 
potentially offer new targeted therapy for AD.  
 
1.1.5. Ocular Allergy 
 
Allergic inflammatory symptoms affecting the eye are less well studied as 
compared to other allergic conditions since often, information on allergic 
conjunctivitis (AC) is included within studies on rhinoconjunctivitis. AC is a 
global disorder that affects 19.1% to 20% of the general population worldwide.  
According to the Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, AC 
is also a comorbidity of allergic rhinitis and asthma (53). AC is commonly under-
diagnosed among patients with asthma and rhinitis even though almost 50% of 
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seasonal allergic rhinitis patients have eye symptoms (SAC; hay fever) and 
sometimes it also co-exists with atopic dermatitis and food allergy. Recent 
studies have highlighted the significance of ocular symptoms showing that they 
are as severe or sometimes even more severe than nasal symptoms in 70% of 
hay fever sufferers (54). This thesis will further investigate the immunological 
mechanisms which are involved in ocular allergy. Using in vitro and in vivo 
models of AC, we will study the immunopathogenic mechanisms involving T cell 
and mast cell-derived cytokines, which are commonly associated with the 
immunopathogenesis of allergy.  
1.1.5.1. Classification and Symptoms 
 
Ocular allergies can be classified in different categories, depending on the 
severity of the symptoms.  The mild forms of AC are seasonal (SAC; hayfever) 
and perennial (PAC), while the more severe and chronic forms of AC include 
vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC). VKC 
and AKC have quite different clinical and pathophysiological features as 
compared to SAC and PAC. Giant papillary conjunctivitis (GPC) is another 
category of ocular allergy, most commonly seen in contact lens wearers.  
 
Seasonal allergic conjunctivitis (SAC) (where inflammation occurs seasonally) 
and perennial allergic conjunctivitis (PAC) (where inflammation occurs all year 
round) are immediate (type 1) hypersensitivity reactions believed to be caused 
by allergen-induced IgE-mediated mast cell activation. In the United States, 
SAC and PAC make up about 95% of ocular allergy cases (55). Different 
reports on rates of AC incidence all over the world is due to AC often being 
classified as rhinoconjunctivitis rather than AC (56)  Most cases of SAC and 
PAC have been shown to have specific IgE antibodies to allergen (57). Signs 
and symptoms of both SAC and PAC are the same; they differ on the specific 
allergens to which the patients are allergic. Common AC symptoms include 
watery, itchy, red, sore, swollen and stinging eyes and they can cause a 
significant reduction in the quality of life. SAC is more common than PAC, whilst 
PAC is caused by allergens that are present all year round (animal dander and 
dust mites) resulting in more prolonged symptoms than in SAC.  Hence PAC is 
considered to be clinically mild but chronic in its symptoms. Although SAC and 
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PAC are generally not sight-threatening, discomfort from ocular symptoms can 
reduce productivity levels for example from daily activities including reading, 
computer use, and restricted outside activity. As a result, the loss of productivity 
leads to costs estimated at €350 per patient per annum in Spain (58). 
 
Vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC) are 
clinically more severe forms of AC. VKC is a rare chronic allergic inflammatory 
disease of the ocular surface which occurs in less than 1% of the population 
(59,60).  It is more common in young males, especially those living in hot and 
dry climates (like the Mediterranean and West African countries) and, in more 
than 95% of VKC children, the symptoms resolve upon puberty and only a 
minority go on to develop adult AKC. In the Asia-Pacific region, the age of onset 
is before the age of 10 years (61,62). Based on an epidemiological report in 
Sweden, VKC is more prevalent amongst the immigrant children of African and 
Asian origin, which suggests that VKC has both genetic and environmental 
impacts on the incidence of the disease (63). VKC never occurs in adults but it 
is not a rare disease amongst children aged 15 years and under (64, 65). Two 
thirds of VKC patients are atopic and VKC is often associated with a previous 
history of other allergic diseases (eczema, asthma and rhinitis). The 
inflammation persists throughout the year but there will often be seasonal 
worsening due to re-exposure to allergens.  
 
Symptoms of VKC worsen in the allergy season but symptoms can also be all 
year round. Typical signs include the presence of giant papillae on the upper 
tarsal conjunctiva, production of sticky mucus, Trantas Dots at the limbus 
(clumps of eosinophils with dead epithelial cells), corneal ulceration and 
scarring. Giant papillae can be easily seen by eye on the tarsal conjunctiva 
(65). Trantas dots can be a measure of disease activity as they only appear in 
active VKC (66). Vernal plaque ulcers can occur which are deposited on the 
surface of the corneal stroma where there is no epithelium. Severe itching, 
photophobia, tearing and redness are normally present in VKC patients. 
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AKC is also a chronic inflammatory disease of the conjunctiva and cornea but, 
unlike VKC, it also involves the eyelids with eczematous appearance. It is 
always associated with another severe allergic disease, either eczema (where 
15-40% of eczema patients also have an ocular involvement) or asthma.  It 
usually affects adults between 20 and 50 years of age (67). Eczematous lesions 
of the eyelids are normally red, elevated and very itchy. Conjunctival giant 
papillae might or might not be present and conjunctival scarring is frequent in 
patients with AKC. Unlike VKC, in AKC, patients tend to develop atopic 
cataracts and sometimes, AKC patients require cataract surgery at a young age 
although it is very uncommon (68). 
 
In giant papillary conjunctivitis (GPC), the inflammation is usually related to the 
wearing of contact lenses or ocular prostheses or due to sutures protruding on 
the ocular surface. GPC affects 5-10% of soft contact lens wearers. GPC is 
characterized by papillary hypertrophy of the superior conjunctiva and its 
appearance is similar to VKC, but GPC is stimulated by an inert substance 
rather than allergen. It can occur in patients at any age, in atopic or non-atopic 
individuals. GPC is not associated with atopy and resolves upon cessation of 
contact lens wear or removal of the protruding suture. 
 
1.1.5.2. Pathophysiology  
 
The pathogenesis of AC is predominantly due to allergen interacting with IgE 
bound to sensitised mast cells. During early phase responses, mast cells 
release their mediators (such as histamine, prostaglandins and leukotrienes) 
upon degranulation, as a result of allergen binding to the IgE FcεRI receptor on 
its surface (69). This then causes itching, vasodilatation and increased vascular 
permeability. These symptoms normally occur during the first hour after allergen 
exposure. Mast cell degranulation also leads to the activation of vascular 
endothelial cells, which in turn express chemokines (such as RANTES and 
monocyte chemoattractant protein (MCP)) and adhesion molecules (such as 
intercellular adhesion molecule (ICAM) and vascular cell adhesion molecule 
(VCAM)) (70). These factors initiate the beginning of late phase responses by 
recruiting more inflammatory cells to the conjunctival mucosa (the central role of 
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conjunctival mast cells in the pathogenesis of ocular allergy). Late phase 
responses occur 6-24 hours after allergen exposure and are dependent on an 
initial interaction of mast cells with antigen during the early phase response 
(71). This involves the recruitment of eosinophils and a few T lymphocytes, 
which release pro-inflammatory Th2 type cytokines (IL-4, IL-5, IL-13). 
 
Immune mechanisms of both AKC and VKC are more complex than the milder 
forms of the disease as they are not triggered by common allergens, rather they 
possess more complex immune mechanisms involving T cells (72). There are 
common pathways between VKC and AKC. Both VKC and AKC involve both 
mast cell degranulation and Th2 type cytokines. Whilst VKC involves mainly 
Th2 lymphocytes, immune mechanisms in AKC involve both Th1 and Th2 
lymphocytes and cytokines. This will be discussed below in further detail.  
 
VKC is a combination of type I and delayed (type IV) hypersensitivity (73). VKC 
is a result of a complex pathogenesis that involves mainly CD4+T  lymphocytes 
(Th2) with overexpression of mast cells, eosinophils, neutrophils and fibroblasts 
(74). The formation of giant papillae is the result of IL-4 and IL-13 involvement 
by inducing the production of extra-cellular matrix and the proliferation of 
conjunctival fibroblasts (74,75). High levels of IgE and mast cell mediators are 
found in VKC patients (76). Since it involves the cornea, VKC can be sight 
threatening but usually leaves no permanent alterations in visual acuity except 
in 6% of patients.  
 
The pathophysiologic mechanisms of AKC involve both mast cell degranulation 
and also immune mechanisms, involving both Th1 and Th2 type cytokines (77). 
This is similar to AD, which is not exclusively mediated by Th2 lymphocytes and 
where involvement of both Th1 and Th2 lymphocyte-derived cytokines leads to 
a severe conjunctival reaction. T cell polarization in AD and in AKC is biphasic. 
During the acute phase, there is a predominantly Th2 cell response whilst 
during the chronic phase, Th1 cells are more predominant (78). Briefly in AD, 
during acute phase, FcεRI engagement with antigen presenting cells in the skin 
contributes to the initiation of inflammation by resident Langerhans cells with 
Th2 cytokine predominance. Thereafter, inflammatory dendritic epidermal cells 
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(IDEC) are recruited into the epidermis and produce high amounts of 
proinflammatory cytokines that prime naïve CD4+ T cells into Th1 cells 
producing IFN-γ (79,80). Acute AD skin lesions are characterised by the 
presence of high levels of Th2 cells and eosinophils with increased levels of 
cytokine IL4, IL-5, and IL-13, and little IFN-γ expression. However, as AD 
becomes more chronic, lesions exhibit increased levels of IFN-γ, IL-12, and 
GMCSF, suggesting the presence of Th1 cells to maintain chronic inflammation 
(81). However, the mechanism of chronic AC and the switch between Th2 to 
Th1 predominant pathways in AKC are still yet to be explored. The switch from 
Th2 to Th1 is thought to involve microbial products from bacterial colonisation in 
the skin that activates Toll-like receptor 2 (TLR2) (82). Unlike AD, in AKC, the 
mechanism behind the shift between Th2/Th1 like pattern is still unknown but 
high levels of IL-4 and IL-13 were found in the tears of AKC and VKC patients 
whereas IFN-γ levels were increased in the tears of patients with corneal 
damage, suggesting that in chronic AC, IFN-γ is important in maintaining 
chronic inflammation in AKC (83,84).  
 
Some of the important complications in chronic AC include a wide range of 
corneal clinical manifestations. In the pathogenesis of punctate keratopathy, the 
tear film becomes unstable due to the changes in the mucin layer of the tear 
film and changes to corneal epithelium permeability. The dots of punctate 
keratopathy may combine together to form syncytial opacity, which often leads 
to a whitish or greyish plaque beneath the epithelium. These plaques may 
interfere with vision and lead to scarring of the cornea. Punctate keratitis may 
evolve to confluent ulceration and shield ulcer as a result of epithelial toxicity 
caused by mediators released by activated eosinophils (85). The vernal plaque 
ulcer is a deposition on the surface of the cornea stroma where there is no 
epithelium. Patients with shield ulcers with visible plaque formation had delayed 
re-epithelization which can cause bacterial keratitis as the cornea is not 
protected by epithelium (Cameron JA Ophthalmology 1995). Mechanical eye 
rubbing, although not the primary cause, can contribute to the worsening of 
keratoconous, which usually causes blurry vision.  Trantas dots consist of 
necrotic eosinophils, neutrophils and epithelial cells and represent an almost 
pure collection of eosinophils. The formation of giant papillae is due to 
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overgrowth of conjunctival connective tissue and abundance of collagen fibres. 
Excessive deposition of extracellular matrix and the formation of giant papillae 
are due to imbalance of the expression of matrix metalloproteinases (MMPs) 
and tissue inhibitors of MMP (TIMP) (86). Conjunctival resident cells, including 
epithelium and fibroblasts, play an important role in the formation of giant 
papillae. Th2 cytokines, growth factors including vascular endothelial growth 
factor (VEGF), epidermal growth factor (EGF) and transforming growth factor 
β1 (TGF-β1) were demonstrated to be increased in VKC and which promote 
fibroblast growth and procollagen production and may be involved in tissue 
growth and remodelling (87–89). Fibroblast and keratocytes may also promote 
inflammation by producing chemokines including G-CSF, eotaxin 1 and MCP-1 
or by expressing adhesion molecules like ICAM-1 in response to Th2 cytokines 
which could facilitate eosinophil infiltration (90,91).  
 
1.1.5.3. Diagnosis and treatment 
 
In both SAC and PAC, the diagnosis is usually confirmed by a history of atopic 
conditions (from personal and family), clinical observation and positive skin 
prick test to suspected allergens. The skin prick test is not always reliable in 
assisting with the diagnosis whereas the conjunctival provocation test, in which 
very small amounts of allergen are administered to the tear film, can be more 
useful in leading to AC diagnosis (92). In PAC, the presence of eosinophils in 
the conjunctival swab and/or an increase of total IgE in serum and tears can 
also confirm the diagnosis (93).  
The first line of treatment for both SAC and PAC is allergen avoidance. In most 
mild cases of AC, oral and topical antihistamines (e.g. mast cells stabilisers like 
cromolyn sodium, or olopatadine which is an H1 receptor blocker and mast cell 
stabiliser)  (94) can be helpful in reducing symptoms. Antihistamines, which 
reversibly block histamine binding to its receptor, provide quick relief from 
redness and itch but do not prevent action from other proinflammatory 
mediators secreted by activated mast cells such as prostaglandin and 
leukotrienes (95). Mast cell stabilisers are also frequently used to treat SAC and 
PAC. Cromolyn sodium inhibits mast cell degranulation (96), and is generally 
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safe with minimal side effects. Currently, antihistamines combined with mast 
cell stabilisers are the most commonly prescribed group of agents as these 
provide better symptom relief and are well tolerated with milder side effects 
(94). Specific immunotherapy can also provide systemic relief in SAC and PAC 
but this does not work in clinically severe disease (VKC and AKC).  
 
In severe chronic AC diagnosis can be done using similar criteria described 
above for clinically less severe AC (SAC and PAC), which include measuring 
eosinophil and IgE levels in tear samples, although these tests are not usually 
required in clinical practice as the diagnosis is usually made clinically based on 
typical symptoms and signs. High levels of IgE and mast cell mediators are 
present in the tear fluids of VKC patients (76,97).  
 
To date, one of the main options to treat severe AC (VKC and AKC) is the 
administration of topical (eye drops) or systemic (oral) corticosteroids, in 
addition to anti-histamine and mast cell stabilising treatments previously 
discussed. Corticosteroids exert rapid anti-inflammatory effects via their 
interactions with glucocorticoid receptors, which modulate protein synthesis of 
cytokines through the blocking of nuclear factor-κB (NFκB). Topical or subtarsal 
steroids may be required to reduce or inhibit the production of inflammatory 
mediators. Systemic steroids which are more potent, are very rarely required for 
more severe cases, and can cause significant side effects in the eye, when 
given long term, including an increase in intraocular pressure (IOP), cataracts, 
glaucoma and susceptibility to infections.  
 
Calcineurin inhibitors such as cyclosporine A (CsA) or tacrolimus can be used 
as a valid alternative to steroids to treat severe VKC and AKC due to their ability 
to block CD4+ T-lymphocyte proliferation, IL-2 production and histamine release 
by mast cells through the inhibition of calcineurin (a phosphate that plays an 
important role in FcεRI -mediated exocytosis of pre-formed mediators from mast 
cells). CsA inhibits histamine release from mast cells and basophils through an 
IL-5 reduction, which may also affect eosinophil recruitment and cause tissue 
destruction on the ocular surface (98). Frequent side effects of topically applied 
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CsA include burning and irritation of the eye. Randomised, double-blind, 
placebo-controlled trials concluded that the use of topical CsA is safe and 
effective in improving symptoms in both VKC and AKC (99,100). More than half 
of patients who were using topical steroids at the beginning of a trial were able 
to be tapered off steroid drops after treatment with topical CsA (101)(101). 
Systemic cyclosporin or tacrolimus may also be required for recalcitrant atopic 
dermatitis associated with AKC. Topical tacrolimus is more potent than 
cyclosporin (77) and is very useful for eyelid eczema (102). In resistant AD 
cases, systemic treatment with mycophenolate (103), methotrexate or 
dupilumab (an anti-IL-4 immunotherapy)  (104) may also be required.   
 
As a consequence of the limited availability of therapeutic options and the 
significant side effects from current treatments, additional strategies for the 
treatment of chronic AC are needed for improvement of clinical outcomes and 
better management for patients.  
 
1.2. Basic Immunology of Allergic Responses 
 
1.2.1. Allergic sensitisation 
 
Dendritic cells (DC), acting as professional antigen presenting cells (APC), will 
first encounter and take up antigen, then migrate back to the local lymph nodes 
in order to induce T cell tolerance or sensitization. Antigen taken up by DC 
undergoes proteolytic cleavage into smaller fragments before being presented 
on the surface of DC via major histocompatibility complex (MHC) class II 
molecules. In order to induce tolerance under normal circumstances, CD103+ 
DC are thought to induce Foxp3+ regulatory T cells (Treg)  which then suppress 
the generation of Th2 cytokines and IgE production (105,106).  
 
In order to elicit allergic responses, an atopic individual must first be exposed to 
a specific allergen, which then leads to sensitization. During allergic 
sensitization, presentation of allergen by DC to naïve T cells induces their 
differentiation into Th2 T cells in the presence of IL-4, which then undergo 
clonal expansion. IL-4 and IL-13 secreted by Th2 cells induce immunoglobulin 
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(Ig) class switching from IgG to IgE and clonal expansion of naïve B-cell 
populations after allergen-specific binding on B cell receptor, which allows IgE 
production by B cells. IgE sensitises both mast cells and basophils by firstly 
upregulating IgE receptors (IgER) on the surface and then IgE will bind to the 
high affinity receptors (FcεRI) on the surface of the mast cells/basophils. 
Besides FcεRI, IgE also binds to the low-affinity receptor, FcεRII (also known as 
CD23) on the surface of B cells. Subsequent presentation of allergen-derived 
peptides to specific CD4+T cells, mast cells and basophils, will drive both the 
early and late phases of allergic responses.   
 
1.2.2. Allergic responses 
 
 
During an allergic response, allergens from the environment penetrate through 
the epithelium into the subepithelial and stromal layer of tissues. This foreign 
allergen will bind to the surface of DC for antigen presentation. DC express high 
affinity FcεRI receptors (trimeric isoform) for binding allergen which is then 
shuttled into lysosomal compartments for loading and presentation on MHC 
class II molecules (107). Besides DC, other myeloid cells can function as APC, 
including macrophages, monocytes and granulocytes. Native allergen protein is 
first degraded by the APC and is then loaded onto MHC molecules for antigen 
presentation to T cells. In allergic individuals (atopics), allergen uptake by DC is 
facilitated by interaction of the allergen with IgE attached to FcεRI.  
 
Immune responses are divided into two components, the innate (non-specific) 
and adaptive (specific) immune responses. During the first exposure to 
microorganisms or allergen that managed to penetrate the epithelial surface, 
cells such as macrophages, DC, neutrophils and mast cells are the first line of 
innate immune cells that will respond. Their responses are rapid and non-
specific. Both macrophages, DC and neutrophils express Toll-like receptors 
(TLRs) that recognise bacterial cell wall (TLR1, 2, 4, 5 and 6) and nucleic acids 
(TLR3, 7, 8 and 9),) enabling recognition and removal of bacteria by engulfing 
and destroying the invading micro-organisms.  
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The innate immune response is crucial in contributing to the activation of the 
adaptive immune response. Innate immune responses can occur alone or can 
be followed by with the slower adaptive immune responses. After the first 
encounter during the innate immune response, antigen-bearing cells will move 
to the lymphoid tissue, whilst some mediators released by immune cells during 
the innate response recruit more immune cells to the site of inflammation, 
hence amplifying the immune response. At the lymphoid tissues, specialized 
long-lived phagocytic cells like the DC interact with antigen-specific 
lymphocytes, which then migrate to the site of inflammation and activate the 
adaptive immune response. Activated DC and mast cells are said to be 
important in linking the innate and adaptive responses since these cells secrete 
cytokines that influence both innate and adaptive immune responses.  
 
1.3. Immune cells in allergic responses 
 
1.3.1. Mast cells 
 
Mast cells (MCs) were first described by Paul Ehrlich in 1878 as cells that 
stained uniquely with large granules. Mast cells are potent effector cells of the 
innate immune system that are haematopoietic in origin. Mast cell precursors 
migrate to tissues where they mature and differentiate depending on the local 
cytokine milieu to become tissue resident cells in the host environment. The 
maturation of mast cells is dependent on the presence of stem cell factor (SCF) 
and its c-kit receptor (108). Besides maturation of mast cells, SCF also 
promotes mast cell adhesion and survival (109).  
 
In the eye, mast cells are mostly found in the conjunctival region. MCs can be 
distinguished by their protease contents and their location in the tissue. In mice, 
MCs can be distinguished based on their anatomical sites; connective tissue 
mast cells (CTMC; located around venules, intestinal submucosa and skin) 
contain both tryptase and chymase while mucosal mast cells (MMC; located in 
the epithelial cell layer of mucosal tissues in lung and intestines) contain only 
tryptase. In humans, mast cell subtypes depend on their protease content; 
MCTC mast cells contain both tryptase and chymase, (resemble murine CTMC) 
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and MCT mast cells only contain tryptase (resemble murine MMC) in their 
granules (110).  
 
It is clear that mast cells exist as subtypes, and migrate depending on their 
environment and this change can occur in both directions. By performing 
immunohistochemistry staining of normal and allergic human conjunctivae, 
Baddely et al. reported that tissue-resident mast cells in the healthy conjunctiva 
contain both MCTC and MCT phenotypes (111). During AC, the distribution of 
mast cell protease expression was altered and an increase in MCT was 
observed in the allergic conjunctivae (111). A similar study was performed by 
staining human conjunctival tissue sections of normal and allergic conjunctivae, 
where it was observed that the proportion of MCT was increased in the 
substantia propria of VKC individuals as compared to normal control individuals 
(76).  
 
Mast cells can be activated in response to many different stimuli including 
activation through toll like receptors (TLRs) in response to pathogens (112,113), 
activation through aryl hydrocarbon receptor (114), the CD40 ligand (115), the 
OX40 ligand (116) or by immune complexes of IgG (117). However, during 
allergic inflammation, mast cells are activated through allergen cross-linking 
with surface IgE receptors (FcεRI), which are present on the surface of the 
allergen-sensitised MC.  Another study has demonstrated that, during allergic 
responses, mast cells can also be activated upon IgG binding to surface FcγRI 
and FcγRIII receptors (118). Mast cells can respond differently depending on 
the strength of the FcεRI signals. (119). Either low or high affinity stimuli, 
different receptor cluster size, mobility and distribution, can all activate 
signalling molecules which are required to release different secretory products. 
For example, adaptor protein LAT-2 is enhanced in high affinity signals resulting 
in MCP-1 production.  
 
In allergic inflammation, mast cells are important during the sensitisation 
process, and to mediate both early and late phase allergic reactions. Once 
activated, mast cells secrete preformed mediators from their granules within 
minutes. One of the secreted mediators, histamine, then binds to its receptors 
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(H1R and H2R), causing the immediate symptoms seen in SAC and PAC such 
as redness of the eye, itching, lacrimation and chemosis. Besides SAC and 
PAC, histamine and tryptase levels are also increased in tears of VKC and AKC 
patients (120,121). Mast cell granules also contain some preformed cytokines, 
chemokines and growth factors including TNF-α, IL-6, IL-8, IL-10, vascular 
endothelial growth factor (VEGF) and SCF. Beside histamine and cytokines, 
mast cells also secrete proteases including tryptase and chymase and other de 
novo bioactive compounds such as lipid mediators (leukotriene C4, 
prostaglandin D2 and platelet activating factor). Tryptase is highly expressed in 
mast cells, but not in basophils. 
 
After 6-12 hours of activation, mast cells also synthesise a wide range of 
cytokines, which are important in the late phase or for initiating a more chronic 
response. Among the cytokines, IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-13, IL-16, 
TNF-α and granulocyte-macrophage colony stimulating factor (GM-CSF) can be 
secreted by human mast cells (122). Depending on the inflammatory signals, 
mast cells are able to replenish their granules upon stimulation. These 
cytokines are responsible for cellular infiltration and eventually lead to tissue 
damage, which can be seen during chronic allergic responses.  
 
After stimulation, mast cells function as the promoters and effectors of adaptive 
immunity. They also shape the inflammatory milieu, which is crucial for adaptive 
immunity. Secreted mast cell products are responsible for recruiting 
inflammatory cells. 
 
1.3.2. T cells 
 
During development, T cell precursors leave the bone marrow and migrate to 
the thymus via the blood stream where they differentiate and begin to express T 
cell receptors (TCR), CD4 and CD8 molecules and develop into naïve T cells. 
Committed T cells subsequently seed the secondary lymphoid organs where 
they encounter antigens and differentiate into distinct T cell subsets. T cells are 
differentiated based on their expression of CD4 and CD8. However, double-
positive CD4+/CD8+ cells have been described in the blood and peripheral 
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lymphoid tissues where this T cell subset is regulated by a very strict 
transcriptional program (123). Cytotoxic CD8+T cells are mainly involved in 
killing cancer cells, virus-infected cells and dying cells by expressing death 
signals and secreting lytic enzymes (granzymes). CD4+T cells, originally termed 
T helper (Th) cells, are responsible during the later stage of inflammation where 
they mainly secrete cytokines and chemokines, the key players in 
upregulating/modulating immune responses.  
 
CD4+T cells are the major contributors in the immunopathology of autoimmune 
diseases and allergic inflammation (124–128), hence, in this section I will 
describe the role of CD4+ T cells in more detail.  During cell-mediated immunity 
of adaptive immune responses, CD4+T-cells are polarised to distinct T cell 
subsets according to the cytokines present in the microenvironment. Naïve 
CD4+ T-cells can differentiate into Th1, Th2, Th9, Th17, Th22, T regulatory cells 
(Treg), and T follicular helper cells (Tfh)(Figure 1).  
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Figure 1: Different T cell subsets. Naïve CD4+ T cells polarise to different T-cell 
subsets; Th1, Th2, Th9, Th17, Th22, iTreg. Tfh, secreting different cytokine 
profiles. These T-cell subsets promote different types of inflammatory 
responses depending on their respective cytokine profiles and specific 
transcription factors. Adapted from (128). 
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1.3.2.1. Th1 cells 
 
Th1 cells, which are mostly defined by their secretion of IFN-γ, are normally 
involved in cell-mediated inflammatory responses and delayed-type 
hypersensitivity and are important in immunity against intracellular pathogens. 
Th1 cells are also defined by the master regulator transcription factor, Tbet, 
which is important in promoting Th1 differentiation. T-bet and GATA3 are co-
expressed in Th1 cells and Kanhere and colleagues found that in Th1 cells, 
GATA 3 is distributed away from Th2 genes and binds to T-bet binding sites 
and T-bet can directly activate its own expression (129). The Th1 signature 
cytokine IFN-γ has long been known to be involved in the immunopathology of 
several autoimmune diseases including multiple sclerosis (MS) and rheumatoid 
arthritis (130). High levels of IFN-γ in MS serum, plus extensive studies using 
adoptive transfer of CD4+T cell subsets in experimental mouse models 
suggested that Th1 cells are immunopathogenic (131,132). IFN-γ can also be 
anti-inflammatory as it is antagonistic for IL-4, by dampening the differentiation 
of other pathogenic T cell subsets and downregulating lymphocyte trafficking 
into the draining lymph nodes (133). Although IFN-γ is considered to be the 
protective response in allergic disorders, many studies have shown that allergic 
inflammation is often due to mixed responses involving both Th1 and Th2 cells 
(134,135).  
 
1.3.2.2. Th2 cells  
 
Th2 cells secrete IL-4, IL-5, IL-9 and IL-13, which are the key cytokines in host 
defence against multi-cellular parasites and in the development and 
immunopathogenesis of allergic diseases. IFN-γ, secreted by Th1 cells, acts as 
a negative regulator for Th2 differentiation, hence both Th1 and Th2 T cell 
subsets can be clearly defined based on their cytokine profiles and transcription 
factors. IL-4, a pleiotropic cytokine which is secreted by activated Th2 cells, T 
follicular helper cells, mast cells, innate lymphoid cells and basophils, is 
important as the survival factor for lymphocytes besides promoting B cell 
differentiation and IgG and IgE class switching (136–140). GATA-3 is the 
master regulator of Th2 differentiation although it was found that GATA-3 is also 
important in the differentiation of innate lymphoid cells (141). The GATA-3 
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transcription factor binds to multiple proximal and distal sites to Il4, Il5 and Il13 
in order to activate the Th2 cytokine locus (129,142–144). IL-4 activates 
downstream signalling transducer and activator of transcription (STAT)-6 which, 
in turn, promotes the expression of GATA binding protein 2 (GATA-2) to further 
activate Th2 cytokine secretion. Besides IL-4, Th2 cells also secrete large 
amounts of IL-5 and IL-13. IL-5 is known to stimulate antibody secretion from 
activated B cells and enhances proliferation and differentiation of eosinophils. 
IL-13 is known to inhibit the proliferation of other proinflammatory cytokines 
secreted from monocytes, B cell co-stimulator for B cell maturation, and 
promotes mucus production (145). Both IL-5 and IL-13 are regarded as 
important in driving the pathology of allergic asthma.   
 
1.3.2.3. Th9 cells 
 
Th9 cells develop from naïve CD4+ T cells in the presence of TGF-β and IL-4 
(146–148). In the presence of IL-4, TGF-β reprograms Th2 cells to differentiate 
into Th9 cells, which produce high levels of IL-9 and IL-10 (148). The Th9 cell 
subset, characterized by its production of IL-9, was recently described as a 
distinct T cell subset, whereas IL-9 was initially identified as a Th2 cytokine. 
Similar to other T cell lineages, Th9 cells are regulated by specific transcription 
factors: STAT6, GATA-3, IRF4 and PU.1. However these transcription factors 
are not specific for Th9 cells as their expression overlaps with other T cell 
lineages, including Th2 and Th17 cells (146–150). Different cytokines and 
transcription factors that regulate and promote Th9 cell development as a 
separate T cell lineage will be discussed later in this chapter. Although IL-9 was 
first described as a growth factor for T cells and mast cells, it is increasingly 
being described now as playing important roles in the pathogenicity of various 
allergic and autoimmune diseases including SLE (127,151–153). Other 
functions of Th9 cells will be discussed later in this chapter.   
 
1.3.2.4. Th17 cells  
 
Besides Th1, Th2 and Th9 cells, Th17 cells are another CD4+T cell subset 
which plays an important role in inflammation. This CD4+T-cell subset is 
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characterised by its secretion of IL-6, IL-8, IL-9, IL-17A, IL-17E, IL-22 and IL-26 
under the control of the master transcription factor RORγt. Th17 cells are known 
to be involved in autoimmune tissue injury and host defence against 
extracellular bacteria and pathogens in the mucosa. Naïve CD4+T cells 
differentiate into Th17 cells in the presence of combinations of IL-23, TGF-β, IL-
6 and IL-21. Much of the pathogenic roles for Th17 cells have been attributed to 
their secretion of IL-17, which is classically known to enhance neutrophil 
differentiation of CD34+ hematopoietic progenitors in a coculture system with 
fibroblasts, to activate innate immune cells and to enhance B cell functions 
(154).  
 
1.3.2.5. Th22 cells 
 
The Th22 cell subset, secreting predominantly IL-22, is considered to be a 
sibling of Th17 cells but having distinct gene expression and functions. IL-22, a 
member of the IL-10 cytokine family, is produced by immune cells including 
CD8+ and CD4+T cell subsets (Th17 and Th22), natural killer (NK) cells and 
gamma/delta (γδ) T cells. The functional effects of IL-22 are confined to non-
hematopoietic cells especially to epithelial cells of the skin, liver, lung and 
intestine (155–157). Increased populations of CD8+ T cells expressing IL-22 
have been observed in the skin of patients with the more severe form of atopic 
dermatitis (158). In patients with rheumatoid arthritis, IL-22 has been shown to 
be important for promoting the differentiation of synovial fibroblasts (159).  
 
1.3.2.6. Other T cell subsets  
 
Other T cell subsets include follicular helper T-cells (Tfh), which secrete IL-21, 
provide helper function to B cells to synthesize antibodies and differentiate into 
plasma and memory B cells in the germinal centre. Similar to other T cell 
lineages, Tfh are associated with a canonical transcription factor. High 
expression levels of Bcl-6 were identified in Tfh (160,161) and are necessary for 
Tfh survivability and development (162,163). Tfh help B cells to regulate 
antibody secretion that precisely target specific pathogens for elimination, at the 
same time limiting autoimmunity and excessive inflammation.  
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Another T cell subset, regulatory T cells (Treg), downregulates CD4+T cell 
proliferation, and suppresses potentially deleterious activities of Th cells by 
maintaining peripheral tolerance. Tregs are the important basic regulators that 
are designed to maintain immune tolerance. Unlike other Th cell subsets which 
respond and proliferate upon T cell receptor (TCR) engagement, Treg cells 
respond by suppressing proliferation of other T cell subsets in response to TCR 
stimulation (164). Treg cells are important to dampen the overwhelming 
responses by other Th subsets and are considered to be the master modulator 
in promoting anti-inflammatory responses. Treg cells have a distinct phenotype 
expressing the transcription factor Foxp3. Two major populations of Tregs have 
been identified; thymically-derived naturally-occurring Tregs (nTregs) and 
peripherally-induced Tregs (iTregs).  
 
nTregs are characterized by CD4+CD25+ surface receptor expression, strongly 
express the Foxp3 transcription factor  and secrete both IL-10 and TGF-β. 
Foxp3 expression is maintained irrespective of extracellular conditions or Foxp3 
signals (165) The main task of nTreg is to dampen inflammatory responses 
mediated by various lymphocytes, especially helper T cell subsets (166–168) . 
There are four different suppression mechanisms used by Treg cells; 
suppression by inhibitory cytokines IL-10, IL-35 and TGF-β, suppression by 
cytolysis, including granzyme A- and B-dependent and perforin-dependent 
killing mechanisms, suppression by metabolic disruption and suppression by 
targeting DC function and maturation (169).  
 
iTregs, on the other hand, have different suppressive properties than nTregs, 
which are cell contact-independent and are mediated mainly by cytokines IL-10 
and TGF-β. iTregs also bear similar phenotypes with nTregs such as the 
expression of CD25, CTLA-4 and Foxp3 (165,170). However, Foxp3 expression 
in iTregs is unstable. In a study done by Floess and colleagues, they 
demonstrated that TGF-β-induced Foxp3 expression is lost after removal of 
TGF-β or TCR stimulation in vitro suggesting that the stability of Foxp3 
expression depends on extracellular conditions (165). These cells developed 
from CD4+ T cells and consist of two different types: Tr1 and Th3 cells, which 
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have different capabilities in secreting cytokines. Tr1 are defined by their ability 
to be induced by IL-10 and secrete large amounts of IL-10 and lower amounts 
of TGF-β, whereas Th3 cells secrete mostly TGF-β. Tr1 cells’ 
immunosuppressive activity is mostly mediated by IL-10 (171). The Tr1 cell 
plays an important role in regulating immune responses against commensal 
organisms and promotes tolerance in the gut (172). Th3, on the other hand, 
plays an important role in tolerance induced by oral antigen delivery (173). 
 
1.3.3. Basophils 
 
Basophils are a rare population of granulocytes, which represents less than 1% 
of peripheral blood leukocytes. After the discovery of mast cells, Paul Ehrlich in 
1879 described basophils as a population of leukocytes which contains 
cytoplasmic granules that stain with basophilic dyes.  
 
Basophils are developmentally similar and share characteristics with tissue 
resident mast cells.  Like mast cells, basophils express the high affinity 
receptors for IgE, FcεRI, on their surface (174) that cross-link upon engagement 
with allergen, resulting in release of a number of mediators including histamine, 
but not prostaglandin 2 (PGD2) or mast cell tryptase (175). Basophils also 
rapidly secrete IL-4, IL-13 and express CD40L and CCR3 (176–178). Basophils 
can be distinguished phenotypically from mast cells by a lack of, or only weak 
expression of cell surface expression of c-kit (SCF receptor). Exogenous IL-3 is 
a prerequisite requirement for basophil development and maturation whereas 
mast cells require both IL-3 and SCF as the main factors for growth and 
development (179,180). Unlike mast cells, which become fully mature in 
peripheral tissues, basophils are believed to complete their maturation in the 
bone marrow before being released into the circulation.  
 
Basophils are known to be key regulators of allergic inflammation and Th2 cell-
mediated disease due to their ability to secrete high levels of IL-4 and IL-13 
(181). After allergen challenge, basophils together with eosinophils and Th2 
lymphocytes were recruited to the site of inflammation including to the skin, lung 
and nose after allergen challenge (182).   
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1.3.4. Eosinophils 
 
Eosinophils are bone marrow-derived leukocytes and can be found in both 
peripheral blood and/or in tissues. They represent 1% to 5% of the whole 
leukocyte population. Eosinophils can easily be identified because of their 
strong affinity to the acidic dye eosin which led to their discovery by Paul Ehrlich 
in 1879. In the bone marrow, IL-3, GM-CSF and IL-5 drive eosinophil 
differentiation. IL-5 is crucial in the final maturation stage in the bone marrow as 
well as eosinophil release into the circulation (183). 
   
Eosinophils are an important source of cytotoxic proteins that can mediate 
pathology of a disease and can modulate immune responses and allergic 
diseases. Granules in mature human eosinophils contain cationic proteins 
which include major basic proteins (MBPs), eosinophil cationic protein, 
eosinophil derived neurotoxin and eosinophil peroxidase (184). Besides 
cationic proteins, eosinophil granules also contains preformed cytokines, 
chemokines, enzymes and lipid mediators such as IL-2, -3, -4, -5, -10, -12 
and -13, IFN-γ, GM-CSF, RANTES, eotaxin-1 and CXCL5 which are capable 
of activating T cells, mast cells, and epithelial cells (185–187). For example, 
eosinophils express Th2 cytokines (IL-4, IL-5, IL-9 and IL-13), Th1 cytokines 
(IL-12 and IFN-γ), proinflammatory cytokines (TNFα, IL-1β, IL-6 and IL-8) and 
regulatory cytokines (TGFβ and IL-10) (188,189). Besides secreting 
mediators, eosinophils also can act as an antigen presenting cells since they 
express MHC class II and costimulatory molecules that directly modify T cell 
activities (190). To my knowledge they do not, however, have the capacity to 
take up antigen for processing, so are considered “non-classical APC’. 
 
Eosinophil-rich inflammation has long been associated with parasitic 
inflammation and allergy. Comparing allergic asthma pathophysiology at the 
cellular level, increased numbers of infiltrating eosinophils at the airway mucosa 
are normally associated with severe asthma (191,192). Hence, higher levels of 
eosinophils in peripheral blood or within specific tissues can be an indicator of a 
pathologic process.  
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1.3.5. Neutrophils 
 
One subpopulation of polymorphonuclear cells (PMNs), neutrophils, are 
important effector cells in immune defence and in IgG-mediated humoral 
immune responses due to their expression of surface receptors including Fc, IL-
2R, IgE-binding proteins and Mac-2/epsilon binding protein (BP) that binds to 
inflammatory mediators including IgE, IL-4 and IL-13 (193–195). Besides 
functioning as phagocytic cells, PMNs also secrete inflammatory mediators 
including TNF-α, TGF-β and IL-1β in response to cell activation.  They have 
also been demonstrated to secrete IL-17 (196,197). 
 
Despite being commonly associated with increased inflammation, the role of 
neutrophils in allergy in general and in the pathogenesis of bronchial asthma 
remains unclear (198,199). However, an increased number of neutrophils has 
been found in the bronchoalveolar lavage of severe asthma, especially after 
allergen challenge (191,200). 
 
1.3.6. Innate lymphoid cells 
 
In addition to mast cells, eosinophils, neutrophils and T cells which are known to 
be involved in the pathogenesis of allergic inflammation, innate cells have also 
been described which are lineage-negative, not expressing surface markers of 
lineage-positive cells, but secrete large amounts of cytokines (201–203). It was 
found that innate lymphoid cells (ILCs) consist of three different subsets, 
namely ILC1, ILC2 and ILC3. ILC2 is a subtype that is of interest with regards to 
allergy since this cell secretes large amounts of classical ‘Th2 cytokines’ 
including, IL-4, IL-5, IL-9 and IL-13. It is thought that ILC2 secrete cytokines 
during the early stage of allergic responses, preceding T cell-mediated 
inflammation. Whilst most studies on ILC2 were performed in mice 
(137,201,204), other groups have also reported an upregulation of ILCs in the 
lungs of patients with chronic obstructive pulmonary disease (COPD) and in the 
gastrointestinal tract of patients with eosinophilic oesophagitis as compared to 
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control subjects (205,206). However, their exact contribution to inflammation in 
relation to T cells and other immune cells is still being investigated.  
 
This brief description of different immune cell types has led us to a greater 
understanding of the role for secreted cytokines in modulating different cell 
types during inflammation, a very important aspect in the regulation of immune 
responses. In this thesis, the role of cytokines, especially IL-9, in the 
development and pathogenesis of allergic conjunctivitis will be investigated and 
discussed in further detail.  
1.4. The cytokine response in allergy  
 
 
Since classical Th2 cytokines (IL-4, IL-5, IL-9, IL-13) are mostly involved in the 
development and pathology of allergic diseases, further roles for these 
cytokines will be discussed in more detail in this section.  
 
These cytokines are derived from mast cells, basophils, eosinophils, B cells and 
T cells during acute and chronic allergic inflammation. During acute allergic 
conjunctival (AC) responses, mast cells release pro-inflammatory pre-formed 
mediators such as IL-4, IL-13 plus other cytokines, chemokines, tryptase, 
chymase, prostaglandins and leukotrienes, all leading to symptoms seen in 
SAC. The release of these mediators also promotes the recruitment of other 
pro-inflammatory cells, which drive the inflammation to become more chronic. In 
PAC, there is an increase in neutrophils and T cells. VKC is marked by an 
increase in eosinophil and T cell infiltration, releasing IL-5 (for upregulating 
eosinophils migration and activation), IL-4 (for driving B-cell activation and IgE 
release) and IL-13 (for promoting mucus secretion and tissue remodelling). This 
inflammatory cascade results in persistent and more pronounced symptoms as 
seen in chronic ocular allergy (83). However, different cytokine profiles can be 
seen in AKC such as an increase in T cell-derived IFN-γ in conjunctival tissues 
(207) and in CD4+T cells derived from AKC tear samples, which suggests that 
AKC may also be driven, in part, by Th1 cells (208). 
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In general, Th2 cytokines have been extensively studied in allergic diseases. 
Besides being secreted by different immune cells including CD4+T helper cells, 
eosinophils, basophils and ILC2 cells, IL-4 is known to be the first cytokine to be 
secreted by mast cells upon stimulation via IgE receptor (209). An earlier study 
conducted by Bradding and colleagues used mast cells purified from the skin 
and lung and demonstrated that human mast cells contain and release IL-4 
upon IgE stimulation (210). A few years later, a study done by Wilson and 
colleagues confirmed that IL-4 was stored within mast cell granules and could 
be one of the earliest cytokines released by mast cells upon activation (209) 
The distribution of IL-4 receptor (IL-4R) expression is extremely broad, 
suggesting that IL-4 has pleiotropic effects that can potentially affect many 
different cell types (211). In the presence of IL-13, IL-4 controls IgE class 
switching in B cells (212) and IL-4 is known to control Th2 phenotype 
differentiation in the presence of IL-2 (213). With its various roles being 
documented, especially the involvement of IL-4 in allergic diseases, IL-4 has 
also been shown to be upregulated in allergic conjunctivitis patients’ tear 
samples. It is also postulated that IL-4 is involved in stimulating conjunctival 
fibroblasts in chronic ocular allergy (214).  
 
Despite sharing a common receptor subunit and sharing many functional 
properties with IL-4, IL-13 has been shown to have distinct functions, especially 
in the development of airway hyperresponsiveness and mucus production 
(215). In hematopoietic cells like monocytes and macrophages, IL-13 enhances 
the expression of integrins, which are important in cell adhesion (216) and 
inhibits the secretion of pro-inflammatory mediators including IL-12 and TNF-α 
(217). IL-13 is mostly functionally important on non-hematopoietic cells like 
endothelial cells, smooth muscle cells, fibroblasts, and epithelial cells. IL-13 
induces vascular adhesion molecule 1 on endothelial cells, which is important 
for eosinophil recruitment (218), upregulates goblet cell metaplasia and 
decreases beat frequency of ciliated epithelial cells (219,220). This summarises 
the importance of IL-13 in the contribution to the pathogenesis of allergic 
asthma.  
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Besides IL-4 and IL-13, IL-5 is another classical Th2 cytokine, which is also 
secreted by mast cells. IL-5 acts on target cells by binding to specific IL-5 
receptors (IL-5R), which contains IL-5Rα (IL-5 specific) and the common signal 
transducing β cytokine (βc) chain (221). Besides eosinophils, IL-5R is also 
expressed on human basophils and B cells (222–224). Since IL-5 is important 
in eosinophil differentiation, migration, activation and survival, IL-5 has been 
recognised as the most specific cytokine for the development of the eosinophil 
lineage (225,226). Besides eosinophils, IL-5 also promotes B cell growth and 
induces terminal differentiation of activated B cells into antibody-forming plasma 
cells (227,228). Horikawa and colleagues showed that IL-5 exerts its effects on 
B cell maturation by regulating several gene clusters including immunoglobulin-
related genes and genes involved in B cell maturation including B lymphocyte-
induced maturation protein 1 (Blimp-1) (229). However, the effects of IL-5 on B 
cells were only observed in mice whereas IL-5 exerted an effect on both mouse 
and human eosinophils. Human B cells also express IL-5Rα and respond to IL-
5 for B cell maturation.  
 
1.4.1 The role of Th2 cytokines: IL-9 
 
The role of IL-9 in ocular allergy, however, is less clear although IL-4, IL-5 and 
IL-13 are all upregulated in tears and tissues of patients with chronic allergic 
conjunctivitis (214). This study will be investigating the contribution of IL-9 in 
ocular allergy in more detail.  
 
Il9 has been shown as a candidate gene for asthma (230). In mice,  the Il9 gene 
is located on chromosome 13, whereas in humans, the Il9 gene is located in a 
syntenic region on chromosome 5 (231). When comparing human and mouse 
gene which encodes for Il4, Il5 and Il13, the region for the interleukin gene 
cluster in human is on chromosome 5q31-q33, and this is syntenic to the mouse 
interleukin gene family, which is located on the long arm of chromosome 11, 13 
and 18 (232). Since in humans, the Il9 gene is located within close proximity of 
the other Th2 cytokine genes (Il4, Il5 and Il13) on human chromosome 5q31 
(233), the role for IL-9 in AC responses will likely be influenced by these other 
Th2 cytokines. Most of the studies on IL-9 have looked at its contribution in 
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asthma but to date no one has studied the contribution of IL-9 in ocular allergy, 
which could also potentially have important roles in AC. Since IL-9 is the 
cytokine of interest in my thesis, more details on IL-9 will be provided below.  
 
1.4.1.1 Sources of IL-9 
 
IL-9, a 28-30 kDa monomeric glycosylated polypeptide, is a pleiotropic cytokine 
which was identified and described more than two decades ago (234). 
Historically, IL-9 was considered to be part of the Th2 cytokine family, but more 
recently our understanding of IL-9 has changed. IL-9 is expressed and secreted 
by many other cell types (235), including natural killer cells (NK cells) (236,237), 
mast cells (238), Th17 (239,240) and Treg cells (241,242), as illustrated in 
Figure 2. Th9 cells predominantly secrete IL-9 and not other T helper cell 
lineage-specific cytokines (147,148). Recently, Wilhem et al. showed that ILC 
can also produce IL-9 in the presence of IL-2 and IL-33 (243). 
 
1.4.1.1.1 Th2 cells 
 
A protein of 144 amino acids, IL-9 was initially described as a Th2 cytokine 
based on the production of IL-9 from T cells isolated from Leishmania major-
infected, Th2-prone Balb/c mice (244). They have also shown that the 
expansion of Th2 cell populations was correlated with IL-9, hence supporting 
the idea of IL-9 as a Th2 cytokine. However, a new CD4+ T cell subset that 
secretes mainly IL-9 was subsequently described as Th9. It is unclear whether 
the correlation of IL-9 secretion with levels of Th2 cells is due to its direct 
production by Th2 cells or whether IL-9 secretion results indirectly from the IL-4 
derived from Th2 cells that supports the development of Th9 cells. To date, 
Chang et al. managed to report low but detectable levels of IL-4 and IL-9 co-
expression during in vitro differentiation of Th2 cells (245). Another study from 
Temann and colleagues reported that Th2 cytokine transcripts of IL-5, IL-13 and 
IL-9 could be detected in the lung tissues of IL-9 transgenic mice, suggesting 
that IL-9 is also a Th2 cytokine (246). However, the evidence linking IL-9 and 
Th2 cells is still not clear and it is known that IL-9 is not a Th2-specific cytokine. 
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As compared to other Th2 cytokines, IL-9 mRNA expression is delayed (246). 
This is true in CD4+Tcells from PBMC of healthy donors which showed delayed 
induction of IL-9 mRNA in which its expression only peaked at 24 hours post 
activation (247). IL-9 expression by T cells may depend on IL-4 and IL-10 which 
are secreted at earlier time points than IL-9 following cell activation (248). Since 
there is a possibility that IL-9 expression might be a consequence of other 
cytokines produced earlier, it is also worth investigating the effects of other Th2 
cytokines on IL-9 expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Sources of IL-9. Different immune cells which produce IL-9 
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1.4.1.1.2. Th9 cells 
 
Th9 cells were initially characterised as the specific CD4+T cell subset that 
secretes IL-9 (148). Th9 T cells are distinct from other T helper subsets 
because they secrete IL-9, but not signature cytokines of other Th1 (IFN-γ), Th2 
(IL-4, IL-5 and IL-13) and Th17 (IL-17) subsets. Th9 cell differentiation is 
induced and regulated downstream of the T cells receptors (TCR) via different 
co-stimulatory and cytokine receptor signalling pathways.  
 
The development of Th9 cells is regulated by the transcription factors PU.1, 
Interferon-Regulatory Factor 4 (IRF-4) and B cell, activating transcription factor-
like, (BAT-F) (147,245,249). Besides Th9 cells, IRF4 also regulates Th2 and 
Th17 cytokine production (149,250). In Th9 cells, IRF4 directly binds to the il9 
promoter and increases il9 transcription, suggesting that IRF4 has an important 
role in directly inducing the transcription of il9 gene and blocking the expression 
of Th1 associated transcription factors (147,249). PU.1, which is induced by 
TGF-β together with antigen receptor stimulation, is crucial for Th9 
differentiation and its capacity to produce IL-9 by binding to the il9 promoter 
(245,251) even though a very recent study from Koh and colleagues have 
demonstrated that another ETS family transcription factor, Etv5, also shows 
similar function promoting the development of Th9 cells (252). BAT-F is 
required for the development of Th17, Th2 cells and more recently, Th9 cells 
(249,253). BAT-F deficiency resulted in the reduction of nearly all of the Th9 
cell-associated genes suggesting that transcription factor BAT-F is required for 
the expression of IL-9 and other Th9 associated genes and it also cooperates 
with IRF4 in activating Il9 locus (249). 
 
In separate in vitro murine studies, both Veldhoen et al. and Dardalhon et al. 
showed that Th9 cell differentiation is dependent upon exposure to TGF-β and 
IL-4 (146,148). This is also true in human T cells where CD4+ memory T cells 
can become IL-9-producing cells in the presence of IL-4 and TGF-β (254).  IL-4, 
which is the major signalling component of the IL-4 receptor (IL-4R), activates 
STAT6 (146,148) and IRF4, whereas TGF-β activates SMAD which activates 
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PU.1 and suppresses T-bet (T-box expressed in T cells) and GATA3 (GATA-
binding protein 3) (255). A combination of these two events eventually drives IL-
9 secretion from the Th9 cells.  Low levels of GATA3 are expressed in Th9 
cells, although GATA3 expression is higher in Th2 cells (251), and GATA3 is 
still required for IL-9 production (146).  
 
The addition of IL-25 and IL-33 to CD4+T cells in the presence of IL-4 and TGF-
β can enhance the production of IL-9 by Th9 cells by activating nuclear factor 
kappa B (NF-κB) which, in turn, induces STAT-1/IRF-1 expression (256). 
Interestingly, a study of murine CD4+T cells suggested that IL-9-producing T 
cells can also be generated in culture in the presence of IL-1β and TGF-β, 
replacing the need for IL-4 (257).   
 
IL-2 is also needed for Th9 development since IL-2 activates STAT5 
phosphorylation in T cells. Deletion of STAT5 in cultured Th9 cells resulted in a 
dramatic decrease in IL-9 production (258,259). Thymic stromal lymphopoietin 
(TSLP) may work together with IL-2 to promote Th9 cell differentiation (260). 
Recently, TL1A was shown to promote Th9 cell differentiation in combination 
with Th9-polarizing cytokines (IL-4 and TGF-β; (153). TL1A is a member of the 
TNF family of cytokines that binds to death receptor signal 3 (DR3); DR3 is a 
member of the TNF receptor family (TNFR), mostly expressed on lymphocytes. 
Binding of TL1A to DR3 enhances IL-2 production and STAT5 activation, which 
is required for IL-9 secretion. TL1A enhances IL-9 production independently of 
PU.1 and STAT6. TL1A co-stimulates T-cells to produce a wide variety of other 
cytokines (261) and can also affect T cell polarisation. In contrast, STAT3 
functions as a negative regulator of IL-9 production. Activation of STAT5 is 
attenuated when STAT3 is activated, hence decreasing IL-9 production (262). 
Another promoter that was also found to be required for Th9 differentiation is 
Itk. Itk is a member of the Tec family of cystolic tyrosine kinases, which is also 
found to be an important component for TCR-mediated signalling and was 
demonstrated to be important in promoting STAT5/Irf4 binding for Th9 
differentiation (263) (Figure 3). 
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Besides IL-9, activated Th9 cells also produce low levels of IFN-γ, IL-17 and IL-
22 (264). However, Th9 cells also secrete high levels of IL-10, comparable to 
the levels of IL-9 (148,264). Although both IL-9 and IL-10 secretion increased 
markedly following stimulation, their kinetics of cytokine production is different. 
IL-9 secretion seems to peak on day 3 of stimulation and decline thereafter, but 
IL-10 secretion increases gradually until day 10 (264). 
 
The pathogenicity of Th9 cells depends on the levels of IL-9 (264). Th9 cells 
that express highest levels of IL-9 induced inflammation whereas Th9 cells 
which express low levels of IL-9 did not induce inflammation. Depending on the 
type of inflammation, Th9 cells could be more or less pathogenic than Th1 or 
Th17 cells (264,265).  
 
Unlike Th1 cells, Th17 and Treg lineage cells exhibit high levels of plasticity 
when exposed to polarising cytokines of specific lineage (266,267). Th9 cells on 
the other hands exhibit various degrees of plasticity, and are able to switch 
towards different phenotypes depending on the cytokine environments. 
Following Th9 cell exposure to various culture conditions used to polarise cells 
towards Th1, Th2 or Th17 lineages, Th9 cells showed moderate switching 
towards Th1 and Th17 cells but massive switching towards a Th2 population in 
which IL-4 intracellular expression levels increased significantly (264). TGF-β is 
responsible for ‘reprogramming’ a Th2 pathway towards a Th9 phenotype (148). 
Stimulation of the Th2 population in the presence of TGF-β causes a significant 
loss in the expression level of Th2 transcription factor (GATA3) and an increase 
in IL-9 levels in vitro. These studies show the close relationship between Th2 
and Th9 cells although Th9 cells are distinct from Th2 cells. It has been 
proposed that there is plasticity between the two populations, depending on the 
environment (268). 
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Figure 3: Signal transduction pathways that promotes Th9 differentiation. The 
polarisation of IL-9 secreting cells requires IL-2/STAT5, IL-4/STAT6 and TGF-β 
derived signalling. A number of other signalling pathways including Activin A, 
TSLP, IL-1β, IL-33 and IL-25 derived signalling have also been identified that 
promote il9 transcription. Adapted from (269). 
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1.4.1.1.3 Th17 cells 
 
Besides Th2 and Th9 cells, there have been reports that Th17 cells, which are 
identified either by their production of IL-17 or expression of the Th17-
associated transcription factor retinoic acid receptor related orphan receptor γt 
(RORγt), can also produce IL-9. Based on an in vivo study using experimental 
autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis, 
Nowak et al. reported that IL-9 blockade in this model downregulated Th17 
responses (240). They also found that cells cultured either with TGF-β and IL-6 
(to differentiate into Th17) or with TGF-β and IL-4 (to differentiate into Th9 cells) 
secreted similar amounts of IL-9. Besides being produced by Th17 cells, IL-9 
also synergizes with TGF-β, replacing IL-6 to differentiate naïve CD4 cells into 
Th17 cells (239). Co-production of IL-17A and IL-9 by CD4+ T cells can be 
further enhanced by IL-1β or IL-21 (270).  Although all of the studies mentioned 
above were performed in mice, this has also been demonstrated in human cells 
where human Th9 cells are a distinct T cell subset which lacked coproduction of 
Th1, Th2 and Th17 signature cytokines (271,272) 
 
1.4.1.1.4 T regulatory cells 
 
IL-9 is important in the differentiation and survival of Treg cells (239) but these 
cells themselves can also produce IL-9. FoxP3-expressing populations of 
mouse nTreg cells and iTreg cells in vivo secrete high amounts of IL-9 (242). 
Co-expression of FoxP3 and IL-9 was also found in isolated Treg cells in vitro 
(240,273). The level of Treg cells in both wild type and IL-9-/- mice were 
identical but Treg cells from IL-9-/- mice were less suppressive as compared to 
wild type mice (239).  
 
1.4.1.1.5 Eosinophils 
 
Besides mediating differentiation, maturation and the survival of eosinophils, IL-
9 was also shown to be synthesized and secreted by eosinophils (274,275). 
Immunostaining of the nasal mucosal tissues from patients with allergic rhinitis 
showed that eosinophils contributed as the second main source of IL-9 after 
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mast cells in these tissues although T cells were found to be another source of 
IL-9 in the allergic nasal mucosa (276). Louahed et al. studied the role of IL-9 
on eosinophils using IL-9 transgenic mice (277), highlighting that IL-5 and IL-9 
had synergistic effects in sustaining eosinophilia.  
  
1.4.1.1.6. Mast cells 
 
Mast cells are mainly studied as the target of IL-9 due to their expression of IL-9 
receptors. However, mast cells have also been reported to produce IL-9. 
Following IgE crosslinking of the FcεR1 on mast cells, degranulation leads to an 
immediate release of preformed mediators. During this degranulation process, 
mast cells also secrete IL-9. However it was also found that the secreted 
products histamine and IL-1β can further upregulate IL-9 production by mast 
cells (278,279). IL-9 secretion by mast cells can promote the survival and 
expansion of mast cells during immune responses.  
 
1.4.1.1.7. Innate lymphoid cells (ILCs) 
 
Lineage negative cells (Lin-) that display lymphoid tissue inducer (LTi) cell-like 
properties such as IL-7 receptor expression, but lack of CD4 and RORγt 
expression and have different cytokine expression profiles are called the innate 
lymphoid cells (ILCs). ILC2 cells are an ILC subset which is characterised by 
the secretion of high levels of IL-5, IL-6 and IL-13 (203,280). By using IL-9 fate 
reporter mice with a papain-induced lung inflammation model, Wilhelm et al. 
have shown that these ILC2 cells also secrete high levels of IL-9, more than 
from IL-9-producing T cells (281). The IRF4-driven IL-9 production by activated 
ILC2, induced by IL-33 and TSLP at the lung epithelium, is responsible for 
autocrine IL-9 secretion (282).  
 
1.4.1.1.8. NK T cells 
 
Natural killer T (NKT) cells, a distinct type of T cells, are characterised by the 
expression of CD-1b, a major histocompatibility complex (MHC) class 1 like 
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protein expressed by antigen presenting cells as the surface marker (283). NK 
T cells express both T cell receptors (TCR) and NK receptors. Once activated, 
invariant NKT (iNKT) cells rapidly secrete large amounts of both Th1 and Th2 
cytokines including IL-4, IFN-γ, GMCSF, and IL-10 (284). NKT cells are found to 
be important in secreting IL-13 which regulates immune responses in asthma 
and oxazolone-induced colitis (285,286). NKT cells also secrete IL-9 (236,287). 
In the presence of IL-4 and TGF-β, iNKT  (type 1 NKT cells) cells demonstrated 
enhanced IL-9 production upon TCR stimulation (288).  Thus IL-9-producing 
iNKT cells were found to be protective against DSS-induced colitis by 
suppressing IFN-γ and IL-17A production, whilst this secreted IL-9 exacerbated 
allergic inflammation in the airways upon intranasal immunisation with house 
dust mite (289). 
 
1.4.1.2. Functions of IL-9 
 
1.4.1.2.1. IL-9R 
 
The functions of IL-9 are mediated by the specific IL-9 receptor (IL-9R), which 
belongs to the hematopoietin superfamily (290). The IL-9R comprises a ligand-
specific alpha chain (IL-9Rα) and a common gamma chain that is shared with 
IL-2, IL-4, IL-7 and IL-15 receptors (291). IL-9Rα can be produced in two forms: 
soluble and membrane-bound forms. IL-9R activation results in signal 
transduction via STAT1, STAT3 and STAT5 activation (292). Besides STAT 
activation, it was found that IL-9-mediated responses are also dependent on the 
Janus kinase-transducer pathway (293). Activation of STAT is required for IL-9-
induced proliferation and inhibition of T cell apoptosis (292,294). IL-9R 
signalling also activates MAP kinase and insulin receptor substrate-P13 kinase 
pathway (293,295). Expression of IL-9R in distinct membrane areas could 
potentially have a crucial role in the regulation of its function. According to 
Nizsalóczki et al. (296), the IL-9Rα chain is co-localised within the molecular 
proximity of IL-2Rα (common gamma c chain), MHC I and MHC II in human T 
lymphoma cell lines.  
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The IL-9R is found on the surface of many different cell types, both in 
hematopoietic and non-hematopoietic cells. Briefly, IL-9R activation on T cells 
and mast cells promoted their survival and proliferation (297,298) and 
enhanced the mRNA expression of several other cytokines in activated mouse 
mast cells: IL-1β, IL-5, IL-6, IL-13 and TGF-β (299). Of these, IL-5 and IL-13 
had direct effects on promoting eosinophil and mucus production in the lung. IL-
9 also upregulated IgE production by B cells (300), inducing chemokine 
expression in epithelial cells (301) and exerting anti-apoptotic effects on 
neurons (302).  Since IL-9 induced chemokine expression in epithelial cells, it is 
also possible that it can exert a similar effect on conjunctival epithelial cells.  
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Figure 4: The IL-9 receptor. IL-9 receptor subunits and its activation pathways. 
Adapted from (303) 
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1.4.1.2.2. IL-9 specific functions on cells and tissues.  
 
As suggested by the distribution of IL-9R expression, IL-9 is a pleiotropic 
cytokine that exerts diverse biological effects on many different cell types. 
Besides being described as a mast cell and T cell growth factor, IL-9 may affect 
different immune cells and also tissue resident cells to promote the 
development of inflammation (243,279,303). IL-9 can function as both a positive 
and a negative regulator of immune responses. In response to helminth 
infections, IL-9 was demonstrated to function as an immune regulator, 
dampening the inflammation caused by helminth parasites whereas, during 
allergic inflammation, IL-9 was found to contribute to the development of allergic 
diseases including allergic asthma (304,305). During parasitic infection, IL-9 
promoted pathogen clearance from the gastrointestinal tract (306). 
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Figure 5: IL-9 functions. Roles of IL-9 secreted by different cell types  
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1.4.1.2.2.1. CD4+T cells 
 
The function of IL-9 on T cells is to promote T cell growth but this is limited only 
to CD4+T cells, not CD8+T cells, and IL-9 is unable to support long term T cell 
growth (234,307). The ability to support the growth of cultured CD4+T cells was 
reported to be independent of IL-2 and IL-4 (234). In an in vivo study, one group 
has shown that IL-9 promoted Th2 cytokine production but the direct or indirect 
effects of IL-9 on Th2 cells are still unclear (246,308). IL-9 also acts in an 
autocrine manner to further activate Th9 cells. The expression of IL-9Rα is 
important for the anti-apoptotic signals (309).  
 
IL-9 has also been shown to influence Th17 and Treg cell development and 
function. IL-9 suppressed the immunomodulatory function of Treg cells but 
facilitated the expansion of Th17 cells in vitro and in vivo, highlighting its role in 
immunopathogenic and protective immune responses (239). IL-9 is a cytokine 
that affects the differentiation of Th17 and Treg cells. It is known that TGF-β 
alone induced Foxp3+ Treg cells but, in the presence of IL-6 or IL-21, induced 
Th17 cells. IL-9, in the presence of TGF-β, differentiated CD4+T cells into Th17 
cells. Besides being known to produce IL-17, Th17 cells also secrete IL-9. IL-9R 
deficiency was shown to attenuate disease severity of the mouse model 
(experimental autoimmune encephalomyelitis) which correlated with the 
downregulation of Th17 cells in the central nervous system (240).  IL-9, 
secreted from Treg, can also promote the maintenance of a tolerant 
environment during skin transplantation (310). IL-9 also modulated virus-
initiated inflammation in respiratory syncytial virus infection (311). 
 
1.4.1.2.2.2. Mast cells 
 
Cross-linking of allergen-specific IgE bound to FcεRI on the surface of mast 
cells leads to immediate activation, degranulation and release of 
proinflammatory mediators including IL-9. Besides being known to secrete IL-9, 
mast cells also express IL-9R on their surface and IL-9 was found to affect mast 
cell functions by supporting the growth of BMMC in vitro (234), inducing IL-6 
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secretion by BMMC, hence, increasing the survival and proliferation of these 
cells (312). Moreover, IL-9 in the presence of IL-1β and SCF, enhanced BMMC 
secretion of other Th2 cytokines and their long term survival, respectively 
(238,279,298). 
 
Based on these studies on IL-9 functions on mast cells, in allergy IL-9 was 
found to promote mast cell expansion and IL-13 production which, in turn, 
promoted mucus secretion in the lung (313).  Increased numbers of mast cells 
were observed in the airway epithelium of IL-9 transgenic mice in which the 
expression of murine IL-9 cDNA was under the control of the rat Clara protein 
CC10 promoter, which was selective for lung tissue, suggesting that 
accumulation, recruitment, enhanced survival and proliferation, differentiation 
and the pathogenicity of mast cells were due to IL-9 (314).  
 
1.4.1.2.2.3. B cells 
 
IL-9 promotes the development and function of B cells but did not affect the 
survival of these cells (315). A study reported an increase in peritoneal CD11b+ 
B cells in in vivo IL-9 transgenic mice (303). Increased accumulation of B cells 
has been detected in these IL-9 transgenic mice (314). IL-4-mediated IgE and 
IgG production by human B cells was enhanced by B cells (300). Increased IgE 
levels produced by B cells were observed in human tonsillar B cells as a 
synergistic effect of IL-9 in IL-4-induced IgE production (316). IL-9Rα and CD27 
expression were also found to be greater on germinal centre B cells than on 
other B cells.   
 
 
 
1.4.1.2.2.4. Eosinophils 
 
Increased airway eosinophilia is the predominant feature of allergic asthma.  An 
increased level of eosinophilia was observed in IL-9 transgenic mice as well as 
wild type mice which had been administered with recombinant IL-9 intra-
tracheally (314,317). High levels of IL-9Rα mRNA and protein were observed in 
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peripheral blood eosinophils and in eosinophils from broncho-alveolar lavage of 
asthmatic patients (274,275). They have also found that IL-9 may potentiate 
eosinophil function by increasing their survival, differentiation and maturation 
via upregulation of IL-5Rα cell surface expression. 
 
IL-9 is also thought to potentiate eosinophilia through inhibition of apoptosis and 
to promote eosinophil differentiation and maturation via IL-5-driven eosinophil 
maturation (277). Together with IL-5, IL-9 appears to have regulatory a role in 
the development of eosinophilia. IL-9 demonstrated a synergistic effect in 
combination with IL-5, resulting in a significant increase in eosinophil number 
and maturation both in vitro and in vivo in peritoneal lavage cells in mice. 
 
1.4.1.2.2.5. Neutrophils 
 
A study using PMNs from asthmatic patients showed high levels of both IL-9Rα 
mRNA and protein as compared with normal subjects (318). Based on 
immunohistochemistry on purified PMNs, they also found that IL-9Rα was 
expressed in the cytoplasm of PMNs from asthmatic donors whilst this was not 
detected in PMNs from normal controls. A functional study of PMNs from the 
same asthmatic donors suggested that IL-9 had a direct biological effect on IL-
9R expression by upregulating IL-8 release from human PMNs, demonstrated 
by adding exogenous IL-9 or a neutralising anti-IL-9 antibody to human 
peripheral blood PMNs. 
 
1.4.1.2.2.6. Antigen Presenting cells  
 
There were also indications that antigen-presenting cells (APC) were one of the 
targets for IL-9. IL-9 promoted TGF-β production in lipopolysaccharide-induced 
activation of mixed monocytes and macrophages (319,320) and limited IL-12 
production by APC, suggesting that IL-9 can suppress the capability of APC to 
promote a Th1 type immune responses which may contribute to the 
development of tuberculosis (321). 
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1.4.1.2.2.7. Innate lymphoid cell 2 (ILC2) 
 
Recently, the ILC2 was found to secrete significant amounts of Th2 cytokines 
including IL-5, IL-13 and also IL-9. Wilhelm and colleague have reported that IL-
9 secretion by ILC2 cells is transient and IL-9 has a positive feedback effect on 
upregulating IL-5 and IL-13 secretion from ILC2 (281). Furthermore, IL-9 
supported the production of IL-5 and IL-13 from ILC2 cells through IL-2 
signalling, which is required for IL-9 expression in ILC2 (281). IL-9 secreted by 
ILC2 cells could potentially be important in the development of allergic lung 
disease via the production of IL-5 and IL-13.  
 
A few years after this finding, using the same reporter mice and IL-9R 
knockouts (il9r-/-), the production of IL-5 and IL-13 from ILC2 was found to be 
dependent on IL-9R signalling, which was crucial for the survival of ILC2s, but 
not Th2 cells (322).  It was also found that besides being the main source of IL-
9, in contrast to Th2 cells, ILC2 also expressed high levels of IL-9R (322). The 
survival of activated ILC2 was dependent on IL-9R signalling. IL-9R signalling 
upregulated the anti-apoptotic protein BCL-3. IL-9 functions in an autocrine 
manner to amplify ILC2 function by promoting tissue repair after heminth-
induced lung inflammation. IL-9-induced ILC2 activation also promoted rapid IL-
5 and IL-13 production by ILC2, which is required for optimal epithelial 
responses in the airways (282).  
1.4.1.2.2.8. Airway epithelial cells 
 
 The airway epithelium produces a variety of cytokines and chemokines to 
promote activation and proliferation of inflammatory cells during immune 
responses. The IL-9Rα component of the IL-9R was found to be expressed 
within human airway epithelium of the bronchus (323,324). The effects of IL-9 
on the airway epithelial cell functions have been investigated by studies in vitro 
and in vivo. Dong and colleagues found that IL-9 increased the level of 
expression of eotaxin (CCL11), macrophage inflammatory protein 1α (MIP-1 α; 
CCL3) and monocyte chemotactic proteins 1, 3, and 5 (MCP-1, -3, -5; CCL2, 
CCL7, CCL12, respectively) (301). Even in the absence of IL-4 (an inducer of 
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chemokine expression on epithelial cells), IL-9 upregulated eotaxin expression 
on cultured primary epithelial cells.  
 
Increased mucin secretion is one of the characteristic features of allergic 
asthma. In a transgenic mouse model, expression of IL-9 in the lung resulted in 
changes in the gene expression of airway epithelial cells, including goblet cell 
metaplasia (314). Many effects of IL-9 on lung epithelial cells have been found 
to be due to the indirect effects of IL-13 on the epithelium. Steenwinckel et al. 
managed to show that mucus production in the lung was only upregulated when 
both il9r and il13 genes were expressed simultaneously (313). This suggests 
that IL-9 promotes mucin secretion through the induction of IL-13 production. 
After stimulation with IL-9, the expression level of mucin genes muc2 and 
muc5ac were increased (324).  
 
 
1.5. IL-9 and allergic diseases 
 
 
IL-9 has been associated with allergic disease. However, to date, there are no 
studies investigating the role of IL-9 in ocular allergy. Most studies have 
investigated the role of IL-9 in the development of allergic airway disease 
(314,325). Initially, IL-9 protein expression was shown to be strongly associated 
with asthma-like phenotypes. In murine studies, it was found that IL-9 
contributed to the disease by promoting mast cell expansion and mucus 
production, leading to airway hyperresponsiveness (313,326). In mice, Th9 cells 
also independently induced bronchial hyperresponsiveness (BHR) mediated by 
eosinophils (327). IL-9 was also reported to promote mast cell expansion, 
growth and activation in chronic asthma (328). Kearley et al. also found that 
reduction in mast cell number upon IL-9 inhibition correlated with the reduction 
in Th2 cytokines (IL-5 and IL-13) and pro-fibrotic mediators associated with 
airway remodelling in the lung. On the other hand, McMillan et al. showed that 
IL-9 is not crucial for the development of allergic eosinophilia and airway 
hyperreactivity in a murine model (329,330). 
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One genetic study concluded that the IL-9 receptor region that is specific to IL-9 
is more often homozygous in asthma patients and may have a role in the 
pathogenesis of asthma (331). Due to differences in the outcome of studies 
which investigate associations of human IL-9 gene with high total IgE levels and 
asthma (332,333), Kauppi and colleagues investigated the association of IL-9R 
gene instead of IL-9 gene with regard to asthma and IgE level. IL-9R was 
identified to be at the pseudoautosomal region of the Xq and Yq chromosomes, 
which are expressed by both X and Y chromosomes, and are found to have 
positive linkage with asthma (331). 
 
The functional role of Th9 cells in asthma pathogenesis was recently reported. 
Jones et al. showed that circulating Th9 cells are detectable in human atopic 
peripheral blood but their numbers were increased in allergic patients compared 
to non-allergic donors (334) and that Th9 cells play an important role in asthma 
development both in humans and in mice. They have demonstrated that by 
transferring Th9 cells to naïve mice before inducing allergic inflammation, 
heightened allergic inflammation in vivo was observed and this was thought to 
be due to infiltration and activation of mast cells into the airways and lung. 
Activin A, a member of the TGF-β superfamily, replicated the function of TGF-β 
in driving the in vitro generation of Th9 cells in the presence of IL-4 (334). 
Furthermore, a humanised anti-IL-9 mAb (MEDI-528), which may be of clinical 
benefit in asthmatic patients, has been developed and its safety profile and 
efficacy are currently under investigation (335). These investigations clearly 
suggest that the functional roles of IL-9 in asthma pathogenesis may be 
clinically relevant.  
 
Besides asthma, IL-9 also plays a significant role in allergic rhinitis, food allergy 
and eczema. During the pollen season, IL-9 levels in the nasal mucosa of 
allergic rhinitis patients were upregulated and these levels correlated with the 
increased number of infiltrating eosinophils (276). Following grass pollen 
immunotherapy, both IL-9 and nasal mast cell expression were reduced, 
suggesting that the IL-9 pathway can represent a therapeutic target.  
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Studies in a murine model of experimental intestinal anaphylaxis demonstrated 
that systemic anaphylaxis was attenuated in IL-9 knockout mice (306,336). This 
is also supported by evidence from studies in patients with peanut allergy, 
where IL-9 responses can potentially be a promising biomarker to differentiate 
peanut-sensitive from peanut-tolerant individuals (337). Interestingly, another 
study also reported that, based on the IL9 gene profile in peanut allergic 
children, they were able to differentiate peanut allergic children from peanut 
sensitised children based on expression profiles of IL5 and IL13. This finding 
suggests that there might be a potential role in characterising children who 
react to peanut allergens with peanut-sensitised and non-atopic children 
(Brough et al., 2014).  Another subset of CD4+ T cells, which are IL-9+ IL-10+, 
has been described (146), and provides the link between the immediate allergic 
response with the late phase reaction in the intestine (339).  
 
A recent finding in atopic dermatitis patients revealed that IL-9 expression was 
significantly increased in lesional skin areas but not in serum (340). They also 
found that IL-9 interacted with mast cells to release VEGF and this contributed 
to the initiation of the pathogenesis of atopic dermatitis via angiogenesis. 
 
Although IL-9 has been implicated in the pathogenesis of allergic diseases, the 
contribution of this cytokine to the inflammatory processes occurring during the 
various clinical subtypes of ocular allergy has not yet been explored. This study 
will examine the contribution of this cytokine in the development and 
pathogenesis of allergic conjunctivitis. 
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1.4. In vivo models of Allergic Conjunctivitis 
 
Animal models are important for investigating the potential inflammatory 
mechanisms involved during AC, for identifying molecular targets and for testing 
novel compounds for therapeutic interventions. There are a few models 
available to study experimental ocular allergy. The guinea pig model of AC was 
the first to be established as an AC model to test the effect of drugs. Both rat 
and murine models were subsequently developed but mice are the preferred 
species to study AC due to the availability of gene-knockout models (341).  
 
In order to elicit AC responses in mice, allergen is administered topically 
following systemic sensitisation (342). Common allergens such as pollens 
(birch, ragweed or house dust mite) and cat dander have been used. 
Sometimes, ovalbumin (OVA) can also elicit AC responses in mice. Following 
sensitisation, this normally resulted in the early phase response (EPR), which is 
thought to be mediated through an allergen-specific interaction with IgE 
receptors on mast cells which cause degranulation and the release of a variety 
of mediators including chemokines and platelet activating factor (PAF). These 
EPR-associated mediators can sustain the allergic reaction until the late phase 
response (LPR) develops.  EPR responses are normally recorded within the 
first 30 minutes after conjunctival challenge, evaluating the scores of itch, 
chemosis, conjunctival redness, lid oedema and tearing. 
 
To induce a more severe form of AC, mice were challenged with a multi-hit 
topical allergen challenge following systemic sensitisation.  Repeated challenge 
with allergen mimics the physiology of more severe forms of AC. Persistent 
exposure towards allergen causes a more severe reaction in late phase 
response (LPR) after 6-12 hours of allergen exposure. LPRs in this model are 
more pronounced with infiltrating eosinophils and increased expression of Th2 
cytokines, namely IL-4, IL-5 and IL-13 as a result of the release of mediators by 
mast cells degranulating during the EPR. It has been found that IFN-γ also 
contributes to the development of murine AC during both EPR and LPR (343). 
Studies in a mouse model of AC suggested that allergen-specific IgE antibody 
is not required to develop LPR once AC is initiated and that LPR can be 
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induced by adoptively transferring T cells from allergen-sensitised donors to 
naïve mice prior to short ragweed pollen (SRW) topical challenge (344,345) 
 
A study using daily allergen challenge mouse models have provided important 
evidence that IFN-γ is crucial for optimum induction of conjunctivitis (343). This 
corresponds well with the increased expression of IFN-γ in AKC and VKC 
patient conjunctival tissues (207) and significant levels of IFN-γ detected in tear 
specimens from SAC, VKC and AKC donors (83). Fukushima and co-authors 
highlighted the importance of co-stimulatory molecules which influence Th2 
responses in LPR and also the presence of Th2 cytokines and IL-17 in EAC 
(346). All of these in vivo murine AC models have been used as important tools 
to further study and understand the mechanism of AC. 
 
Although much effort has been made to understand the molecular mechanisms 
involved in AC, these models have only been useful to investigate the cellular 
involvement in the clinically milder forms of AC. There are very few T cells 
found in the conjunctival tissues in these models, making it impossible to study 
the contribution of T cell-derived cytokines in clinically more severe forms of 
chronic allergic eye disease. Therefore, the relevance of these models to 
clinically more severe forms of AC in man is less obvious.  
 
Schlereth et al. developed a clinically more severe model of murine AC by 
injecting OVA-loaded dendritic cells into the subconjunctival (SCJ) space and 
then immediately challenging the mice topically with OVA via eyedrops (347). 
They repeatedly challenged mice for up to 10 days following SCJ injection, 
which resulted in successful induction of severe AC model with the presence of 
T cells and dendritic cells. 
 
Using a clinically severe mouse model, this thesis will be investigating the 
contribution of Th2 cytokines, in particular IL-9, towards the 
immunopathogenesis of severe AC. 
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1.6. Conjunctival epithelial cells 
  
 
Mucosal surfaces are the largest surface area of contact with the external 
environment and provide the main gateway for both allergens and pathogens to 
access the body. A great amount of research has been invested to understand 
the molecular components which are the first line of defence at the mucosal 
surfaces and how the components are altered during disease. The ocular 
surface consists of the cornea and conjunctivae that are constantly being 
exposed to the environment. The components of the mucosal surface of cornea 
and conjunctival epithelium prevent damage to the ocular surface but can be 
disrupted under several pathological conditions. The basis of the ocular surface 
epithelial barrier will be discussed in more detail below.  
 
1.6.1. Structure 
  
The conjunctiva consists of two layers: the epithelium and substantia propria. 
The epithelium is continuous with the skin junction on the lid and the corneal 
epithelium at the limbus. The stratified epithelium normally consists of a few 
layers of epithelial cells, goblet cells, melanocytes, Langerhans cells and 
inflammatory cells intercalated within them. Desmosomes and tight junctions 
connect these epithelial cells and provide a seal to the barrier. The substantia 
propria is located subjacent to the epithelium, providing space for immune cells 
including mast cells, lymphocytes, plasma cells and neutrophils of which will 
increase in number during allergic inflammation.  
 
The ocular surface epithelium consists of different layers, which are important in 
providing a barrier against the external environment (Figure 6). The tear film is 
important in lubricating the eye as well as continuously flushing out noxious 
agents from of the ocular surface. The tear film consists of 2 layers: the outer 
layer is a lipid-based layer; the middle layer is an aqueous layer. The lipid layer 
is mainly present to protect the tear film from evaporation of the natural tears 
whereas the aqueous layer is mainly important for lubricating the eye and 
washing away particles. It contains antimicrobial peptides such as lysozymes, 
 56 
 
 
lipocalin and lactoferrin, and, together with immune cells within the conjunctival 
tissues, protects the epithelial barrier.  
 
The conjunctival epithelium consists of two major cell types, stratified squamous 
cells and goblet cells. Stratified squamous cells form another layer that also 
provides an additional layer of protection at the ocular surface epithelium. This 
layer forms the heavily O-glycosylated transmembrane mucins MUC1, MUC4 
and MUC16. Suppression of MUC16 on the corneal epithelial cells leads to loss 
of surface protection (348). 
  
 57 
 
 
Ac n	
Tight	junc on	
Ac n	
Apical	junc on	
complex	
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6:The structure of the normal conjunctival epithelium. The normal 
conjunctival epithelium consists of tight junctions that seal the barrier from 
external pollutants and allergens. Adapted from (120). 
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1.6.1.1. Goblet cells 
 
Goblet cells are another major cell type found in the conjunctivae. These cells 
occur singly or in clusters and are surrounded by stratified squamous cells. In 
comparison to stratified squamous epithelial cells, goblet cells secrete different 
types of mucins, including MUC5ac, which is a large, high molecular weight 
molecule, and a gel-forming mucin. MUC5ac is secreted into the tear film, 
forming a mucous layer that covers the glycocalyx and the epithelium 
underneath.  It functions by trapping ocular allergens and removing them from 
the surface of the eye, which is important in ocular surface disorders including 
allergy, dry eye and infection where goblet cells are severely depleted during 
disease (349). 
 
MUC2 is another soluble gel-forming mucin produced by goblet cells. MUC2 
transcripts have been detected by RT-PCR on the ocular surface of normal 
conjunctiva but their abundance is lower than that of MUC5ac (350). A few 
studies have described the changes in MUC2 expression in patients with ocular 
allergy and dry eye disease where the expression levels were significantly lower 
in dry eye disease compared to normal conjunctiva (351). The expression of 
MUC2 in the conjunctival epithelium was reported to be increased in AKC 
tissues (352). IL-13 levels were found to be elevated in the tears of AKC 
patients (214). MUC2 mRNA expression and protein expression were both 
found to be increased in the presence of IL-13 in primary conjunctival epithelial 
cell cultures (353).  
 
1.6.1.2. Tight junctions 
 
Intracellular junctional complexes exist at different depths on the stratified 
epithelium. There are four different types of junctions. These include tight 
junctions (zonula occludens), desmosomes (macula adherens), adherens 
junctions (zonula adherens), and gap junctions. Besides cellular components, 
conjunctival barrier functions and permeability are also determined by tight 
junctional complexes, which consist of predominantly proteins - occludins, 
zonula occludins and claudins. These tight junctions appear as a series of 
 59 
 
 
connections between adjacent cells, serving as a barrier to the diffusion of 
molecules by sealing the intercellular space, thereby preventing the free 
passage of molecules between adjacent cells (paracellular pathway).  
 
Occludin is a 65-kDa tetraspan intergral transmembrane protein associated with 
the cytoplasmic face of the junction (354). Occludin contributes to the stability of 
tight junctions and maintains optimal barrier functions. This protein can be 
regulated by phosphorylation at multiple sites. For example, phosphorylation of 
occludin at a highly conserved motif containing tyrosine may disrupt its binding 
to ZO-1 and ZO-2 which then leads to separation of occludin from the 
membrane tight junctions, causing barrier dysfunction (355). It has been 
reported that in low humidity conditions, the c-jun N-terminal kinase 2 (JNK2) 
can trigger occludin dysfunction together with the involvement of other 
proinflammatory cytokines including IL-1α and IL-1β (356). Vitamin D, on the 
other hand, has been shown to be involved in the remodelling of the cornea 
after injury via upregulation of occludin expression after stimulation with vitamin 
D metabolites 25(OH)D3 and its active metabolite 1,25(OH)2D3 (357). 
 
Another component of the tight junction (TJ), the Zonula Occluden (ZO) proteins 
(ZO-1, ZO-2 and ZO-3) are cystolic scaffolding proteins that regulate the 
assembly of multiple proteins including occludin at the intercellular TJ. These 
proteins also provide a link between integral membrane proteins on the plasma 
membrane (like occludins) and the cell nucleus through a filamentous 
cytoskeleton of the cytoplasm (358). ZO proteins can also be a component of 
adherens junctions (359). Lipopolysaccharides (LPS), normally associated with 
gram negative bacteria, were found to be detrimental to epithelial tight junctions 
by disrupting ZO-1 and ZO-2 proteins (360).  
 
Proinflammatory cytokines, such as TNF-α, were found to be able to activate 
the NFκβ pathway and disrupt both tight junctional proteins, occludin and ZO-1 
(361). As shown in cultured human corneal epithelial cells, another 
proinflammatory cytokine IL-1β can also disrupt the subcellular localisation of 
these TJ proteins (362).  
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1.7. Hypothesis and aims of this thesis. 
 
Previous studies with lung epithelium specimens and bronchoalveolar lavage 
fluids from individuals with asthma revealed that a high level of IL-9 correlates 
with disease severity (325,363). Our group has been studying the contribution 
of cytokines in allergic conjunctivitis. To date, Th2 cytokines including IL-4, IL-5 
and IL-13 were found to be upregulated in the conjunctival tissue sections of 
VKC & AKC patients (207,364,365). In addition, we observed an upregulation of 
MUC2 mRNA after the exposure of a human conjunctival epithelial cell line 
(IOBA-NHC) to rhIL-9 (Porter et al, unpublished data). It has therefore been 
proposed that IL-9 might play a proinflammatory role in allergic conjunctivitis.  
 
Based on these data, the hypothesis of this study is that conjunctival IL-9 is 
upregulated during allergic conjunctivitis and contributes to the 
immunopathogenesis of the disease. 
To address this hypothesis, the specific aims of this thesis were as follows: 
 
1. To investigate the presence of IL-9 during allergic conjunctivitis in 
both human and mouse conjunctival tissues.  
 
2. To investigate the role of IL-9 secreted by mast cells and its effect(s) 
on mast cell responses. 
 
3. To investigate the impact of IL-9 on conjunctival epithelial cells. 
 
The novel findings from this thesis contribute to our understanding of the role of 
IL-9 during allergic conjunctivitis, especially the role of IL-9 secreted by mast 
cells. Understanding the IL-9 mechanisms in AC could potentially lead to IL-9 
being used as a biomarker for the disease and to the discovery of a potential 
therapeutic target for the treatment of allergic conjunctivitis.   
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Chapter 2 
 
Materials and Methods 
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2.1. Mouse models of experimental allergic conjunctivitis 
 
2.1.1. Mice 
 
For the purpose of this study, eight to twelve-week-old female C57BL/6 mice 
(Charles River, UK) were used for the severe model of allergic conjunctivitis. 
Mice were housed in the UCL Institute of Ophthalmology animal facility. 
 
2.1.2. Induction of murine model of allergic conjunctivitis 
 
Mouse studies were carried out in accordance with the Animals (Scientific 
Procedures) Act 1986 and housed in accordance with Home Office 
Regulations. Treatment of animals conformed to the ARVO statement for the 
use of animals in ophthalmic and vision research. 
 
2.1.2.1. C57BL/6 mice induced by ovalbumin (OVA). 
 
The severe allergic conjunctivitis model was induced using the protocol 
described (347). Mice were immunized once by intraperitoneal injection with a 
100µl of suspension containing 1mg of aluminium hydroxide (Alum Imject, 
Sigma-Aldrich) diluted in phosphate buffer saline (PBS), 300ng of pertussis 
toxin (Sigma-Aldrich), and 100µg of ovalbumin (Sigma-Aldrich). Mice were left 
for 21 days before the first OVA topical challenge. This time is required for the 
generation of systemic T cell responses. On day 22, mice were challenged 
topically once daily for 7 days with 5µl of OVA eye drops per eye, containing 
50mg/ml of OVA diluted in sterile PBS. Mice were harvested for whole eye, 
conjunctiva and draining lymph nodes on day 28, after 7 days of topical 
challenge. The mouse model of EAC that was used in this thesis is illustrated in 
Figure 7 below: 
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OVA sensitised and challenged C57BL/6 mice (347): 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Diagram of allergic conjunctivitis (AC) mouse model with OVA 
sensitised and challenged in C57BL/6 mice. 
 
 
 
 
 
Samples collected: 
1. Whole eye: H&E, 
Toluidine blue and 
immunofluorescence 
staining. 
2. Conjunctiva: Cells 
explanted from 
conjunctiva, re-stimulated 
with PMA/ionomycin and 
analysed by FACS. 
3. Draining lymph nodes: 
Preparation of single cell 
suspension, re-stimulated 
with PMA/ionomycin and 
analysed by FACS.  
Immunize i.p. with 
OVA+ Alum + Pertussis 
toxin  
Day 0 
Day 22 23 24 25 26 27 28 
harvest 
Daily OVA topical 
challenge 
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In each experiment, there were 5 mice in PBS-challenged groups (control) and 
10 mice in the OVA challenged groups. A clinical scoring scheme previously 
described (366) was used to evaluate chemosis, lid edema, tearing and 
conjunctival vasodilation (redness). Each parameter was graded on a scale 
ranging from 0 (absent) to 3+ (maximal) by two independent masked observers.  
Mice were sacrificed one-hour post OVA challenge and whole eyes were 
enucleated from each mouse. Each eye was kept in 4% glutaraldehyde for 2 
hours then fixed in formalin before being embedded in paraffin wax. Eyes were 
processed and prepared for staining.  
 
2.1.2.2. Mouse conjunctival mast cell isolation 
 
After 20 minutes following the 7th topical challenge, mice were euthanized, and 
conjunctivae were surgically removed and placed on ice cold PBS. Single cell 
suspensions were prepared for conjunctival explants. Conjunctivae were 
minced into small fragments and left in 24-well culture plates containing just 
enough supplemented RPMI-1640 (Sigma-Aldrich) medium to cover the bottom 
of the well. The culture medium was supplemented with 10% heat inactivated 
fetal calf serum (Sigma-Aldrich), 1mM sodium pyruvate, 100 µg/ml penicillin 
streptomycin, 1x non-essential amino acid (Thermo Fischer), and 10 ng/ml SCF 
(PeproTech, London, UK). Cultures were left in a 5% CO2 humidified incubator 
at 37°C for 3 days to allow mast cells to migrate out from the tissues.  
 
2.1.2.3. Mouse draining lymph nodes isolation 
 
After mice were euthanized, draining lymph nodes were placed on ice cold 
PBS. Single cell suspensions were prepared for intracellular cytokine staining 
where cells were stimulated with 500ng/ml of ionomycin and 50ng/ml of phorbol 
2-myristate 13-acetate (PMA) in the presence of brefeldin A (BFA) for 3 hours 
prior to staining with fluorochrome conjugated antibodies. 
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2.2. Intracellular cytokine staining 
 
Cell culture plates containing the cells were spun at 200g for 5 minutes, the 
medium aspirated and the cells resuspended by vortexing. For detection of cell 
surface CD4 expression, cells were incubated for 30 minutes at 4˚C with anti-
CD4 mAb (BD Biosciences). To wash, plates with cells were spun at 200xg for 
5 minutes and vortexed. 100µl/well of Cytoperm (BD Biosciences) was added 
and incubated at 4˚C for 20 minutes. 100µl/well diluted Perm/Wash (BD 
Biosciences) was then added and plates were spun and vortexed again to stop 
permeabilisation. Directly conjugated antibodies were added to the pellet.  After 
30 minutes, 100µl/well of Perm/Wash was added and plates were spun and 
vortexed as above. 200µl per well PBS was added and cells were run on a 
LSRFortessa-x20 using FACSDiva, with compensation applied where 
necessary (BD Biosciences).  This data was analysed using FlowJo with 30,000 
events in a live gate acquired, as determined by forward and side scatter plots 
(FSC v SSC).  
 
Similar staining techniques were also used in in vitro stimulated single cell 
suspensions from mouse draining lymph nodes (dLNs), and conjunctival 
explants were fixed in 1x Cell Fix (BD Bioscience, UK), as described above (see 
2.11). All antibodies used for staining single cell suspensions from mouse dLNs 
and conjunctival explants are listed in Table 1. Staining was detected on a flow 
cytometer LSR Fortessa-x20 and analysed by FlowJo software (FlowJo LLC, 
Ca, USA).  
 
For conjunctiva and lymph node gating, a gate was drawn around the 
cells/lymphocyte region respectively. Within this gate, another region was drawn 
around single cells to remove doublets, followed by a live cell gate. Gating 
strategy will be explained further in chapter 3. Results are shown in 
percentages or in some samples, the number of cells were calculated using 
FACS counting beads which was added to each sample of 200µl. 
Compensation was set using BD Multicolor CompBeads (BD Biosciences) 
during acquisition. 
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Table 1: List of anti-mouse antibodies used for intracellular cytokine staining  
Antibody Source Conjugates Volume/concentration 
c-kit, eBioscience PE 1µl/test 
FCεR1 eBioscience PE 1µl/test 
IL-9 BioLegend BV 421 1µl/test 
IL-4 BD Bioscience AF 488 1µl/test 
CD4+ BioLegend  BV 395 1µl/test 
PU.1 BioLegend APC 1µl/test 
GATA-3 BD Bioscience AF 700 1µl/test 
2.3. Immunostaining 
 
2.3.1. Immunohistochemistry on human tissue sections with DAB 
staining. 
 
Human conjunctival tissue sections were obtained from the archived UCL 
Institute of Ophthalmology Tissue Bank (Calder Lab). These were conjunctival 
punch biopsies, which had been obtained from out-of-season challenged 
allergic conjunctivitis (AC) donors at 8 hours post allergen challenge (n=8 from 
3 males; age 31-57 years). Normal, non-inflamed conjunctival tissues were 
previously collected from anonymised donors (n=8, from all males; age: 16-65 
years). Prior ethical approval had been obtained to use these tissues for 
ongoing immune studies. Tissues were embedded in glycol methacrylate (GMA) 
using a standard protocol, prior to cutting 3μm thick sections for 
immunostaining.  
 
Sequential tissue sections were ringed with a wax pen (DAKO, UK) and fixed in 
acetone for 10 minutes at 4˚C. Endogenous peroxidase was blocked using 
peroxidase blocking solution (Dako UK) for 15 minutes and then washed twice 
with PBS (5 minutes each). To prevent non-specific binding to Fc, a blocking 
buffer (1.5% goat serum in 10% bovine serum albumin BSA) was added for 30 
minutes at room temperature. Sections were incubated with purified rabbit 
polyclonal anti-human IL-9 antibody and IL-9R mAb (Abcam, Cambridge, UK) 
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diluted 1:300 and anti-human tryptase (DAKO; clone AA1) diluted 1:100 
overnight in a humidified chamber at room temperature. For negative controls, 
primary antibody was replaced with PBS. 
 
After washing twice with PBS, biotinylated rabbit and mouse anti-rat Fab 
fragment IgG (DAKO UK Ltd.; 1:200 dilution) was added for 2 hours at room 
temperature. After washing, avidin-biotin complexes (ABC)-alkaline 
phosphatase (V) was added for 2 hours at room temperature. Unbound ABC 
was removed by washing twice with PBS and Ab binding was visualized using 
substrate 3, 3’-diaminobenzidine tetrahydrochloride (DAB; Vector Labs), 
incubating for 3 to 4 minutes depending on the intensity of staining. After rinsing 
with PBS and running tap water for 3 minutes, slides were counterstained with 
haematoxylin (DAKO UK Ltd) for 1 minute and mounted with fluorescence 
mounting medium (Vector Labs). Positively stained cells were visualized using 
light microscopy at x200 and x400 magnification. 
 
2.3.2. Double immunofluorescence staining of human sections on GMA 
embedded sections. 
 
In order to investigate the colocalisation of IL-9 or IL9R on mast cells, tissue 
sections from human biopsies were double stained for both IL-9 (or IL-9R) and 
tryptase. The tissue area was ringed with a wax pen (Dako UK Ltd) and fixed in 
acetone for 10 minutes at 4˚C. The slides were then washed twice in PBS and 
non-specific binding sites were blocked by adding 5% goat serum (in 1% PBSA, 
0.1% triton). Excess serum was tipped off and slides were incubated with 
purified rabbit anti-human IL-9 or IL-9R mAb (Abcam; diluted 1:100) and anti-
human tryptase (Dako UK Ltd; clone AA1; diluted 1:100) in 1% PBSA (BSA 
diluted in PBS) overnight in a humidified chamber at room temperature. After 
overnight incubation, slides were washed twice in PBS before incubation with 
Alexa Fluor® 488 Goat Anti-Rabbit IgG and Alexa Fluor® 546 Goat Anti-Mouse 
IgG (Life Technologies), diluted 1:250 for 2 hours at room temperature. Slides 
were then washed twice in PBS (5 minutes each wash) and stained with DAPI 
(Vector Labs) for 5 minutes. The slides were washed twice again with PBS and 
mounted in fluorescence mounting medium. Slides were stored in the dark at 
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4˚C and visualized using a Zeiss 710 laser scanning confocal microscope with 
the 40x objective. 
 
To quantify the staining of the tissue sections, positively stained individual cells 
were counted from a total of 3 fields (at x400 magnification) per section.   
 
2.3.3. Double immunofluorescence (immunocytochemistry) staining of 
human epithelial cells. 
 
In order to investigate the expression of IL-9 on human conjunctival epithelial 
cells, the IOBA-NHC cell line cells (Diebold et al., 2003; a kind gift from Prof. M. 
Calonge, University of Valladolid, Spain) were grown in Lab Tek® chamber 
slides (Thermo Scientific) until 80% confluent. Cells were fixed with 4% 
paraformaldehyde (PFA) in TBS for 10 to 15 minutes before being washed 
twice with TBS. Slides were incubated with 1% Triton X-100 in TBS for 3-5 
minutes at room temperature and washed again twice with TBS before 
incubation with blocking reagent or 10% BSA for 30 minutes to block non-
specific Fc binding. Excess blocking reagent was tipped off and diluted primary 
antibodies (Table 2) in 1% BSA were added to the slides and incubated for 1 
hour at room temperature.  Slides were washed 3 times for 2 minutes each with 
TBS-Tween 20 (0.1% v/v). Secondary antibodies (diluted 1:300 in 1% BSA) 
were added for 1 hour at room temperature and washed again 3 times for 2 
minutes each with 0.1% TBS- Tween 20. Slides were mounted with 
Vectashield-DAPI and stored in the dark at 4°. Cells and sections were viewed 
on a Zeiss 710 confocal microscope using 40x water immersion objective 
(Zeiss, UK).  
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Table 2: List of conjugated primary and secondary antibodies used for 
immunofluorescence staining on human conjunctival sections and IOBA 
epithelial cells.  
 
 
Anti-human 
Antibodies 
Host 
Species  Conjugate Dilution Source 
Primary 
IL-9 Rabbit - 1 in 100 Abcam  
IL-9R Rabbit - 1 in 300 Abcam 
tryptase AA1 Mouse - 1 in 100 DAKO 
ZO-1  Goat - 1 in 300 Abcam  
Occludin  Rabbit - 1 in 100 Life Technologies 
Secondary 
Rabbit anti-
goat   FITC 488  1 in 200 Life Technologies 
Donkey anti-
rabbit   PE 555  1 in 200 Life Technologies 
Goat anti-rat   APC 633  1 in 200 Life Technologies 
 
 
2.4. Generation of BMMC 
 
BALB/c mice were chosen as they are a Th2-dominant strain and are commonly 
used in studies of allergic responses.  
 
Naïve BALB/c mice (4-6 weeks old) were sacrificed by cervical dislocation. 
Intact tibias were dissected and stored in 70% ethanol on ice. Under sterile 
conditions, bone marrow cells were carefully harvested by repeated flushing 
with IMDM. 
 
The cell culture was established at a density of 1 x 106 cells/ml, in Iscove’s 
Modified Dulbecco’s Medium (IMDM) (Sigma Aldrich, Dorset, UK), 
supplemented with 10% heat-inactivated foetal calf serum (FCS; Biosera, East 
Sussex, UK), 4mM L-glutamine, 1mM sodium pyruvate, 100 U/ml penicillin, 
100μg/ml of streptomycin, 0.1mM non-essential amino acid (NEAA), and 50μM 
2-mercaptoethanol (Life technologies, UK), 5ng/ml recombinant murine IL-3 and 
10ng/ml stem cell factor (SCF; PeproTech, London, UK)(as shown in  
 73 
 
 
. Cells were incubated at 37oC in a 5% CO2 humidified incubator. 
Non-adherent cells were transferred to fresh 75mm2 culture flasks every 2-3 
days for a total of at least 3 weeks to remove any contaminating macrophages 
and fibroblasts. After 4-5 weeks of culture, cells were assessed for phenotypic 
expression of both FcεRI and c-Kit by flow cytometry. Cells were used for 
further assays when the population consisted of >95% FcεRI and c-Kit positive 
cells (BMMCs).  
 
 
 
 
 
 
 
 
 
 
Figure 8: Bone marrow mouse mast cells extraction 
  
4-5 weeks 
culture IL-3 + 
SCF 
Mast cell 
characterization
: > 95% c-kit, 
stimulation 
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2.5. In vitro BMMC cytokine assays 
2.5.1. In vitro BMMC stimulation 
 
BMMCs were counted and plated at 106/ml in culture medium without IL-3 and 
SCF. Prior to IgE stimulation, cells were sensitised overnight with monoclonal 
anti-DNP (2µg/ml; clone SPE-7; Sigma) and washed twice by spinning down 
the cells at 200g for 5 minutes, removing the supernatants and resuspending 
with fresh medium to eliminate the unbound IgE. Cells were stimulated with 
either phorbol 2-myristate 13-acetate (PMA) and ionomycin, 0.5µg/ml ionomycin 
(Sigma, Dorset, UK) alone or with 50µg/ml DNP-BSA (Biosearch Technologies). 
Supernatants were collected at different time points (24, 48, 72, 96 and 120 
hours) and stored at -20°C for further analysis.  
 
2.5.2. Pre-treatment of BMMCs for IL-9 and IL-9R neutralising experiments. 
 
In some experiments, cells were treated with anti-mouse IL-9R mAb (R&D 
Systems) or isotype-matched antibodies (R&D Systems), 30 minutes prior to 
stimulation. Table 3 lists the concentrations of antibodies that were used for 
titration experiments.  
 
Table 3: Antibody titration in BMMC stimulated cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anti-Mouse 
Antibodies 
Host 
Species  
Ig 
Subclass 
Concentration 
anti-IL-9 (R&D) 
clone ab203386 
Goat  
 
 
 
IgG 5µg/ml 
9µg/ml  
20µg/ml 
anti-IL-9R (R&D) 
clone ab61196 
Rat  IgG2a 5µg/ml 
10µg/ml  
20µg/ml 
Rat IgG2a (R&D) Rat  9µg/ml 
Goat IgG (R&D) Goat  10µg/ml 
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2.5.3. IL-9 rescue experiment in BMMCs. 
 
In order to confirm that the effects of blocking IL-9R with neutralizing IL-9R 
antibodies in BMMC were in fact due to an IL-9-specific inhibition, rescue 
experiments were done where anti-IL-9R mAb was added to BMMC culture 10 
minutes prior to ionomycin stimulation and recombinant mouse IL-9 (mIL-9; 
R&D Systems) was added 30 minutes following the addition of IL-9 and IL-9R 
neutralizing antibodies and ionomycin stimulation (2.3.2. Pre-treatment of 
BMMCs for IL-9 and IL-9R neutralizing experiments). Different concentrations of 
mIL-9 were added to the culture (0.01, 0.05, 0.1 ng/ml) in order to titrate the 
optimal mIL9 concentration to reverse the effect of the neutralizing antibodies. 
Briefly, cells were plated at a concentration of 1x106/ml in 96 well plates. 
Neutralizing antibodies were added to appropriate wells after 30 minutes 
stimulating cells with ionomycin and anti-IgE. Plates were left at 37˚C, 5% CO2 
for 30 minutes before mIL9 was added at different concentration. Cells were 
incubated and supernatants were collected at 0, 24, 48 and 72 hours for 
cytokine analysis by multiplex bead arrays. Cell-free supernatants were stored 
in aliquots at -20˚C.  
 
2.5.4. IL-9 and IL-9R gene expression inhibition in BMMC with the addition 
of small interfering RNA (siRNA) IL-9 and IL-9R.  
 
Besides blocking IL-9 and IL-9R functions with neutralizing antibodies, it is also 
possible to investigate the effect of IL-9 and IL-9R gene knock down. For this, 
pre-designed small interfering RNA (siRNA) of IL-9 and IL9R (Thermo 
Scientific) was used. These siRNA have specific sequences that are known to 
target the genes for IL-9 and IL-9R in mouse (Table 4). A scrambled gene that 
targets the non-targeting siRNA was used as the negative control since it has 
minimal targeting of known genes to human, mouse and rat cells. Ionomycin-
stimulated cells and unstimulated cells were used as the positive and negative 
controls for the experiment.  
 
Briefly, 3μl of IL-9 and IL-9R siRNA and scrambled control (final concentration 
of 1μg) was diluted in 50μl Optimem serum reduced medium (Life technologies 
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UK) for each reaction. Lipofectamine 2000 Reagent (Life Technologies) was 
used as the transfection reagent. 2 μl of Lipofectamine was diluted in 50 μl 
Optimem for each reaction/ well. The diluted siRNA and diluted Lipofectamine 
were mixed and left for 20 minutes at room temperature in order for the gene to 
bind to the transfection reagent. Cells were plated in 24 well plates at 1x106/ml 
and 500 μl per well in supplemented medium without Penicillin and 
Streptomycin as antibiotics could interfere with the transfection process. 100 μl 
of the mixed Lipofectamine and siRNA were then added to each well and 
incubated at 37˚C, 5% CO2 for 24 hours for transfection to take place. IL-9 and 
IL-9 knockdown efficacy was tested by real time PCR.  
 
Table 4: Small interfering RNA (siRNA) transfection. 
 
Gene Assay ID Source 
IL-9 62595 Thermo Scientific 
IL-9R 62596 Thermo Scientific 
 
2.6. Measurement of histamine release (ELISA) 
 
Histamine levels in the supernatants of BMMC cultures were measured by 
ELISA (IBL International, Hamburg). The method was carried out according to 
the manufacturers’ instructions. Briefly, cell culture standards, control and 
samples were acylated in a 96 well plate for 30 minutes. The reaction was 
stopped by diluting with assay buffer. A six points cell culture standard curve 
was provided with the highest standard of 219ng/ml and the minimum standard 
of 0.67ng/ml. Diluted acylated standard, control and samples were transferred 
to a 96-well microtiter plate pre-coated with anti-histamine antibody, and 
enzyme conjugate and histamine antiserum were added. Plates were incubated 
for 3 hours on an orbital shaker at room temperature. After washing, TMB 
(3,3′,5,5′-tetramethylbenzidine) substrate solution was added and incubated for 
20 minutes at room temperature on an orbital shaker. To stop the enzymatic 
reaction, TMB stop solution was added to each well.  The optical density at 405 
nm, with a reference wavelength of 600nm, was read with a microplate reader 
 77 
 
 
(Titertek™, Vienna, Austria). The concentrations of histamine in the samples 
were determined from a best-fitting standard curve (absorbance against known 
concentration) generated by the plate reader.  All assays were conducted in 
triplicate.    
 
2.7. Measurement of cytokine release (Multiplex bead arrays) 
 
Cell-free supernatants from unstimulated and stimulated BMMC cultures were 
simultaneously assayed for IL-4, IL-5, IL-9, IL-10 and IL-13 using customised 5-
plex bead immunoarrays (Bio-Rad, Hertfordshire) according to manufacturers’ 
instructions. Single vial standards were reconstituted in culture medium. Eight 
point serial dilution standards including blanks were prepared (Table 5) 96-well 
filter plates were pre-wet with 100µl of assay buffer and liquid then removed 
using a vacuum manifold (wash). Previously prepared 1x beads were then 
added to the assay plate. 50µl of standards, blank and samples were added to 
the plates in duplicate. Plates were covered and incubated in the dark at room 
temperature on orbital shaker for 30 minutes. After the incubation time, plates 
were washed 3 times with wash buffer. 25µl/well of detection antibody was 
added, the plate covered, and incubated in the dark on an orbital shaker for 30 
minutes. Plates were washed 3 times and 50µl/well of freshly prepared 
streptavidin-PE were added. After 10 minutes in the dark at room temperature 
on an orbital shaker, plates were washed 3 times with wash buffer and beads 
were resuspended in 125µl assay buffer for analysis.  Cytokine measurements 
were acquired using a Luminex- 100 plate reader and analysed from a standard 
curve for each cytokine using Luminex software. Cytokine levels were 
expressed in pg/ml. 
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Table 5: Bio-Plex Pro™ (Bio-Rad) Mouse Cytokine Standard 5-Plex 
 
Cytokine Highest standard (pg/ml) 
 
IL-4 125 315 
IL-5 48 602 
IL-9 33 358 
IL-10 23 425 
IL-13 48 663 
 
2.8. ELISA for determining IL-9 pAb specificity  
 
Enzyme-linked immunosorbant assay (ELISA) was used to determine the IL-9 
pAb (Abcam, Ab111915) specificity for immunostaining on human conjunctival 
tissue sections. Recombinant human (rh) IL-9 (R&D 209-IL/CF) in bicarbonate 
buffer (Sigma; C304) was coated onto an ELISA plate (NUN96ft) at 4µg/ml and 
incubated overnight at room temperature. After incubation, plate was washed 
three times for 5 minutes with 0.1% Triton x100 or PBS with 300µl per well. 
Plate was then blocked with 3% BSA or PBS (at 300µl per well) for 1 hour at 
room temperature. Rabbit polyclonal Anti-IL9 (Abcam, Ab111915) was added at 
6 different dilutions (1:125, 1:250,1:500, 1:1000, 1:2000, 1:4000) plus a blank 
control and incubated for 1.5 hour at room temperature. IL-9 pAb was also 
prepared in carbonate/bicarbonate buffer. Plate was then washed 6 times for 5 
minutes each 0.1% Triton x100 or PBS at 300µl per well.  Goat anti-Rabbit HRP 
(Dako, P0448, 1:2000) was added and incubated for 1.5hr at room temperature. 
Plate was then washed 6 times for 5 minutes each 0.1% Triton x100 or PBS at 
300µl per well. Then, ELISA Substrate Reagent kit (R&D Systems, DY999) was 
added to each well. Substrate A (stabilised hydrogen peroxide) and substrate B 
(stabilised tetramethylbenzidine) were mixed in equal portions just before use 
and 100µl per well of the mixture was added and left to develop in the dark for 
20 minutes. 2N sulphuric acid was then added at 50µl per well to stop the 
reaction. The plate was read in a plate reader (TECAN, software; Safire, 
XFLUOR4) with the absorbance at 450nm (reference wavelength 540nm).  
 
In another experiment, rhIL9-coated wells were incubated with 
neutralising  human IL-9 (R&D,AB-209-NA), or neutralising mouse IL-9 (R&D , 
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Ab-409-NA) at 4 different dilutions (1:250, 1:500, 1:1000 and 1:2000) at the 
same time as IL-9 pAb at 1:1000 (based on previous experiment). Plate was 
incubated for 1.5 hour at room temperature and then subsequent steps were 
followed for ELISA plate as described above. 
 
 
2.9. Human epithelial cell culture 
 
2.9.1. In vitro culture of IOBA-NHC cells 
 
IOBA-NHC is a conjunctival epithelial cell line spontaneously immortalised from 
a normal human conjunctival explant (a kind gift from M. Calonge, Valladolid, 
Spain). The cells were cultured in DMEM Nutrient mixture F-12 HAM medium 
(Sigma-Aldrich, Dorset, UK), supplemented with 10% heat inactivated foetal calf 
serum (FCS; Biosera, East Sussex, UK), 100U/ml Penicillin/Streptomycin (Life 
Technologies, UK), 2ng/ml of mouse endothelial growth factor (EGF) (Sigma-
Aldrich), 1μg/ml bovine insulin (Sigma-Aldrich), 5μg/ml hydrocortisone and 
0.1μg/ml Cholera Toxin (Sigma-Aldrich) at 37oC, in a 5% CO2 humidified 
incubator. At confluence, cells were detached using trypsin-EDTA (Life 
Technologies) and were incubated at 37˚C, 5% CO2 for 5 minutes. Once 
detached, cells were centrifuged for 5 minutes at 1200 rpm and resuspended in 
fresh medium in a 75cm2 flask and cultured as above. Cultures were split and 
fed when the monolayer became confluent.  
 
2.9.2. In vitro culture of 16-HBE cells. 
 
16-HBE cell line is a human bronchial epithelial cell line (a kind gift from P. 
Lackie, University of Southampton, UK). The cells were cultured in DMEM 
Nutrient mixture F-12 HAM medium (Sigma-Aldrich), supplemented with 10% 
heat inactivated foetal calf serum (FCS; Biosera) and 100U/ml 
Penicillin/Streptomycin. Cells were split and fed as described in 2.4.  
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2.10. Epithelial cell cytokine treatments 
 
Epithelial cells were detached from the culture flask as described above. Cells 
were centrifuged for 5 minutes at 1200 rpm, suspended at 1x105 cells/ml, plated 
in 24-well plates and incubated overnight.  The medium was replaced with 
serum free medium in the presence or absence of recombinant human 
cytokines (all from R&D Systems) as described in Table 6. Cells were 
incubated as above and harvested at 2, 6 and 24 hours post cytokine treatment 
where RNA were removed and kept frozen in -20˚C until ready for qPCR.  
 
Table 6: Recombinant human cytokines for human epithelial cell cytokine 
treatments. 
 
Human Recombinant 
Cytokine 
Final Concentration 
(ng/ml) 
IL-1β 20 
IL-9 10 
IL-13 40 
IL-17A 0.2 
 
 
2.11. RT-PCR 
 
2.11.1. RNA isolation 
 
For total RNA isolation, the procedure was carried out using RNeasy Mini kit 
(Qiagen, Crawley, UK), according to the manufacturers’ instructions. For human 
epithelial cells, 300µl of RLT-lysis buffer (supplied in the kit) was added to the 
cells, using a vortex, and kept frozen at -70˚C until ready for RNA isolation. For 
suspension cells like BMMC, cells were centrifuged for 5 minutes at 1200rpm 
and washed once with PBS to remove FCS. BMMC were then washed again 
and resuspended in 300 µl of RLT-lysis buffer. To lyse mouse conjunctival 
tissues, Trizol was used instead of adding lysis buffer. All lysates were kept 
frozen at -70˚C until ready for RNA isolation.  
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Cell lysates were homogenized by centrifugation using Qiashredder spin 
columns (Qiagen). The remaining procedure was carried out using RNeasy spin 
columns according to manufacturers’ instructions. 20 µl of RNase free water 
was added to the column to elute the RNA in 1.5ml RNase-free Eppendorf 
tubes (supplied in the kit).  The concentration of RNA was measured by 
spectrophotometry (Nanodrop) and its purity was analysed by measuring the 
ratio of the readings at 260nm and 280nm (A260/A280), with readings greater 
than 1.9 indicating a high level of purity. Extracted RNA specimens were then 
stored at -80˚C or used immediately for making cDNA. 
 
2.11.2. Reverse Transcription (RT) 
 
RNA was reverse transcribed into cDNA copies using High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems). All samples were prepared on 
ice. Firstly master mix, which comprises dNTP mix, Multiscribe® Reverse 
Transcriptase, RT buffer, RNase inhibitor, RT Primers and Rnase free water 
(supplied in the kit), was prepared according to Error! Reference source not f
ound.7 below: 
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Table 7: Reagents added to a master mix per reaction. 
 
 
Component 
 
Per 7.5µl 
reaction/reaction(µl) 
 
 
dNTPs (100mM) 
 
 
0.075 
 
Multiscribe® Reverse 
Transcriptase 
 
 
0.500 
 
RT Buffer  
 
 
0.750 
 
Rnase Inhibitor 
 
 
0.094 
 
RT Primers Or Random 
Hexamers 
 
 
1.5 
 
RNase free water 
 
 
2.081 
 
 
 
 
3.5µl/well of reverse transcription buffer was aliquoted into wells of a 96-well 
reaction plate in triplicate followed by 2.5 µl aliquots of RNA added into 
respective wells, giving a total volume of 6 µl per well. Plates were capped and 
spun for 10 seconds before being incubated for 10 minutes at 25˚C in a thermal 
cycler, followed by 30 minutes at 48 ˚C and 2 minutes at 95 ˚C (to inactivate the 
reverse transcriptase in the reaction), before an indefinite holding stage at 4 ˚C. 
Samples were stored at -20 ˚C until qPCR was carried out.  
 
2.11.3. qPCR 
 
In order to quantify the relative amount of mRNA, TaqMan gene expression 
assays were used (Applied Biosystems, Warrington, UK) which contain primers 
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and probes, all from Applied Biosystems (refer to Table 8). 2X Taqman Gene 
Expression Master mix containing Ampli Taq Gold NA polymerase, Uracil-DNA 
Glycosylase and dNTPs with dUTP (Applied Biosystems) was diluted in RNase-
free water (Table 9) to set up a 10 µl reaction in a 96-well reaction plate. 
 
9.33 µl of TaqMan Master Mix was added to each well followed by 0.67 µl of the 
cDNA product to corresponding wells in the reaction plate. Each reaction was 
set up with β actin as the housekeeping gene with the following cycle condition: 
a) 50 ˚C for 2 minutes; b) Initial activation of DNA polymerase at 95 ˚C for 10 
minutes; c) denaturation for 15 seconds at 95 ˚C; d) annealing and extension 
step at 95 ˚C for 60 seconds in 40 cycles using the 7500 HT Real-Time PCR 
system (Applied Biosystems). An annealing temperature of 95 ˚C was used in 
all primers. Results were analysed with SDS 2.2.2. software.  
 
Table 8: Genes of interest and their target sequences 
 
Gene Assay ID/Part number/ 
Target sequence 
Human/Mouse Beta-
actin 
Hs01060665_g1 
Human MUC2 Hs03005103_g1 
Human MUC5ac Hs00873651_mH 
Mouse IL-9 Mm00434305_m1 
Mouse IL-9R Mm00434306_m1 
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Table 9: Conditions for qPCR 
 
Component Per 10 µl reaction (µl)  
TaqMan 2x Universal PCR Master 
Mix, No AmpErase UNG 
 
5.000 
RNase-free Water 
 
3.335 
AOD OR 18S or Housekeeping 
gene 
 
1 
 
 
2.11.4. Analysis of Real Time qPCR 
 
RNA was normalized to expression levels of β-actin. Relative RNA expression 
was calculated using the change-in-threshold method of –ΔΔCT: 
Fold change = 2
-∆∆Ct  
where  
 
Δ= change;   
∆Ct = Ct target gene - Ct housekeeping gene;   
∆∆Ct = ∆Ct sample - ∆Ct unstimulated  
 
 
2.12. Statistical analysis of results 
 
Data were analysed using Prism 6 (GraphPad Software Inc, LA, Jolla, Calif). 
Data were shown as means ± SEMs and SDs. For human data, analyses used 
Mann-Whitney U-tests for comparison of means. Student’s T-tests were used to 
evaluate statistical significance in all mouse experiments. A P value of <0.05 
was considered statistically significant. 
  
 85 
 
 
 
 
 
CHAPTER 3 
 
Mouse model of Allergic Conjunctivitis 
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3.1. INTRODUCTION 
 
Animal models are important for investigating the potential inflammatory 
mechanisms involved during allergic conjunctivitis (AC), for identifying 
molecular targets and for testing novel compounds for therapeutic interventions. 
Since studies done in human samples can give limited information due to 
limited availability of human samples, the stage of disease at the time of 
sampling, and the effects of treatment on the specimens, having access to 
allergic conjunctivitis animal model enable us to assess the effects of anti-
allergic and newly-developed compounds and also to study in more detail the 
cellular and molecular mechanisms in ocular allergy.  
 
There are different strains of mice that have been used for establishing models 
of AC which includes SWR/J mice, AJ mice, BALB/c mice and C57BL/6 mice. 
This study used the C57Bl/6 mice since C57Bl/6 mouse immune responses are 
more biased towards Th1 responses, which can cause a clinically more severe 
allergic reaction (368).  
 
Mouse models of AC have been used to study the effects of topical application 
of inhibitors (369,370). Besides testing new pharmacological compounds, these 
mice have also been extensively used to study the mechanisms underlying AC. 
A study done by Li and colleagues has found that AC mediated by short 
ragweed pollen in BALB/c mice involves a TLR-4-dependent, TSLP/OX40 
ligand binding leading to activation of the OX40 signalling pathway, which 
triggers the secretion of IL-4, IL-5 and IL-13 in the cornea, conjunctiva and 
cervical lymph nodes (371).  
 
 
Although much effort has been made to understand the molecular mechanisms 
involved in AC, most AC models have only been useful to investigate the 
cellular involvement in the clinically milder forms of AC. There are very few T 
cells found in the conjunctival tissues in these models, making it impossible to 
study the contribution of T cell-derived cytokines in clinically more severe forms 
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of chronic allergic eye disease. Therefore, the relevance of most AC models to 
clinically more severe forms of AC in man is less obvious.  
 
This study uses an adaptation of an AC model previously described by 
Schlereth et al (347). Schlereth and colleagues developed a clinically more 
severe model of murine AC by injecting OVA-loaded dendritic cells into the 
subconjunctival (SCJ) space and then immediately challenging the mice 
topically with OVA via eyedrops. The mice were repeatedly challenged for up to 
10 days following SCJ injection. This model was based on a similar approach 
previously developed for an allergic asthma model (372). Combining the 
approach from Kuipers et al., with the understanding of the interaction of 
antigen-specific T cells as playing a key role in experimental immune-mediated 
blepharoconjunctivitis (373), Schlereth et al successfully induced a severe 
model of AC. Schlereth et al investigated expression of CCR7, as the marker for 
activated dendritic cells, and demonstrated that antigen-specific T cell-dendritic 
cell interactions are crucial for inducing AC in this model. The presence of 
antigen-specific T cells and dendritic cells in this model were evidenced by the 
similar levels of Th2 cytokines (IL-4 and IL-13) in AC-induced mice receiving 
CCR7-/- dendritic cells as compared to AC induced mice that did not receive 
SCJ injection of wild type dendritic cells. This suggests the importance of 
activated dendritic cells in eliciting chronic AC responses in C57BL/6mice.  
 
This model was adapted, by omitting the antigen-loaded DC and chosen for this 
study due to the outcome of repeated challenge with allergen that mimics the 
physiology of more severe forms of AC with increasing eosinophils infiltration 
and expression of Th2 cytokines.  Following sensitisation and repeated OVA 
challenge, early phase responses which are normally recorded within 30 
minutes after conjunctival challenge can be evaluated by scoring of itch, whilst 
late phase responses were also recorded after 4-24 hr (conjunctival redness, lid 
oedema and tearing (374)). 
 
This severe form of AC requires relatively high doses of topical antigen during 
the repeated challenge at the ocular surface, making it physiologically less 
relevant to chronic AC in man. However, this model is more similar to chronic 
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AC affecting man with respect to its CD4+T cell involvement, making it possible 
to study the role of Th9 cells in the chronic AC model.  
 
To date, most studies investigating the role of IL-9 have been done using 
mouse models of allergic airway disease. Sehra et al have used both BALB/c 
and C57BL/6 mice to study the functions of Th9 cells in promoting mast cell 
responses during both acute and chronic allergic lung inflammation (127). Due 
to the availability of genetically modified mice, mouse models are normally 
preferred for studying the mechanisms underlying certain diseases. Liao et al 
used Il2-/- knockout mice to study in detail the downstream mechanisms of il9 
promoter expression and Th9 differentiation which is modulated by B cell 
lymphoma 6 (BCL6) regulation (258). Another study using IL-9 knockout mice 
with oxazalone-induced colitis suggested the pathogenicity of Th9 subset as an 
important role in driving ulcerative colitis (375). Together, using mouse models, 
these studies have highlighted the current understanding for the role of IL-9 in 
various diseases.  
 
Using the eye as the model of inflammation in transgenic mice expressing anti-
hen egg lysozyme (HEL) TCR-specific T-cells, Tan et al., showed that after 
activation with HEL and antigen presenting cells (APC) in the presence of IL-4 
and TGF-β, IL-9 expressing Th9 cells were immunopathogenic in mice 
receiving Th9 cells via their lens (264). Tan et al., studied in greater detail the 
kinetics of IL-9 secretion relative to IL-10 secretion by Th9 cells in whole eyes. 
In 2015, the same group had also discovered that the TNF family cytokine TL1A 
promoted IL-9 producing T cells (Th9) by signalling through DR3 receptor, 
which resulted in a more severe form of ocular inflammation (153). However, to 
date, no published study has used a mouse model of AC to study the 
contribution of IL-9 and Th9 cells in ocular allergy. This chapter describes our 
study to detect the presence of IL-9 in AC and investigating which immune cells 
secrete IL-9, using the mouse model of the severe form of AC as developed by 
Schlereth et al (347). We hypothesise that IL-9 is contributing to the severity of 
the disease in this mouse model.  
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To address this hypothesis, the specific aims were as follows: 
1. To determine the expression of IL-9 in the conjunctiva and draining 
lymph nodes of mice with AC; 
2. To define the cellular source of IL-9 during disease in this model. 
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3.2. RESULTS 
 
 
3.2.1. OVA induced a clinically severe form of AC. 
 
In order to investigate the expression of IL-9, its cellular sources during disease 
and the functions of IL-9 in vivo, experiments were performed using a mouse 
model of AC. The C57BL/6 mice were sensitised and subsequently  topically 
challenged with OVA (376). Generally, OVA-challenged mice exhibited a 
clinically severe form of AC. Data shown in this chapter is a representative from 
three independent experiments that were performed at different times, unless 
stated otherwise. In each experiment, mice were divided into two different 
groups; 1) antigen-immunised mice topically challenged with OVA as EAC and 
2) antigen-immunised mice topically challenged with PBS (control); with each 
group consisting of 5 or more mice per group (n ≥5). 
 
EAC was induced in C57BL/6 mice, which were immunised with OVA together 
with alum and pertussis toxin and left for 21 days. After that time, the mice were 
challenged once daily with topical OVA for 7 days. In OVA-challenged mice, 
inflammatory responses were observed that mimic allergic conjunctivitis 
symptoms in man. Inflammatory responses in this model were recorded and 
scored according to a scoring system previously described (374); scoring the 
following symptoms; lid oedema, redness (hyperemia), itching and tearing.  
Mice were scored by two independent masked observers (Dr. Virginia Calder 
and Dr. Malihe Eskandarpour). EAC mice resulted in a more severe 
inflammation with higher total clinical score as compared to control mice 
(Figure 9). This experiment was recently repeated and data shown in Figures 
13 to 19 were provided by Dr. Malihe Eskandarpour. 
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Figure 9: Clinical scoring A. Clinical features of mouse eye in both control and 
EAC group B. Clinical scoring of control and EAC mice. Daily scores were 
based on lid swelling, tearing, redness and conjunctival oedema, ranges from 0-
3 for each symptom. Mice were scored by two independent masked observers 
and plotted as mean±SEM. 
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In order to analyse the histological changes in the eye during disease, 7-days 
post challenge, mice were sacrificed and whole eyes were enucleated, 
processed and embedded in paraffin. 5 μm thick sections were prepared and 
stained for haematoxylin and eosin (H&E) to identify nucleated cells in the 
tissue, allowing a good observation on the overall structure of the tissues and 
cell distribution throughout the tissue. As compared to controls, more cells were 
observed at the forniceal area of the conjunctival sections from EAC mice 
(Figure 10). There was a high number of cells at the forniceal area of the 
conjunctivae in EAC mice, suggesting that the conjunctivae of OVA-challenged 
mice were severely inflamed, which was supported with the inflammatory 
scoring data. In Figure 10, EAC slides were presented at different exposure 
than control slides due to the microscope automatic exposure setting that was 
initially set when obtaining the photos.  These photos were obtained on different 
days. 
 
In addition to H&E staining, tissue sections were stained with toluidine blue to 
determine the distribution of mast cells within the conjunctiva. The thiazine 
metachromatic dye in toluidine blue will stain acidic tissue components including 
mast cell granules. As observed in Figure 11, in control tissues, mast cells were 
mostly dispersed within the stromal region of the conjunctiva, however most of 
these positively stained mast cells were observed within the subepithelial layer 
of the conjunctiva of EAC tissues. Positively stained cells were counted within 
three separate fields (x400) and total numbers of positively stained cells were 
plotted in graphs (Figure 12). Significant increases in the levels of mast cells 
were observed in EAC tissues as compared to the control group (p<0.05).  
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Figure 10: H&E staining of conjunctival sections from control and EAC mice, 7 
day post challenge. Conjunctival fornix (B and D). Fewer cells visible at the 
forniceal conjunctiva in control challenged sections (A and B) as compared to 
more infiltrating cells that are visible (in dark purple) in EAC challenged 
conjunctiva (C and D). Images were taken with x200 (A and C) and x400 
magnification (B and D). Scale bar: 20µm. 
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Figure 11: Toluidine blue staining for mast cells on control and EAC tissue 
sections. Positive mast cells were stained deep blue as compared to other cells, 
A and C (x200); B and D (x400). Scale bar: 20µm. 
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Figure 12: Toluidine blue positive cells in control and EAC mice. Positive cells 
were counted from a total of 3 fields per sections for each mouse, and from 10 
mice per group. Data represented from one of two independent experiments 
and were plotted as mean±SEM. * p< 0.05 by Student’s t-test. 
 
 
3.2.2. Cell characterisation in the murine conjunctiva  
 
In order to analyse different cell types that are present in the mouse 
conjunctivae, most studies have used enzyme digestion of the fibrous layers of 
conjunctival tissues to allow single cells to be released into the medium for 
further analysis by flow cytometry. The aim of this study is to investigate the 
presence of different cell types during AC, including mast cells and CD4+T cells. 
However, mast cells and activated T cells have low viability and potentially may 
not survive a strong enzymatic conjunctival digestion process. Another way to 
isolate the single-cell suspension is by conjunctival explant, a method that is 
widely used to isolate and expand conjunctival epithelial and goblet cells in 
culture (377). Based on the methods used for conjunctival explants, this 
experiment was modified and optimised, tailoring to the aim of the experiment. 
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Briefly, small pieces of conjunctival tissues were left in supplemented medium 
with the addition of mast cell and T cell growth factors to support viability and 
create a concentration gradient that will encourage both mast cells and T cells 
to migrate out from the tissue into the medium. In our system, leaving these 
tissues in supplemented medium for 3 days was sufficient to obtain enough 
cells whilst maintaining >90% cell viability (based on trypan blue exclusion 
assay) for further cell staining. A similar method was also used by Miyazaki et 
al, where conjunctival tissue explants were left in supplemented medium for two 
days in order to isolate mast cells from the tissue (378). 
 
 
3.2.2.1 Gating strategy 
 
For repeat experiments and data presented in this chapter, cells were stained 
for flow cytometry and acquired on a BD LSRFortessa-x20 using FACSDiva, 
with compensation applied where necessary.  The data was analysed using 
FlowJo v10.  
 
Cells were first gated for all cells or lymphocytes. Subsequently, live cells were 
gated on an area which was negative to zombie NIR™ which binds to dead 
cells. In order to remove the doublets, live cells that appear at a perfect 
diagonal line (at 45 degrees, passing the zeros) when viewed in FSCH and 
FSCA were gated as single cells. Further gating was performed from a live 
single cell gate. 
 
In some samples, the numbers of cells were calculated using FACS counting 
beads which were added to each sample of 200µl. 
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3.2.2.2 Analysis of murine conjunctiva. 
 
In order to investigate the presence of mast cells in EAC conjunctiva, 
conjunctival cells were stained for mast cell markers, c-kit and FcεRI. Initial 
gates were applied as seen in figure 13 where all cells were selected, followed 
by live cells and the single cell gate. Further gates were drawn for c-kit and 
FcεRI respectively (Figure 14). In order to draw gates, a fluorescence minus 
one (FMO) control is needed. The FMO control includes cells stained with all 
the fluorophores minus one, and this is normally used to set the cut-off point 
between positive and negative gates. FMO is especially important for 
intercellular staining since there is no clearly defined population that can be 
seen during staining.  However, no FMO controls were acquired in this 
experiment due to initial experiment set up which did not include FMO controls 
and subsequent gates were not set using the FMOs. The percentages of mast 
cells (c-kit and FcεRI positive) increased significantly in EAC mice in 
comparison to control mice. This data also correlated with the levels of mast 
cells in the conjunctiva of these mice stained with Toluidine blue (Figure 12), 
where the levels of mast cells were significantly increased in EAC mice as 
compared to control. It is not possible to draw gates for CD4+ and ckit+ cells in 
one dot plot since markers for mast cells and T cells in the conjunctiva were 
stained in different tubes. 
 
Conjunctival cells were also stained for intracellular expression of IL-9. A 
representative FACS dot plot for c-kit+/IL-9+ cells from single cell gate is shown 
in Figure 15A. Significant increases in the levels of c-kit+/IL-9+ cell expression 
were observed in EAC as compared to controls (Figure 15B) suggesting that IL-
9 expression by mast cells might reflect a role for IL-9 in the ocular allergy in 
OVA challenged mice (P<0.005). Not all IL-9 positive cells are c-kit positive 
(mast cells) cells suggesting there could be IL-9-expressing cells within the 
conjunctival tissues which are not mast cells. To address this possibility, IL-9 
expression by conjunctival CD4+T cells was investigated. Similar experiments 
have been repeated by Dr. Malihe Eskandarpour after this data has been 
produced and through personal communication, she has confirmed similar 
results to the ones presented in this chapter.   
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Figure 13: Representative dot plot analysis for initial gating for cells from the 
conjunctivae of control and EAC mice. A. Initial gates around cells, followed by 
B. live cells and C., single cells. 
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Figure 14: Summary of total percentages of FcεRI and c-kit positive cells in the 
conjunctivae based on FACS plots, in 200l volumes of cells A. Representative 
FcεRI gating in both control (n=5) and EAC (n=5) mice with total percentage of 
FcεRI  positive cells shown in the far right graph B. Representative c-kit positive 
gating in both control and EAC mice with total percentage of c-kit positive cells 
shown in the far right graph. C. Representative double c-kit+ FcεRI+ dot plot 
from EAC conjunctiva. Data were plotted as mean±SEM from a representative 
from 3 experiments. * p< 0.05. Student’s t test was performed on this data. 
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Figure 15: Summary of IL-9 staining in c-kit positive cells. A. Representative of 
c-kit/+IL-9+ from single cell gate in control and EAC mice. B. Summary of total 
number of IL-9 positive, c-kit positive cells. Data were plotted as mean ± SEM 
from a representative from 3 separate experiments. * p< 0.005 by Student’s t-
test. 
In addition to conjunctival mast cell infiltration, the presence of CD4+T cells in 
the conjunctivae of allergic mice was also investigated. Based on the gating 
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strategy shown in Figure 16, the percentages and number of CD4+T cells 
increased significantly in EAC mice as compared to PBS challenged control 
group (Figure 16A) suggesting that CD4+T cells are involved in mediating the 
disease in EAC mice, ***p<0.0005.  
 
In order to investigate expression within these CD4+ T cells, conjunctival cells 
were also intracellularly stained for IL-9 and PU.1 (Figure 16B and C) and 
GATA3 (Figure 17). The levels of CD4+/IL9+ and CD4+/PU.1+ cells significantly 
increased in challenged mice *p<0.05 (Figure 16B and C). Representative of 
quadrant gates drawn from CD4+ cells looking at IL-9+/PU.1+ and IL-
9+/GATA3+ are also shown in Figure 17C and D. This data suggests that Th9 
and Th2 cells are involved in mediating the disease in EAC mice.   
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Figure 16: Representative dot plot analysis for CD4+T cells, CD4+ /IL-9+ cells 
and total PU.1+ cells on single cell suspension from the conjunctiva of PBS 
control and OVA challenged EAC mice. A. CD4+ gates and total percentages 
and total numbers of CD4+ cells as shown in graphs, B. CD4+/IL-9+ gates and 
total percentages of IL-9+ in CD4+ cells, C. PU.1 gates and total percentages of 
PU.1 positive cells in live cells. Data were plotted as mean±SEM from a 
representative from 3 independent experiments, *p<0.05, **p<0.005, 
***p<0.0005. Student’s t test was performed on this data. 
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Figure 17: Representative dot plot analysis for CD4+ cell in conjunctivae of 
control and EAC mice. Representative quadrant gates from single cell 
population for A. CD4+ vs IL-9+ cells, B. CD4+ vs IL-9+ cells. C. and D. show 
gates from CD4+ population. Representative of C. IL-9+ vs PU.1+ quadrant 
gates and D. IL-9+ vs GATA+ quadrant gates.  
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3.2.3. Cell characterisation in the murine draining lymph nodes.  
 
In order to investigate the different types of CD4+T cells that are present during 
disease, a single cell suspension from the draining lymph nodes from each 
mouse was prepared for intracellular cytokine staining. Similar to the 
conjunctiva, since this study aimed to investigate the different sources of IL-9 
during AC, cells were stained for different T cell subsets, Th2 and Th9. Different 
CD4+T cell subsets were distinguished based on their specific transcription 
factors and cytokine profiles. The Th2 cell lineage was identified by GATA3/IL-
4, whilst the Th9 cell lineage was identified by expression of PU.1 transcription 
factors and can be identified by PU.1/IL-9 positive cells. 
 
Based on size and granularity, cells were initially gated for lymphocytes (Figure 
18). Within the lymphocyte gate, the live cell gate was drawn around the APC 
Cy7 negative population before further selecting the single cell population when 
viewed as FSCH and FSCA. All further gates were drawn from the hierarchical 
single cell population based on clearly defines.  
 
There were similar percentages of CD4+T cells in draining lymph nodes of EAC 
mice as compared to control mice (Figure 19A). Within the CD4+ population, 
there was no significant difference in intracellular expression of IL-4+/GATA3+ 
cells of EAC mice and control mice (Figure 19C). However, levels of CD4+/IL-
9+/PU.1+ cells were significantly increased in EAC mice as compared to control 
(p<0.005). This data suggests that IL-9 expressed by Th9 cells, but not IL-9 
expressed by Th2 cells, might correlate with disease in this model. 
 
This experiment shows that in EAC mice, both IL-9 secreted by mast cells and 
Th9 cells could potentially drive the disease within the conjunctiva whilst IL-9 
secreted by Th9 cells, but not Th2 cells, could be pathogenic by exacerbating 
the disease by migrating from the lymph nodes to the conjunctiva.  
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Figure 18: Representation of FACS dot plot which shows the initial gates for 
draining lymph nodes in control and EAC mice. A., Initial gates were selected 
for lymphocytes and subsequently for live cells in B. Further gates for single 
cells (C) were selected from live cells gates.   
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Figure 19: Representation of flow cytometric analysis for Th2 and Th9 positive 
cells on the draining lymph nodes of control and EAC mice. Following single cell 
gates, A, Dot plot of CD4+ gates and summary of total percentages of CD4+ 
cells shown in graph. B, Dot plot of CD4+/IL9+/PU.1+ gates and summary of 
total percentages of IL9+/PU.1+ in CD4+ cells shown in graph. C, Dot plot of 
CD4+IL4+GATA3+ gates and summary of total percentages of IL-4+/GATA3+ 
in CD4+ cells shown in graph Data were plotted as mean±SEM from a 
representative from 3 independent experiments. ** p< 0.005. Student’s t test 
was performed on this data. 
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3.3. DISCUSSION 
 
Since, at the time of this study, there was no evidence to suggest that IL-9 is 
upregulated in AC, we first used a mouse model to study the presence and the 
contribution of IL-9 in EAC. Animal models have been extensively used to study 
mechanisms of disease, some studies have highlighted the importance of 
different signalling molecules, chemokines, inflammatory cells and mediators in 
AC, but very few have focused on the role of cytokines, especially the role of IL-
9, in AC mouse models. 
 
Firstly, there is one main technical issue which should be addressed when 
presenting results in this chapter. As previously mentioned, there are no FMO 
controls to set the gates during analysis. FMO controls are essential especially 
in setting gates for intracellular cytokine staining where cytokines can be 
partially expressed in cells with no obvious positive population to be seen. All 
gates in this chapter were set not based on FMO controls since no FMO 
controls were included during experiment setup. 
 
The initial aim of this chapter was to investigate the presence of IL-9 in the 
conjunctival tissues of the mouse models. During innate immune responses, 
mast cells are known to be one of the first cells that respond to allergen on the 
surface of conjunctival tissues. The initial mast cell responses then result in 
further recruitment of inflammatory cells, including CD4+T cells that are 
responsible for adaptive immune responses and prolonging allergic reactions. 
Since both mast cells and CD4+T cells can express IL-9, this experiment 
investigated the presence of IL-9 in mast cells and in CD4+ T cells within the 
conjunctivae of AC mouse models. 
 
To date, this is the first study to investigate mast cells secreting IL-9 in the 
conjunctiva in a mouse model of AC.  Based on this study, mast cells 
expressing IL-9 were significantly upregulated in EAC mice compared to 
controls. Chen and colleagues showed that IL-9 producing mucosal mast cells 
(MMC) promoted IgE-mediated food allergy both in mice and humans (379). 
This data is also supported by other studies. IL9/IL-9R signalling is shown to be 
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important in mediating IgE-dependent oral and systemic anaphylaxis in mouse 
models (336,380).  
 
Since CD4+ T cells regulate late phase responses during AC (381), a significant 
increase was observed in the levels of CD4+ T cells in the conjunctivae of OVA-
challenged mice.  The data also shows that IL-9 secreted by Th2 and Th9 cells 
was significantly upregulated in the conjunctivae of EAC mice as compared to 
control mice. In a recent study, Tan and colleague showed that Th2 and Th9 
cells that were adoptively transferred to recipient mice migrated to the 
conjunctiva and initiated allergy-like inflammatory responses (382) which 
support data presented in this chapter that Th2 and Th9 can drive allergic 
responses in the eye. As most studies have investigated the role of CD4+ T 
cells during disease by investigating the lymph nodes, subsequent experiments 
were performed by staining CD4+ T cells in the draining lymph nodes. 
 
In order to identify the CD4+ T cell region in the conjunctivae, besides CD4, 
extra surface markers including CD3 and CD45 can be useful in selecting CD45 
lymphocyte populations followed by CD4- and CD3- positive gates. An initial 
region of CD45+ cells to gate all lymphocytes can be then followed by CD4+ and 
CD3+ gates. However, in some cell samples, I have managed to stain for CD3 
and CD45 and, by backgating the plots, cells selected for CD4 expression are 
also positive for both CD3 and CD45, suggesting that selected CD4+ cells are 
lymphocytes (data not shown). Besides Th2 and Th9 cells, it will also be useful 
to be able to distinguish other cell types that secrete IL-9 in both conjunctivae 
and draining lymph nodes including ILCs, given that ILC2 cells are known to 
secrete high levels of cytokines including IL-9 and the role of ILC2 and IL-9 
during AC has not yet been explored. In order to test this aim, more antibodies 
need to be included in this antibody panel.  
 
Th2 cells are known to be involved in allergic hypersensitivity, including ocular 
allergy. During allergic hypersensitivity, the Th2 cytokine IL-4 plays many 
different roles including regulating B cell IgE production (383). In our 
experiments, we investigated the presence of Th2 cells and the possibility of 
Th2 cells as a source for IL-9 in AC. The data suggests that when using Th2 
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cell transcription factor GATA3 as a marker of Th2 cells, there is a significant 
increase in the levels of Th2 cells in the conjunctivae of EAC mice but no 
difference in the level of Th2 positive cells in the draining lymph nodes of EAC 
as compared to control mice. Schlereth et al have also reported similar findings 
on Th2 cytokine secretion using this same OVA model, by measuring the level 
of Th2 cytokines (IL-4, IL-5 and IL-13) in the supernatants of the recall 
stimulated lymph nodes from these mice (347). Since Th2 T cells are 
upregulated in the conjunctiva, but not in the draining lymph nodes of EAC 
mice, it suggests that Th2 cells play a role in driving AC.  
 
Besides Th2 cells, Th9 cells were initially thought to be the main source of IL-9. 
However, a recent study found that innate lymphoid cells-2 (ILC2) secrete most 
Th2 cytokines, including IL-9 (127). IRF4 and PU.1 transcription factors are 
important in driving CD4+T cells to differentiate into Th9 cells. IRF4 is important 
during Th9 cell differentiation in which IRF4 levels were upregulated after T cell 
stimulation (384) and T cells cannot differentiate into Th9 cells in IRF4-deficient 
T cells (147). Another study characterised Th9 cells as CD4+/PU.1+/IL-9+ since 
the PU.1 transcription factor controls the transcription of Il9 gene and Th9 
differentiation (251). In this study, Th9 cells were significantly upregulated in 
both conjunctivae and draining lymph nodes of EAC mice as compared to 
control mice, suggesting that Th9 cells play important roles in the pathogenesis 
of the disease.  Th9 cells have been shown to be upregulated in several 
diseases including allergic asthma, food allergy, inflammatory bowel disease, 
and multiple sclerosis (239,304,375,385,386). 
 
In addition, this study has also shown that IL-9 secreted from mast cells in the 
conjunctivae can also be contributing to the disease in mice. Since mast cells, 
producing IL-9 in the conjunctivae also contribute to the pathogenesis of AC, 
further in vitro experiments on IL-9 functions in mast cells will be presented in 
the next chapter. 
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CHAPTER 4 
 
Mast cells as IL-9 producers and responders in vitro. 
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4.1. INTRODUCTION 
 
 
IL-9 is a pleiotropic cytokine that exerts heterogeneous effects on different cell 
types (as outlined in Chapter 1). For mast cells, IL-9 promotes their proliferation, 
activation, protease expression and also upregulates IgE receptor expression 
on the surface of mast cells. Apart from its effects on T cells and mast cells, IL-9 
also exerts effects on epithelial cells; decreased mucus secretion in the lungs 
has been observed in mice with allergic hyperresponsiveness treated with 
neutralising anti-IL-9 antibody (387). The effects of IL-9 on lung epithelium (for 
example mucus production) could also occur due to the indirect effects of IL-13 
(388). In addition, IL-9 enhances IL-4-mediated IgE and IgG production from 
human B cells (388). Despite many groups researching the roles of IL-9, the 
effect of IL-9 on other cytokine networks has not yet been thoroughly 
investigated. 
 
As mentioned previously in chapter 1, IL-9R is a heterodimeric protein 
composed of specific IL-9Rα chain and γ chain, the common subunit of which is 
shared with different cytokine receptors including IL-7. IL-9R binding activates 
signal transducer and activator of transcription-1 (STAT-1), STAT-3 and STAT-5 
(292,389). IL-9R was found to be expressed on the surface of mast cells and 
polymorphonuclear cells (390,391)  
 
Although IL-9 is not thought to be important in mast cell accumulation in 
bronchial tissues, IL-9 is important for promoting mast cell growth and functions 
(238). Wiener and colleagues found that IL-9 secretion by mast cells was 
upregulated in the presence of IL-9, SCF and IL-1β, suggesting that IL-9 
secreted by mast cells works in a positive feedback loop (279). Another study 
has found that IL-9 can also act as a growth enhancer together with SCF in 
human mast cells (238). 
 
Having detected IL-9 expression in mouse conjunctival tissues (chapter 3), it 
was important to identify the contribution of mast cell-derived IL-9 to mast cell 
responses. Hence, in this chapter, bone marrow-derived mouse mast cells 
(BMMC) were used to further investigate the role of IL-9 on mast cell 
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responses. The reasons for using mouse mast cells are several: they can be 
expanded in sufficient numbers for experimental studies; they share similar 
characteristics to human mast cells, as both of these cells express both FcεRI 
and c-kit on their surface; they are characterised by their FcεRI surface receptor 
expression. Other cells that also express FcεRI include basophils. However, 
only mast cells express both FcεRI and c-kit.  These mouse mast cells also 
require both IL-3 and SCF (392) to proliferate and differentiate into mature mast 
cells. Previous studies used the RBL-2H3 cell strain to mimic real mast cell 
stimulation in vitro (393,394). However, this is a rat basophilic leukaemia cell 
line, which does not exhibit the full characteristics of mast cells. Other mouse 
mast cell lines including CTFL-15 and MCP 5/L also express high affinity IgE 
receptor alpha chain but they have relatively immature mast cell phenotypes 
(395). Hence, using primary BMMC is thought to be the best in vitro model to 
study mature mast cell functions, as these cells are relatively easy to proliferate 
in abundance.  
 
In this chapter, three different types of stimulation were initially used to stimulate 
BMMC; PMA and ionomycin stimulation, ionomycin stimulation alone and a 
physiological stimulant, anti-IgE. These stimulations work in different ways. 
PMA is a small organic compound which diffuses through the cell membrane to 
the cytoplasm and directly activates Protein Kinase C (PKC), causing 
degranulation. Cell degranulation via PMA stimulation omits the need for cell 
surface receptor stimulation. Ionomycin, a calcium ionophore, on the other hand 
triggers calcium release to promote exocytosis of granules, which is needed for 
nuclear factor for T cell (NFAT) signalling during degranulation. Ionomycin can 
be used as an addition to PMA stimulation in order to achieve maximal 
degranulation or it can be used on its own as a stimulant. Ca2+ responses 
coupled with PKC activation are essential for mast cell degranulation (396,397).  
 
Anti-IgE antibody stimulation is a more physiologically relevant stimulant as it 
involves IgE ligand binding to specific FcεRI surface receptor on mast cells. IgE 
crosslinking activates a series of biochemical events which is regulated by 
NFAT (398) that leads to the release of preformed mediators from granules and 
the generation of newly synthesized mediators. FcεRI is a tetrameric formed by 
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the complex αβγ2 chains of which is activated by the activation of non-receptor 
protein tyrosine kinases. Once aggregated, a series of phosphorylation of 
kinases downstream of FcεRI leads to release of Ca2+ from endoplasmic 
reticulum (ER) resulting in a decrease of free Ca2+ from the ER. When ER Ca2+ 
stores are depleted, more Ca2+ influxes across the plasma membrane result in 
activation of calcineurin which in turn dephosphorylates NFAT, which is 
responsible for regulating the transcription of several cytokine genes. FcεRI 
stimulation also activates phosphorylation and degradation of inhibitor IκB, 
which allows the release of NFκB via nuclear translocation in order to activate 
genes which are responsible for the synthesis of several cytokines.  
 
Several previously mentioned studies have highlighted the role of IL-9 in mast 
cell functions (279,328,399). Mast cells clearly play important roles in 
contributing towards innate and adaptive immunity in several acute and chronic 
diseases including allergy, due to their ability to secrete many different 
proinflammatory cytokines including IL-9. However, these studies have not 
focussed on the effect of IL-9 on other mast cell functions such as histamine 
secretion and cytokine secretion; especially, proinflammatory Th2 cytokines (IL-
4, IL-5 and IL-13) which are commonly associated with allergic diseases 
including ocular allergy. Since in the previous chapter (Chapter 3), it was found 
that IL-9-expressing conjunctival mast cells are upregulated in the EAC mouse 
model as compared to PBS-challenged controls, we wished to further 
investigate the effect(s) of IL-9 on mast cells in vitro, using BMMC. The 
hypothesis of this chapter is that IL-9 upregulates Th2 cytokine (IL-4, IL-5 and 
IL-13) and histamine secretion by mast cells in vitro. 
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To address this hypothesis, the specific aims were as follows: 
 
1. To establish cultures of differentiated, purified mouse bone marrow-
derived mast cells in vitro; 
2. To utilise these cells to determine the effects of IL-9 and IL-9R on mast 
cell expression of FcεRI. 
3. To determine the effects of IL-9 and IL-9R on mast cell degranulation; 
4. To determine the effects of IL-9 and IL-9R on mast cell secretion of 
cytokines. 
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4.2. RESULTS 
 
Given that levels of IL-9 expressing mast cell levels were significantly increased 
in the conjunctival tissues of allergic conjunctivitis mice relative to controls, the 
aim of this chapter was to investigate the effects of IL-9 on mast cell functions in 
vitro. In this chapter, BMMC were used for all in vitro experiments.  
 
4.2.1. Phenotypic characterisation of BMMC 
 
After 4-5 weeks in culture, BMMC were stained for c-kit (stem cell factor 
receptor) to characterise the cells. Cells were considered to be mature mast 
cells only when they were >95% c-kit positive (Figure 20). The maturation 
status of the mast cells was also characterised by its FcεRI expression (>95% 
FcεRI expression). Once the mast cells are mature they are then ready to be 
used for experiments. 
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Figure 20: Phenotypic characterization of BMMC after 4-5 weeks in culture. A. 
Forward and side scatter (FSC, SSC) of single population of live cells, 
containing the mast cells (R1)(A). FACS plot of c-kit and FcεRI staining showing 
double positive c-kit+/FcεRI+ mast cells in the upper right-hand quadrant (R6) 
(B).   
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4.2.2. BMMC viability 
 
 
BMMC were also stained with propidium iodide (PI) in order to determine the 
percentage of dead cells (staining positively for PI) in the cell culture flask. 
Approximately 99% of cells were shown to be live cells (Figure 21) and this is 
also similar when the cells were counted under the microscope with trypan blue 
exclusion staining, which will stain dead cells blue (data not shown). BMMC 
viability was checked weekly when in culture and each time prior to conducting 
experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: BMMC Viability staining with PI. Cells were stained with propidium iodate 
(PI) in order to determine the percentage of live cells before experiments were 
performed. Representative FACS plot and gating strategy for dead cells in BMMC 
culture. Cells stained with PI can be viewed in a. Dead cells (blue dots) were 
observed in FCS vs SSC scatter plot (b). 
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4.2.3. Functional BMMC characterisation 
 
 
Once the cultured cells were phenotypically confirmed to be fully differentiated 
mast cells, these cells were then compared for their ability to release histamine 
following ionomycin stimulation or FcεRI crosslinking relative to unstained 
controls (Figure 22). Cells stimulated with ionomycin secreted significantly 
increased levels of histamine (P<0.005), whilst anti-IgE stimulation also resulted 
in increased levels of histamine although the changes did not reach 
significance. Anti-IgE stimulation did not significantly increase levels of 
histamine relative to controls, which could be due to the IgE stimulation not 
properly working in this setting. These cells were then used for further 
experiments.  
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Figure 22: Histamine secretion (mean ± SEM) at 24 hours post 
ionomycin or anti-IgE stimulation. Cells were used for further in vitro 
experiments once their ability to secrete histamine had been confirmed 
by histamine ELISA. Data reflect one of four experiments (n=4)  
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4.2.4. EFFECTS OF IL-9 ON BMMC FUNCTION 
 
 
4.2.4.1. Effects of functional blocking of IL-9 on histamine secretion  
 
 
Since histamine is one of the earliest mediators released by mast cells upon 
stimulation and histamine is largely stored preformed in mast cell granules, the 
effect of IL-9 on histamine secretion was investigated. IL-9 had previously been 
shown to increase histamine release by BMMC in response to ionomycin and 
IL-9 stimulation (279). In that study, Wiener and colleagues used histamine-free 
mast cells from transgenic mice to further study the relationship between IL-9 
and histamine. They concluded that IL-9 production by mast cells might act in a 
positive feedback loop and that a lack of histamine can disturb this loop. 
Another group has also confirmed that IL-9 increased histamine release from 
mast cells in mice treated with IL-9 (399). Based on this evidence, the effects on 
histamine secretion upon blocking IL-9 or IL-9R in response to PMA and 
ionomycin, ionomycin alone or FcεRI crosslinking were investigated in this 
chapter. 
 
4.2.4.2. Anti-IL-9 and anti-IL-9R antibody optimisations 
 
Throughout this chapter, three different types of mast cell stimulation will be 
used; PMA+ionomycin, ionomycin alone and anti IgE stimulation. PMA activates 
protein kinase C and in the presence of ionomycin (which In this calcium 
ionophore), it becomes a strong cell stimulus for mast cell degranulation. Anti-
IgE stimulation is a more physiological stimulus, requires IgE crosslinking of cell 
surface IgE receptors to cause downstream activation and signalling which 
activate mast cells and only causes partial mast cell degranulation.  
 
In order to identify the optimal working concentration for mouse anti-IL-9 mAb in 
vitro, antibody was titrated at different concentrations; 8, 9, 10µg/ml (according 
to the manufacturers’ instructions). In this preliminary experiment, histamine 
secretion was measured in response to PMA+ionomycin stimulation in the 
presence of different concentrations of anti-IL-9 mAb. Histamine secretion was 
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downregulated in cells treated with all concentrations of anti-IL-9 mAb (Figure 
23) but the lowest level of histamine was detected in cells treated with 9µg/ml of 
anti-IL-9 mAb. Hence, further subsequent experiments were done using this 
concentration of anti-IL-9 mAb.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Since PMA combined with ionomycin is a very potent stimulus, causing mast 
cells to release very high levels of histamine and cytokines, subsequent 
experiments were performed by stimulating cells with either ionomycin alone or 
with FcεRI cross-linking. Based on previous experimentation using 
PMA+ionomycin stimulation, histamine was maximally secreted at 72 hours 
post-stimulation, and the larger difference on histamine levels was observed at 
48 hours post stimulation; hence, the following experiments measuring 
histamine release were repeated up to 48 hours post-stimulation.  
Figure 23: Histamine secretion in BMMC supernatants following 
PMA+ionomycin stimulation treated with different concentrations of anti-
IL-9 mAb for 120 hours (5 days). Data shown as mean ± SD from 
triplicate wells from a single preliminary experiment. 
0 24 48 72 96 120
0
200
400
600
800
Hours after stimulation
H
is
ta
m
in
e
 s
e
c
re
ti
o
n
 n
g
/m
l
PMA+iono+ 8µg/ml anti IL-9
PMA+iono+ 9µg/ml anti IL-9
PMA+iono+ 10µg/ml anti IL-9
PMA+iono
PMA+Ionomycin
H
is
ta
m
in
e
 s
e
cr
e
ti
o
n
 (
n
g
/m
l)
 
PMA+io 8µg/ml mAb anti IL-9 
P i no+9µg/ml Ab anti-IL-9 
P iono+10µg/ml Ab anti-IL-9 
 123 
 
 
 
In order to find the optimal working concentration of anti-IL-9R mAb 
concentration, BMMC were treated with different concentrations of anti-IL-9R (5, 
10, 20µg/ml) prior to stimulation with ionomycin and anti-IgE, relative to an IgG 
control. Histamine secretion was downregulated in cells treated with all 
concentrations of anti-IL-9R mAb, with 5µg/ml and 10µg/ml doses inducing the 
most profound effects on histamine release (Figure 24). 
 
The most striking effect on histamine secretion was observed at 48 hours 
(Figure 24) where histamine levels were downregulated in cells treated with 
neutralising antibody as compared to untreated (stimulated) cells with isotype-
matched control antibodies. Histamine secretion decreased when IL-9 function 
was neutralised (in PMA with ionomycin-stimulated cells, figure 23) and a 
similar effect was observed when blocking IL-9R (in ionomycin-stimulated cells, 
figure 24). Since the maximum inhibitory effects on histamine release were 
seen with adding 10µg/ml of anti-IL-9R mAb to mast cell cultures (Figure 24a 
and b), this concentration was used in all subsequent experiments. Figure 24c 
shows that adding anti-IL-9R antibody significantly downregulated histamine 
levels at 48 hours post ionomycin and anti-IgE stimulations, p<0.05; p<0.005.  
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Figure 24: Histamine secretion upon a. ionomycin and b. anti-IgE stimulation in 
BMMC supernatants treated with anti-IL-9 (9µg/ml) and different concentrations 
of anti-IL-9R. c. Summary of histamine secretion treated with 10μg/ml of anti-
IL-9R at 24 and 48 hours post stimulation. Values were plotted as mean ± SD 
of triplicate wells from one experiment in a and b whilst values in c were plotted 
as mean ± SEM from a total of 3 independent experiments, *p<0.5, **p<0.005. 
Student’s t test was performed on this data. 
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4.2.4.3. Anti IL-9R antibody downregulates surface FcεRI receptor 
expression in BMMC. 
 
Once both anti-IL-9 and anti-IL-9R mAbs were optimised in the BMMC assays, 
we investigated the effects of these antibodies on mast cell functions.  
 
Firstly, the effect of IL-9 on FcεRI expression in BMMC was investigated. A 
previous study by Lora et al. demonstrated the differential effects of Th2 
cytokines (including IL-9) on FcεRI expression on human mast cells (400). 
Hence, further experiments aimed to investigate the effect of IL-9 alone on 
FcεRI expression after stimulating the mouse BMMC via FcεRI cross-linking (by 
adding anti-IgE mAb). BMMC were subsequently stained for surface FcεRI and 
the percentages of FcεRI-positive cells were obtained by flow cytometric 
analysis. Median fluorescence intensity (MFI) of FcεRI positive cells were 
calculated and then normalised relative to stimulated cells without treatment at 
each time point (Figure 25b).  
 
MFI of FcεRI expression on the BMMC cell surface from flow cytometric 
histogram plots were analysed at 24, 48 and 72 hours post stimulation (Figure 
26). The level of FcεRI expression was initially upregulated after 24 hours of 
anti-IL-9R mAb treatment as compared to stimulated cells with no treatment. 
However, after 48 and 72 hours post anti-IgE stimulation, the level of FcεRI 
expression on the surface of BMMC showed downregulated trend as compared 
to anti-IgE stimulated control cells even though these levels did not reach 
significance. 
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Figure 25: Gating strategy for FCεRI positive cells. a. Representative FACS dot 
plot of single population in BMMC viewed in FSC vs SSC. b. Representative of 
gating on FCεRI positive cells (FL4-H).  
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4.2.5. Effect of functionally blocking IL-9 on cytokine secretion  
 
Mast cells are known to secrete a range of cytokines upon stimulation. Since 
previous experiments have shown that exogenously added IL-9 can upregulate 
histamine secretion by mast cells, the effect of IL-9 on other cytokines produced 
by BMMC was investigated.  
 
4.2.5.1. Cytokine secretion upon BMMC stimulation.  
 
In order to establish a cytokine secretion profile for BMMC, a panel of cytokines 
(IL-4, IL-5, IL-9, IL-10 and IL-13) was chosen for multiplex bead arrays to detect 
simultaneous secretion in BMMC culture supernatants, comparing mast cells 
Figure 26: Relative FCεRI MFI by anti-IgE-stimulated cells upon treating with 
either IL-9 or IL-9R (a). antibodies over 72 hours post stimulation. Data was 
normalised relative to stimulated cells with no treatment (a-IgE) at each time 
point. Normalised values were calculated as 2^
-(x) 
with x= y-z; y= % of 
stimulated cells without treatment; z= % of stimulated cells with treatments. 
Normalised values were representative from three independent experiments.  
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either unstimulated (in the presence of isotype-matched control antibodies) or 
stimulated with PMA+ionomycin, ionomycin or anti-IgE (DNP-BSA) (Figure 27). 
 
IL-9 was secreted in response to all modes of stimulation. Since PMA and anti-
IgE stimuli (which cross-links FcεRI surface receptors) induced an immediate 
release of secretory granules from mast cells as compared to ionomycin 
stimulation, which triggers calcium release needed for NFAT signalling, the time 
courses of IL-9 secretion in response to ionomycin alone, PMA+ionomycin and 
anti-IgE stimulated cells are different. 
 
In response to PMA+ionomycin or ionomycin stimulation alone, BMMC secreted 
IL-4, IL-5, IL-9, IL-10 and IL-13. However, following anti-IgE stimulation, much 
lower levels of these cytokines were detected. Ionomycin (a Ca2+ ionophore) 
stimulation resulted in exocytosis of granules in an all-or-none process whereas 
cell surface stimulation via FcεRI crosslinking induced only a partial degree of 
degranulation (401), explaining the reduced levels of cytokines secreted by 
mast cells in response to IgE crosslinking. Even though anti IgE stimulation can 
be very limited in the amount of secreted mediators, it is more physiologically 
relevant since this type of stimulation can also be observed in response to 
allergen exposure in man. Nevertheless, significant increases in cytokine 
secretion were detected in response to each mode of BMMC stimulation, 
relative to unstimulated BMMC. 
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Figure 27: Cytokine secretion (IL-4, IL-5, IL-9, IL-10 and IL-13) from 
supernatants of BMMC stimulated with PMA+ionomycin, ionomycin alone and 
anti-IgE over 120 hours (5 days) post-stimulation with pma+ionomycin and over 
72 hours post stimulation with ionomycin or anti-IgE. For PMA+ionomycin 
stimulation, data were plotted in means ± SD of triplicate wells from one 
representative experiment. For ionomycin and anti-IgE stimulation (b and c), 
data were plotted in means ± SEM from a total of 3 independent experiments, 
*p<0.05, **p<0.005. Student’s t test was performed at each individual time 
point. 
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The effects of different stimuli were also observed in more detail at 24 hours 
post stimulation, as shown in Figure 28. IL-4, IL-5 and IL-13 were significantly 
upregulated 24 hours post stimulation by ionomycin; p<0.05, p<0.005 (Figure 
28b). Although cytokines were secreted at lower levels in anti-IgE stimulated 
cells, all cytokines IL-4, IL-5, IL-9, IL-10 and IL-13 were significantly upregulated 
24 hours post stimulation with anti-IgE (Figure 28c).  
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Figure 28: Cytokine secretion in BMMC 24 hours post stimulation with a. PMA and 
ionomycin, b. ionomycin and c. anti-IgE crosslinking. Data were plotted in means ± 
SD from triplicate wells from a preliminary experiment in a. For ionomycin and anti-
IgE stimulation (b and c), data were plotted in means ± SEM from a total of 3 
independent experiments, *p<0.05, **p<0.005. Student’s t test was performed on this 
data. 
 
 132 
 
 
4.2.5.2. Blocking IL-9 and IL-9R with neutralising antibodies affects 
cytokines secreted from BMMC  
 
After confirming that IL-9 is secreted by BMMC upon degranulation in response 
to a range of different stimuli, this in vitro model was used to further investigate 
the effect of IL-9 on cytokine secretion by BMMC. Upon neutralising IL-9 
function using a neutralising mouse anti-IL-9 mAb (described in Chapter 2 of 
this thesis) in PMA+ionomycin treated cells in comparison with cells treated with 
an isotype-matched control Ab, both IL-4 and IL-13 secretion increased 
markedly in those wells in which IL-9 function had been neutralised (Figure 29). 
This preliminary experiment was performed only once, and further experiments 
were undertaken using ionomycin and anti-IgE stimulation.  
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Figure 29: Time course of cytokine secretion in PMA+ionomycin stimulated cells 
treated with neutralizing anti-IL-9 antibody over 120 hours (5 days). Values were 
plotted as mean ± SD of triplicate wells from one experiment. 
 
 134 
 
 
The levels of cytokines secreted in response to PMA and ionomycin stimulation 
were very high, and often they exceeded the values within the standard curve of 
the multiplex bead array hence, the values were read after extrapolating the 
standard curve and some values exceeded those extrapolated from the 
standard curve. Since the levels of cytokines were too high to be assayed by 
multiplex bead arrays in PMA and ionomycin stimulated cells, the levels of 
cytokines were assayed in cells treated with only ionomycin in order to 
determine the effects of neutralising the functions of both anti-IL-9 and anti-IL-
9R in BMMC cultures (Figure 30). The most obvious effect was seen in anti-IL-
9R mAb-treated mast cells. Upon blocking IL-9R function, all cytokines (IL-4, IL-
5, IL-9, IL-10 and IL-13) were markedly reduced at 48 and 72 hours after which 
time these levels increased again. It appears that blocking IL-9R function with 
anti-IL-9R antibody resulted in reducing cytokine production by BMMC. 
However, this effect did not last beyond 72 hours’ stimulation, possibly due to 
degradation of the anti-IL-9R antibody (which was added 30 minutes prior to 
stimulation) or internalisation of the anti-IL-9R antibody after 3 days in culture.  
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Figure 30: Cytokines secretion in ionomycin stimulated cells treated with anti-
IL-9 or anti-IL-9R antibody. Cells treated with anti-IL-9 (green) downregulated 
the level of IL-4, IL-5, IL-9, IL-10 and IL-13 at 48 and 72 hours post ionomycin 
stimulation. Cytokine levels increased again at 96 hours post stimulation 
suggesting that the effects of anti-IL-9R antibody diminished after 72 hours post 
stimulation. Values were plotted as means of duplicate wells from a single 
preliminary experiment. 
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Subsequent experiments were repeated up to 72 hours post stimulation when 
the maximum differences in cytokine levels were observed. Blocking IL-9R 
significantly decreased levels of IL-4, IL-5, IL-10 and IL-13 secreted at 48 and 
72 hours (p<0.05, p<0.005) (Figure 31).  
 
However, in anti-IgE stimulated mast cell cultures, neutralising both IL-9 and IL-
9R did not affect other cytokines secreted, although IL-9 levels in cells treated 
with anti-IL-9R were significantly reduced (*p<0.05) (Figure 32). The levels of 
cytokines were very low, suggesting that the IgE stimulation was not potent 
enough to be used to investigate the effects of IL-9 and IL-9R neutralising 
antibodies on cytokine secretion in BMMCs. It is also possible that the levels of 
cytokines were very low due to IgE stimulation not working optimally. 
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Figure 31: a. Cytokine expression profile of ionomycin stimulated BMMC over 72 
hours post stimulation with ionomycin. Downregulation of cytokine secretion was 
observed in cells treated with anti-IL-9R antibody, but not in cells treated with anti-
IL-9 antibody. Mean ± SEM from 3 independent experiments (n=3) is shown b. 
Summary of all cytokine levels at 72 hours on a log scale (pg/ml). *p<0.05, 
**p<0.005. Student’s t test was performed at each time point. 
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Figure 32: a. Cytokine expression profile of anti-IgE stimulated BMMC over 72 
hours post stimulation with anti-IgE. Downregulation of IL-4 secretion was 
observed in cells treated with anti-IL-9R antibody, but all other cytokines were 
unaffected by treatment with anti-IL-9R or anti-IL-9 antibodies Mean ± SEM 
from 3 independent experiments (n=3) is shown b. Summary of all cytokine 
levels at 72 hours (pg/ml). *p<0.05. Student’s t test was performed at each time 
point 
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4.2.5.3. Reversing the inhibitory effects of anti-IL-9 and anti-IL-9R 
neutralizing antibodies in vitro with IL-9.  
 
 
In order to confirm that the effects of blocking IL-9R with mouse neutralizing IL-
9R antibodies in BMMC were in fact due to an IL-9-specific inhibition, rescue 
experiments were done where anti-IL-9R mAb was added to BMMC culture 10 
minutes prior to ionomycin stimulation. These cells were then treated with 
mouse recombinant IL-9 (mrIL-9), 30 minutes after antibodies and ionomycin 
stimulation were performed.  
 
4.2.5.3.1. Histamine secretion 
 
Histamine levels were measured in BMMC supernatants from this reconstitution 
(rescue) experiment. Previous experiments showed that adding anti-IL-9R 
antibody downregulated histamine secretion. The mIL-9 was first titrated at 
different concentrations in order to find the optimum concentration that was able 
to reverse the decrease of histamine levels to normal levels. As expected, by 
adding mIL-9 to ionomycin stimulated cells, histamine levels increased 
markedly (blue bar) as compared to stimulated cells (Figure 33). At 48 hours 
post ionomycin stimulation, cells treated with mIL-9 at different concentrations 
(0.01, 0.05 and 0.1ng/ml) secreted histamine at similar concentrations as the 
cells that were stimulated with only ionomycin. The ability of histamine secretion 
in anti-IL-9R antibody-treated BMMC to return to baseline levels (ionomycin 
stimulated cells) after rescuing with mrIL-9 suggests that the downregulation of 
histamine secretion was a specific effect of IL-9 due to the effects of the anti-IL-
9R neutralizing antibody treatment.  
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4.2.5.3.2. Cytokine secretion. 
 
BMMC supernatants from the rescue experiments were also assayed for 
cytokine secretion. Cells rescued with rIL-9 which had previously been treated 
with anti-IL-9R mAb, secreted similar levels of IL-4, IL-5, IL-10 and IL-13 as 
control treated cells after 72 hours post stimulation with ionomycin (Figure 34). 
However, IL-9, IL-10 and IL-13 levels were significantly upregulated at 48 and 
72 hours post stimulation in cells treated with anti-IL-9 mAb as compared to 
stimulated cells as control. 
 
This experiment was able to demonstrate that cytokine secretion in rescued 
cells treated with anti-IL-9R antibody returned to the baseline level (cytokine 
secretion in response to ionomycin stimulation) and this could support previous 
results described in Figure 31 and 32 of this chapter which showed that 
blocking IL-9R downregulate mast cell cytokine secretion. 
Figure 33: Histamine secretion after rescuing with mIL-9. Histamine level in the 
supernatants returned back to the baseline level after rescuing BMMC with 
different concentrations of mIL-9. Data shows values in mean ± SD represented 
from 2 independent experiments.  
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 Figure 34: Cytokine secretion level in BMMC supernatants after rescuing with 
mIL-9 over 72 hours post ionomycin stimulation. As compared to ionomycin 
stimulated cells, cytokine levels in cells treated with anti-IL-9 and anti-IL-9R 
antibodies remain lower and higher respectively and failed to return to baseline 
(ionomycin stimulated cells) after rescuing with mIL-9. All data are shown as 
mean±SEM from 2 independent experiments. 
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4.2.5.4. The effects on histamine and cytokine secretion by blocking il9 
and il9r gene expression in mast cells. 
 
 
In addition to inhibitory antibodies, another approach to demonstrate that IL-9 
functions via IL-9R on the mast cell surface would be to block IL-9 and its 
receptor at the gene level. This could be achieved by using silencing RNA gene 
specific to IL-9 or IL-9R.  This section will discuss in more detail the results from 
silencing RNA gene experiments to validate previous data on the effects of 
blocking IL-9R on mast cell functions.  
 
4.2.5.4.1. Optimising the gene transfection. 
 
Most gene transfection studies have used cell lines transfected with the gene of 
interest (402,403) and very few studies have used primary cells, in particular 
BMMC. A study by Zhang et al used BMMC to investigate the effect of silencing 
mouse phosphatase gene (404). Based on the protocol from that study, the first 
thing I did was to optimise the duration of transfection. The aim was to achieve 
a maximum silencing of the gene and to determine the level of silenced gene 
expression by means of quantitative PCR.  
 
After 24 hours post siIL-9 gene transfection (Figure 35), relative to the 
scrambled control, the level of il9r was reduced by 30% in siIL-9 transfected 
cells whilst in cells transfected with siIL-9R, il9r expression decreased by 50%. 
When the transfected cells were cultured for longer times, after 48 hours post 
transfection with both siIL-9 and siIL-9R, il9r gene expression in BMMC was 
reduced by more than 60%, suggesting that the transfection with both silencer 
genes supressed il9r expression in mast cells after 48 hours post transfection. 
Hence, for subsequent experiments, cells were used only after 48 hours’ 
transfection. 
 
When il9 was knocked down, il9r expression was also reduced. This is most 
likely due to positive feedback loop regulation where the presence of IL-9 is 
required to enhance IL-9R expression, whilst Figure 35 shows that the absence 
of il9 also downregulates il9r expression. This is also similar to what was 
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previously observed where IL-9R blocking also downregulated IL-9 protein 
secretion in BMMC (Figure 30 and 31). In this experiment, I also measured the 
levels of IL-9 mRNA after stimulating IL-9- and IL-9R- transfected BMMC with 
ionomycin. However, the level of IL-9 mRNA expression was undetectable in all 
cells (control, siRNA IL-9 and siRNA IL-9R) except in ionomycin stimulated cells 
alone (data not shown). This is probably due to il9 only being upregulated to 
detectable levels in non-treated ionomycin stimulated cells. 
 
Besides measuring the levels of il9r gene, another way to measure transfection 
efficiency is by measuring IL-9R protein in transfected cells. However, due to 
limited numbers of cells and the main aim of this experiment being to show the 
function of mast cells after il9r gene suppression, only the levels of IL-9 protein 
were measured in this experiment.  
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Figure 35: Relative il9r expression in BMMC after transfection with silencer 
genes, il9 and il9r over 24 and 48 hours by qPCR. il9r was more than 60% 
downregulated only after 48 hours post-transfection. Il9r expression was 
measured relative to scrambled control. Data shows mean ± SEM as a 
representation from 3 independent experiments, *P<0.05; **P<0.005. Student’s 
t test was performed on this data. 
 
 144 
 
 
 
 
4.2.5.4.2. Histamine secretion 
 
 
Transfected cells were stimulated with ionomycin and histamine levels in the 
BMMC supernatants were measured by ELISA. Following 24 hours’ stimulation 
of cells transfected 48 hours previously, cells transfected with siIL-9R secreted 
the lowest levels of histamine as compared to cells transfected with siIL9 or 
scrambled controls (Figure 36). This result suggests that blocking IL-9R at the 
gene level could have a downregulatory effect on histamine secretion in 
ionomycin-stimulated BMMC, although the levels did not reach significance.  
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Figure 36: Histamine secretion in transfected BMMC 24 hours after stimulation 
with ionomycin. Cells transfected with IL-9R (siIL-9R) resulted in downregulated 
histamine secretion after ionomycin stimulation. Values are plotted as 
mean±SEM from 3 independent experiments.  
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4.2.5.4.2. Cytokine secretion 
 
BMMC supernatants of ionomycin-stimulated cells were also assayed for 
cytokine production. A time course of secretion of Th2 cytokines IL-4, IL-9 and 
IL-13 is shown (Figure 37). IL-5 was not detected in this assay. As can be 
seen, the decreased levels of cytokines secreted were only observed 72 hours’ 
post ionomycin stimulation. The levels of IL-9 and IL-13 were significantly 
decreased in mast cells transfected with siIL-9R as compared to control cells 
and cells transfected with siIL-9 (Figure 37). However, the levels of IL-4 were 
significantly decreased in cells transfected with IL-9, and not IL-9R, as 
compared to scrambled controls (p<0.05). This suggests that silencing il9r and 
il9 downregulates the proinflammatory cytokines (IL-4, IL-9 and IL-13) secreted 
by mast cells. Blocking IL-9R is more effective in downregulating the secretion 
of proinflammatory cytokines since it also downregulated IL-9 secretion, where 
IL-9 was working in a positive feedback loop. This also suggests that IL-9 binds 
specifically to IL-9R and by blocking IL-9R, a downstream decrease in IL-9 
secretion was observed followed by the downregulation of other Th2 
proinflammatory cytokines (IL-4, IL-13) produced by mast cells (Figure 37). 
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Figure 37: Cytokine secretion over 72 hours post stimulation with ionomycin. 
Relative to the scrambled control, cells transfected with il9r demonstrated 
decreased levels of pro-inflammatory cytokines, especially IL-9 and IL-13. 
Data were plotted as a representative with mean±SEM from 3 independent 
experiments. P<0.05, p<0.01. Student’s t test was performed on this data at 
each time point.  
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4.3. Discussion 
 
 
In this study, BMMCs were used as an in vitro model of mast cells to further 
evaluate the effect of IL-9 secreted by mast cells following stimulation.  BMMCs 
are a commonly used mast cell population for in vitro studies although they 
have a distinct lineage from connective tissue mast cells (MCtc) which normally 
reside in the conjunctival tissues (405). However, during allergic inflammation, 
both types of mast cells (MCt and MCtc) are found in the inflamed conjunctivae 
of active vernal conjunctivitis sections, and it would be expected that MCt 
increase in allergic disease (406). BMMCs, grown in the presence of SCF and 
IL-3, most closely correspond with the characteristics of human mucosal type 
mast cells (MCt), hence, this in vitro model is relevant when studying ocular 
mast cells in allergic conjunctivitis. Human cord blood derived mast cells is 
another in vitro model that could be more relevant in studying mast cell function. 
However, since I had previously demonstrated IL-9 expression in mouse, using 
mouse mast cells to determine IL-9 function in vitro, BMMC was considered a 
more relevant source of cells than human mast cells hence, BMMC was the 
preferred in vitro model for these experiments.  
 
There were a few technical issues that I would like to address in regard to 
conducting experiments in this chapter. Firstly, a wider range of antibody (anti-
IL-9 and anti-IL-9R) concentrations should be used during antibody titration 
experiments. This would enable a correct dose response curve to be drawn by 
determining the optimum concentration of antibodies to be used for subsequent 
experiments. Although IL-9R was suppressed and resulted in downregulation of 
secretion of histamines and cytokines, it is also possible that a suboptimal 
concentration of anti-IL-9 antibody (too low) was used, which resulted in no 
difference being observed in the levels of histamine and cytokines after treating 
ionomycin-stimulated cells with anti-IL-9 antibody. Also, the fact that I was able 
to measure IL-9 protein in the supernatants despite anti-IL-9 having been added 
to the cells suggests that the wrong concentration of anti-IL-9 antibody was 
used in these experiments. Anti-IL-9 antibody binds to soluble IL-9 whilst anti-
IL-9R antibody binds to IL-9R on the surface of mast cells. When antibodies are 
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not titrated properly, there will be some free circulating IL-9 and unbound IL-9R 
which are able to elicit downstream IL-9/IL-9R signalling upon activation, hence 
can give rise to false positive results on mast cell functions. However, in this 
study, when mast cells were treated with anti-IL-9R antibody, no IL-9 was 
secreted by mast cells suggesting this was not the case and that IL-9R blocking 
did not give false positive results. Another possible reason as to why IL-9 
suppression by anti-IL-9 antibody did not work efficiently might be due to the 
antibody itself which was unable to bind to IL-9 within the cytoplasm of mast 
cells which can also cause IL-9/IL-9R activation. 
 
Secondly, in the siRNA experiments, there could be alternative approaches for 
showing transfection efficiency despite monitoring the level of il9r expression 
after IL-9 and IL-9R knockdown. It is possible to measure IL-9R protein level in 
these cells, as another way to show the efficiency of IL-9 and IL-9R knockdown. 
However, since this experiment was focusing more on the functional effects on 
mast cells after gene knockdown, I only measured the levels of IL-9 protein in 
the supernatants of these cells, not IL-9R protein. 
 
Mast cells express various types of receptors on their surface including 
chemokines, interleukins (IL), amines (histamines), Toll-Like Receptors, and Fc 
receptors. Since the aim of this study was to investigate the effects of mast cell 
degranulation in cytokine release, BMMCs were stimulated through FcεRI 
crosslinking, to mimic an allergen-specific stimulation via IgE receptor (FcεRI), 
which is a more physiological stimulant that mimics an allergic reaction. 
However, as stimulation via FcεRI is not a very potent stimulus as compared to 
calcium ionophore (ionomycin), it resulted in a lower concentration of secreted 
mast cell products such as histamine and cytokines (407). It is also possible 
that in these experiments, the anti-IgE stimulation was not properly optimised 
and resulted in technical error. Based on these possibilities with anti-IgE 
stimulation, I continued using ionomycin instead of FcεRI crosslinking for 
stimulating BMMC. It was also previously shown that FcεRI crosslinking and 
treatment with calcium ionophore on murine mast cell lines increased secretion 
of classical Th2 cytokines (408). Since ionomycin stimulation of BMMC resulted 
in higher levels of degranulation products as compared to stimulation via FcεRI, 
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it was easier to observe a larger difference in histamine and cytokine secretion 
in ionomycin-stimulated mast cells. Addition of PMA and ionomycin for 
activation is a very strong stimulus, which resulted in an even higher level of 
histamine and cytokine secretion. Similarly, this was observed by Plaut et al. 
who found that addition of PMA to ionomycin stimulation lowered the threshold 
ionomycin concentrations required for [3H]thymidine uptake (as a marker of cell 
division) by mast cells (407). In this study, Plaut and colleagues used murine 
mast cell lines that were derived from foetal liver. These cell lines are similar to 
BMMC, requiring IL-3 for growth. Hence, based on the previous study by Plaut 
et al., ionomycin stimulation was considered the best mode for BMMC 
stimulation for this current study, given that stimulation by ionomycin produced 
levels that were detectable by multiplex bead arrays. 
 
In this chapter, we chose primary BMMC as the in vitro model to study the 
functions of mast cells, as these cells have many shared characteristics of 
human mast cells. These cells have been used extensively by other groups to 
study mast cell functions. More experiments can be done using these cells, as 
they can divide in culture in large quantities. Previous studies investigating mast 
cell functions have used transformed mast cell lines including rat basophilic 
leukaemia cells (RBL), human mast cell lines (HMC-1, LAD-1 and LAD-2) which 
are readily available in large quantities and easier to grow in culture. However, 
transformation of cell lines alters the normal functions of the cells in which KIT 
in HMC-1 is permanently phosphorylated, hence becoming independent of 
SCF. Another type of in vitro mast cell model would be primary cultures of mast 
cells derived from tissues. This was not feasible for culturing conjunctival mast 
cells due to the low amounts of tissue available. In mice, resident peritoneal-cell 
derived mast cells (PCMC) have been shown to have the characteristics of 
mature serosal-type mouse mast cells with retained morphological, phenotypic 
and functional characteristics (409). However, as compared to BMMC, PCMC 
secreted very low amounts of chemokines and cytokines, making it unsuitable 
to study the effects on cytokine secretion by mast cells.  
 
The data included in this chapter has suggested that IL-9 downregulates BMMC 
histamine secretion. More than a decade ago, a study done by Temann et al. 
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reported that mast cells are significantly reduced in the lung tissues of IL-9-
deficient mice that were stained with toluidine blue although the histamine 
levels observed in lung lavage fluid, as determined by ELISA, did not increase 
significantly in IL-9 expressing mice (314). A few years later, Wiener et al. found 
that IL-9 enhanced the ability of ionomycin-stimulated mast cells to secrete 
histamine (279). Through in vivo studies, they found an indirect effect on the 
reduction in IL-9 expression in histamine-deficient mast cells. Another study 
reported the effect of IL-9 to increase histamine release in a mast cell line which 
then led to an exacerbation of neonatal exocytotoxic damage in a mouse model 
of cereberal palsy (410) which was also shown previously (400).   
 
The functional effect of blocking IL-9 and its receptor (IL-9R) on surface 
expression of the IgE receptor (FcεRI) on the BMMCs was investigated. 
Blocking IL-9R in vitro resulted in the downregulation of FcεRI surface 
expression. In 1993, IL-9 was first shown to promote IgE production via IL-4-
induced human B cells (300) and later this was supported by others (316). Our 
findings are consistent with another study which demonstrated that mRNA 
expression of FcεRI was upregulated in the presence of IL-9 in a few mast cell 
lines including primary mast cell cultures, BMMC (411). Since FcεRI is also 
expressed on the surface of other immune cells including neutrophils, an 
interesting study has suggested that IL-9, not IL-4, has a direct effect on 
neutrophils by increasing FcεRI expression in neutrophils isolated from allergic 
asthmatics (412). 
 
Since the il9 gene is located in the exon in close proximity to other Th2 cytokine 
genes (il5 and il13), it was postulated that IL-9 secretion could also be linked to 
the secretion of other Th2 cytokines. Previously, it has been shown that IL-9 
can have co-stimulatory functions with ionomycin and antigen-specific IgE to 
stimulate secretion of several Th2 cytokines (IL-4, IL-5, IL-9, IL-13) by BMMC 
(279). Similarly, the in vitro study of IL-9 neutralisation described herein was to 
investigate the functional role of IL-9 on mast cell cytokine secretion but my 
results suggested otherwise. In my system, blocking IL-9 function in vitro alone 
did not have a significant effect on cytokines secreted by mast cells. This was 
probably due to the nature of the antibody which only binds to secreted IL-9, but 
 151 
 
 
not the IL-9 that might still be stored within the cytoplasmic granules of mast 
cells. Upon secretion of this IL-9 protein, it can further bind to the IL-9R, thus 
activating further downstream signalling for Th2 cytokine secretion.  
 
Hence, it was thought that since IL-9 binds specifically to its receptor (IL-9R), 
blocking the IL-9R could also be a more effective approach for downregulating 
Th2 cytokine secretion by BMMC. In this chapter, for the first time, I have been 
able to demonstrate that blocking IL-9R is effective in downregulating mast cell 
cytokine secretion. This novel finding suggests that by blocking IL-9R, soluble 
IL-9 will be prevented from binding to its receptor, thus blocking further 
downstream signalling for cytokine secretion.  
 
Results in this chapter also suggested that blocking il9 and il9r at the gene level 
resulted in similar effects to those seen when neutralising antibodies were used. 
In most transfection experiments, gene suppression can only be achieved 48 
hours’ post transfection with small interfering RNA, which is the same time 
frame required for gene transfection to occur in this study. 48 hours was 
required for gene suppression to occur probably due to the recently plated cells 
that need time to recover within the first 24 hours prior for the transfection to 
occur. The effect of il9r blocking can only be observed at 72 hours post 
ionomycin stimulation, 24 hours later than the effect observed in mast cells 
treated with blocking IL-9R with neutralising antibody. This was probably due to 
the effect of gene silencing that might take longer time to exert a regulatory 
effect as compared to when just adding neutralising antibodies that have 
immediate regulatory effects.  
 
Since IL-9 secretion was also downregulated upon IL-9R blocking (in both 
conditions with anti-IL-9R antibody and siil9), this study demonstrated that 
secreted IL-9 binds specifically to mast cell IL-9R in an autocrine manner to 
amplify inflammatory responses. This positive feedback loop of IL-9 secretion 
suggests that IL-9 and other Th2 cytokines could be secreted via the activation 
of MAPK signalling downstream of IL-9R activation. IL-9 positively regulates 
cytokine production from mast cells. Based on this study, it is postulated that 
blocking the function of IL-9R on the surface of mast cells can modulate 
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cytokine secretion from mast cells (Figure 38). In this chapter, we have 
demonstrated that IL-9, which is secreted by mast cells, could have functional 
stimulatory effects on mast cell degranulation, including histamine and cytokine 
secretion.  
 
 
 
 
 
 
 
 
Figure 38: Schematic diagram of proposed mechanism of IL-9 on mast cells via 
IL-9R which then leads to the secretion of other mast cell mediators including 
cytokines that causes the symptoms observed during allergic conjunctivitis. 
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Chapter 5 
 
 
IL-9 Expression in Human Conjunctival tissues 
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5.1. Introduction  
 
Initially, in chapter 3, it was shown that IL-9 was upregulated in the conjunctivae 
of EAC mice and, besides CD4+ T cells, mast cells were reported to be one of 
the cell types which secrete IL-9 (as discussed in Chapter 1). In chapter 4, 
further in vitro experiments were performed using BMMC as a mast cell in vitro 
model in order to understand the role of IL-9 on mast cell functions. In this 
chapter, I investigate IL-9 expression levels in human conjunctival tissues.  
 
It has been well established that IL-9 supports allergic inflammation, especially 
in promoting mucus production and mastocytosis in the lung of an allergic 
airway disease mouse model (251). IL-9 has been detected in the lungs of 
asthmatic patients and its overexpression results in an asthma-like phenotype 
of inflammation and bronchial hyperresponsiveness (314,413).  
 
Besides studies on the role of IL-9 in asthma patients, many other studies have 
also investigated the contribution of IL-9 in allergic diseases including allergic 
rhinitis, food allergy and allergic skin disease. Recently, it was concluded that 
IL-9 plays a role in regulating allergen-specific Th1 responses in allergic contact 
dermatitis (414), while Ma and colleagues found that IL-9 and Th9 cells were 
upregulated in atopic dermatitis patients (415).  
 
It is understood that IL-9 plays an important role in driving allergic diseases and 
studies are now focused on understanding the mechanisms by which IL-9 
drives allergic responses. However, it is still not known whether IL-9 plays a role 
in the pathogenesis of allergic conjunctivitis. Based on findings of upregulation 
of IL-9 in allergic diseases, we hypothesise that IL-9 is present and upregulated 
in patients with allergic conjunctivitis. 
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To address this hypothesis, the specific aims were as follows: 
 
1. To compare the expression of IL-9 in donor conjunctival biopsies from 
allergen-challenged, out-of-season AC individuals with normal, 
unchallenged controls, using immunohistochemistry staining. 
2. To investigate whether IL-9 in these biopsies is expressed by mast cells 
using confocal microscopy to visualise immunofluorescence stained 
tissue sections. 
3. To analyse the proportion of IL-9- and IL-9R-expressing cells that are 
mast cells (tryptase positive) with those IL-9 and IL-9R-expressing cells 
that are tryptase negative. 
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5.2. Results 
 
5.2.1. Determining polyclonal Ab (pAb) specificity for human IL-9 by 
ELISA. 
 
At the time of undertaking this study, the only anti-human IL-9 Ab available for 
tissues staining was a polyclonal Ab. To ensure that the polyclonal Ab (pAb) 
recognising human IL-9 used for experiments in this chapter will bind 
specifically to IL-9, antibody validation experiments were done by Dr. Malihe 
Eskandarpour.  Firstly, an ELISA plate was coated with rh IL-9 and 
subsequently incubated with different concentrations of rabbit polyclonal anti-
human IL-9 Ab (Abcam Ab111915). Figure 39A shows that OD value increased 
with increasing concentrations of IL-9 Ab, suggesting that IL-9 Ab at increasing 
concentrations binds to rhIL-9, which resulted in increased absorbance values. 
A 1:1000 dilution factor for IL-9 Ab was chosen for subsequent experiments 
since, at this concentration, IL-9 Ab produced an absorbance value which was 
halfway between the baseline and the maximum value. 
 
Subsequent experiments were done to confirm that the anti-IL-9 Ab binds 
specifically to rh IL-9, even in the presence of neutralising human IL-9 Ab. In a 
plate which was precoated with rh IL-9, the anti-IL-9 Ab competed with 
neutralising human IL-9 Ab and neutralising mouse IL-9 antibody respectively. 
Two neutralising antibodies against mouse and human were used in this 
experiment in order to confirm that this antibody did not cross-react between 
different species. Figure 39B shows that at increasing neutralising human IL-9 
Ab concentrations, absorbance values decreased. This shows that neutralising 
human IL-9 Ab can bind to rhIL-9 at increasing concentrations and competes 
with anti-IL-9 Ab binding to rhIL-9 on the plate, resulting in reduced absorbance 
values. On the other hand, similar absorbance values were observed in plates 
with rhIL-9 which was subsequently incubated with IL-9 Ab, in the presence of 
increasing concentrations of neutralising mouse IL-9 Ab. This data shows that 
unlike neutralising human IL-9 Ab, neutralising mouse Ab binds less specifically 
to IL-9 Ab, which allows IL-9 Ab to bind to rhIL-9 on the plate and resulted in 
similar absorbance values across increasing concentration of neutralising 
mouse IL-9 Ab (Figure 39C). This experiment shows that the IL-9 pAb used for 
 158 
 
 
human conjunctival tissue immunostaining is specific for IL-9, although it does 
not demonstrate whether the pAb binds to other proteins.  
 
 
 
 
 
 
Figure 39: Absorbance values from IL-9 pAb validation experiments. Data 
shows absorbance values from plates incubated with increasing concentration 
of: A. IL-9 pAB; B. Neutralising human IL-9 Ab; C. Neutralising mouse IL-9 
antibody. Data are presented as mean±SD from triplicate wells. 
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5.2.2. IL-9 and IL-9R expression in human conjunctival tissue sections.  
 
In order to investigate the baseline expression of IL-9 in normal, uninflamed 
tissues, non-AC control human conjunctival biopsy sections were stained with 
polyclonal anti-IL-9 antibody. The same anti-IL-9 antibody, which was used for 
staining these conjunctival biopsies shown in this chapter was previously 
validated by ELISA (as explained in 5.2.1). 
 
Sequential biopsy sections were singly stained for tryptase (as a marker for 
mast cells) as the positive control for the staining, and for IL-9, to investigate IL-
9 colocalization with mast cells. For negative controls, primary antibody was 
replaced with water. A few attempts were made to repeat the staining however, 
due to the quality of the tissues and limited tissue availability, staining on these 
conjunctival biopsies was unable to be repeated.  
 
 
5.2.2.1. Immunohistochemistry- Healthy tissues 
 
Both IL-9 and tryptase were expressed in normal uninflamed conjunctivae and 
these positive cells were localised predominantly within the vessels (Figure 40). 
These sections were obtained from non-allergic, non-inflamed donors. 
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Figure 40: Expression of IL-9 protein (immunohistochemistry) in sequential 
sections of normal, unchallenged tissues. a. Unstained tissue section incubated 
without primary antibody as negative control. b. IL-9 positive cells are seen 
within the vessels (x200 magnification). c. IL-9 positive cells at higher 
magnification (x400). d. Tryptase positive cells (marker for mast cells) within 
vessels (x200). e. Tryptase positive cells at (x400). Scale bar: 20µm.  
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5.2.2.2. Immunohistochemistry- Allergen challenged conjunctival tissues 
 
 
Since a low level of IL-9 expression was detected at baseline in normal, 
uninflamed tissues, this was compared with IL-9 expression in allergen-
challenged SAC tissues. Allergen-challenged SAC tissues were stained for IL-9 
and tryptase. These tissue sections were obtained from a previous clinical trial 
which investigated the role of a chemokine inhibitor in donors with SAC. In this 
trial, there were two groups; the control group comprising challenged SAC 
donors receiving placebo, and the treatment group comprising challenged SAC 
donors who received the treatment. Therefore, I was unable to obtain sections 
from a non-allergen challenged SAC group as the study did not include non-
allergen challenged SAC donors. 
 
In allergen-challenged AC tissues, both IL-9 and tryptase positive cells were 
found to be localised within the subepithelial and stromal layers of the tissues 
(Figure 41). This suggests that in normal tissues, IL-9 positive staining that 
colocalised to areas containing mast cells was contained within the vessels and 
that, during allergen challenge (as seen in the challenged AC biopsies), IL-9-
expressing mast cells migrate to stromal and sub epithelial layers. Since IL-9 
positive cells and tryptase expressing cells were seen within the same areas of 
the sequential sections, it is postulated that mast cells express IL-9 in 
conjunctival tissues of both normal and challenged AC donors. Cells stained 
positively for IL-9 were then counted in a masked fashion where two 
independent, masked observers were blinded by using numbers allocated to 
each slide without knowing the details of the slides. A total of three random 
fields per section were recorded. IL-9 expression was significantly upregulated 
in challenged AC tissues (n= 8) as compared to normal tissues (p<0.01; n=8) 
(Figure 42).  
 
 
 
 
 
 162 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41: Expression of IL-9 protein in sequential sections of challenged AC 
(Allergic Conjunctivitis) tissues. AC eyes were challenged with mixed grass 
pollen extract a. SAC section stained only with secondary antibody as control. 
IL-9 positive cells are seen within sub-epithelial and stromal layers of the tissue 
(b,d. and f.). Tryptase positive cells (c, e and g) are also seen colocalised with 
IL-9 positive cells in the sub-epithelial layers (x200 and x400 magnification). 
Scale bar: 20μm. 
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Figure 42: Total IL-9 and tryptase expressing cells. IL-9 and tryptase expressing 
cells were counted and data normalized from 3 separate fields. Data were 
shown as means+/- SEM of 8 donors per group. AC = allergen-challenged. 
*P<0.001 
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5.2.2.3. Immunofluorescence staining- Healthy and allergen challenged 
tissues 
 
 
Besides IL-9, sections were also stained for IL-9 receptor (IL-9R) as an 
indication of which cells could respond to IL-9. Sections were stained by three-
colour immunofluorescence staining for IL-9 or IL-9R, tryptase and DAPI 
(fluorescent dye that bind strongly to DNA to detect nuclei on tissue sections) 
on the same slide and visualised by confocal microscopy (Zeiss 710). Three-
colour staining was done in order to determine the proportion of IL-9 and IL-9R 
expressing mast cells. Double-positive cells (yellow), suggesting the 
colocalisation of IL-9, or IL9R, and tryptase, were counted in at least 3 fields. 
 
Similar to the previous immunohistochemical single colour staining results, with 
normal unchallenged tissue sections, IL-9 and IL-9R expressing mast cells 
(yellow) were seen within the vessels, whereas few mast cells (stained in red) 
were seen in the tissue stroma (Figure 43).  However, in allergen challenged 
tissues, more cells stained positively for IL-9 and IL-9R (Figure 44). Double 
positive cells (stained yellow) for both IL-9/IL-9R and tryptase are seen within 
the stromal areas of the tissues. There were also some IL-9 and IL-9R positively 
stained cells that did not colocalise with tryptase-positive mast cells.  
 
IL-9 and IL-9R expressing cells were counted within 3 fields per slide and were 
expressed in total number of cells. Figures 45a and b depict the absolute 
number of IL-9 and IL-9R positive cells that colocalised with mast cells, whilst 
Figure 45c and d shows absolute numbers of IL-9 and IL-9R positive cells that 
did not colocalise with mast cells. Based on figures 45a and b, mast cells in 
both normal and challenged tissues expressed both IL-9 and IL-9R and there 
were significantly more mast cells expressing IL-9 and IL-9R in challenged 
biopsies as compared to control (p<0.05). When compared to control 
conjunctivae, there are significantly more IL-9 and IL-9R expressing cells that 
did not colocalise with mast cells (single green colour staining) in challenged 
biopsies (Figure 45c and d) (p<0.005, p<0.0005; n=8), suggesting that IL-9 is 
also secreted by other immune cells (for example eosinophils, CD4+T cells and 
ILC) during allergic responses. However, due to limitations of time and 
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availability of tissue biopsies, and given that the aim of this study was to 
investigate IL-9 and IL-9R expression on mast cells, no further staining was 
performed to investigate the other cell types which also expressed IL-9 and IL-
9R in these biopsies 
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Figure 43: IL-9 and IL-9R expression in normal unchallenged tissues. a and b. 
IL-9 positive cells (green) are seen within the vessels whereas a few mast cell 
(red) are seen within the stromal area of the tissues, c and d. IL-9R and mast 
cell double-positive cells (yellow) are seen within the vessels. e. negative 
control. Scale bar: 20μm. Arrows indicate double positive cells which are IL-
9/IL-9R positive mast cell positive. 
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Figure 44: IL-9 and IL-9R expression in challenged tissues. a and b. IL-9 positive 
cells and c and d. IL-9R positive cells which colocalise with mast cells (yellow) 
are seen within the stromal areas of tissues. A few IL-9 positive cells (green) 
which are not mast cells are also seen within this area. X400 magnification. e. 
negative  control. Scale bar: 20μm. Arrows indicate double positive cells which 
are IL-9/IL-9R positive mast cell positive. 
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Figure 45: Absolute numbers of IL-9 and IL-9R expressing cells. IL-9 and IL-9R 
expressing cells were counted from 3 separate fields. Data were shown as 
means +/- SEM of 8 donor specimens per group.  Total number of IL-9 a. and IL-
9R b. positive and tryptase positive cells (double positive) in normal and 
challenged biopsies. Total number of c. IL-9 and d. IL-9R positive cells but 
tryptase negative in both normal and challenged AC tissues. *p<0.05, **p<0.005, 
***p<0.0005. 
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5.3. DISCUSSION  
 
 
 
IL-9 has long been associated with allergic diseases, especially in asthma, 
where this has been supported by a recent genome-wide association study 
which has identified that severe asthmatic patients with IL-9 polymorphisms are 
more likely to interact with house dust mite and can lead to exacerbations of 
severe asthma (416). Besides asthma, increased IL-9 levels have also been 
associated with other allergic diseases including food allergy, allergic rhinitis, 
and eczema. However, there are still no reports on the role of IL-9 in allergic 
conjunctivitis. Data shown in previous chapters supported the concept that IL-9 
is upregulated in a mouse model of allergic conjunctivitis and that mast cells 
were a source of IL-9 in these tissues. Further in vitro studies shown in chapter 
4 were carried out in order to understand the role of IL-9 on mast cell function. 
The next aim was to investigate IL-9 levels in allergic conjunctivitis in human 
conjunctival tissues. Since the level of IL-9 is known to be upregulated in 
allergic asthma and given that the conjunctiva is also a mucosal surface, we 
postulated that IL-9 might also be involved in allergic conjunctivitis. First, we 
needed to investigate the expression of IL-9 in the conjunctiva of AC donors 
with and without allergen challenge. However, due to the study design that 
initially took place, only allergen-challenged out-of-season SAC samples were 
obtained, but not conjunctiva of AC donors without allergen challenge. Hence, 
in this study, instead of using conjunctiva of AC donors without allergen 
challenge, I used normal conjunctivae without SAC as control sections. 
 
 
Despite several studies which have investigated the role of cytokines in eye 
diseases, including the roles of pro-inflammatory cytokines in allergic 
conjunctivitis (347,417), there have been very few studies focussing on the role 
of IL-9 in eye diseases, in particular AC. In an in vivo study on experimental 
autoimmune uveoretinitis (EAU), it was found that IL-9 was upregulated in the 
splenocytes and draining lymph nodes of EAU mice (418).  Recently, it was also 
shown that IL-9 produced by Th9 cells drive inflammation in the eye (264,382).  
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There are a few technical issues which I would like to address in this chapter. 
Firstly, this experiment did not include unchallenged SAC samples due to the 
design of the initial study, which did not include unchallenged SAC. It would 
have been ideal to obtain unchallenged AC samples due to the fact that 
baseline IL-9 and IL-9R expression might also be upregulated in these samples, 
although since all patients recruited to that trial were “out-of-season”, it is 
unlikely.  
 
In this chapter, a polyclonal IL-9 antibody was used for immunohistochemical 
staining instead of a monoclonal antibody, as that was unavailable at the time. 
A monoclonal antibody would have been preferable to use for immunostaining 
since it would bind more specifically to the designated IL-9 epitopes on tissue 
sections. Polyclonal antibodies are a heterogenous mixture of antibody which 
recognizes different epitopes from an antigen. Different antibodies are produced 
against these different epitopes and then harvested from the serum of the 
animal directly. Monoclonal antibodies on the other hand are produced from 
single clone of B cell which recognizes and bind to single epitope on the 
antigen. For immunostaining purposes, polyclonal antibody is not suitable since 
it binds to many different epitopes of specific antigen and could cause false 
positive binding. In this chapter, an attempt to show IL-9 pAb specificity by 
ELISA was not sufficient since this experiment only showed that IL-9 pAb could 
bind specifically to rhIL-9, but did not take into account the other possibility that 
other immunoglobulin which present in the antibody could bind non-specifically 
on other epitopes expressed in the conjunctival tissues. Hence, a better way to 
demonstrate IL-9 pAb specificity is by doing Western blot, which was not done 
in this study due to technical limitations. 
 
 
Based on immunostaining of human conjunctival tissue sections, it was found 
here that IL-9 expression was upregulated in challenged AC tissues as 
compared to normal biopsies. Tryptase positive staining was used to identify 
mast cells in AC. It is already well known that mast cells are upregulated in the 
lamina propria of SAC conjunctiva (419). To date, no studies have investigated 
the presence of IL-9 in the conjunctiva. However, Metz et al. previously 
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discovered the presence of Th2 proinflammatory cytokines namely IL-4, IL-5 
and IL-13 in the conjunctiva of VKC patients using in situ hybridization (207). 
This is the first time that IL-9 has been shown to be present in the conjunctiva of 
both normal and challenged SAC tissues and our findings demonstrated that IL-
9 expression levels were upregulated in challenged SAC tissues.  
 
Since increased numbers of tryptase-positive and IL-9-positive cells in the same 
area of the tissues was observed by light microscopy, these IL-9 positive cells 
were thought to be mast cells using serial sections, although this could not be 
confirmed using light microscopy. Double immunofluorescence staining 
confirmed that IL-9 expression colocalised with tryptase expression in some 
cells, suggesting that the mast cell can potentially secrete IL-9 in the 
conjunctiva during allergen challenge.  
 
Double immunofluorescence staining also revealed that IL-9 and IL-9 receptor 
(IL-9R) positive cells also colocalised with tryptase positive cells, suggesting 
that mast cells in the conjunctiva express IL-9 and IL-9R and these levels 
increased significantly in challenged biopsies as compared to control biopsies. 
This study shows that in challenged biopsies, there are more IL-9/IL-9R positive 
mast cells which might contribute to the symptoms seen in AC.  
 
Although no studies have investigated the expression of IL-9 and IL-9R in 
conjunctivae, Lin and colleagues have investigated the expression of IL-9 and 
IL-9R protein in the nasal tissue sections of control subjects and patients with 
chronic rhinosinusitis, where they found that IL-9 and IL-9R were both present 
in control tissues but these levels were upregulated in patients with chronic 
rhinosinusitis. In Lin’s study, IL-9 and IL-9R positive cells were seen as 
positively stained mucosal epithelial and submucosal inflammatory cells (420). 
This IL-9 and IL-9R mucosal study confirmed the presence of IL-9 and IL-9R 
positive cells in the nasal mucosa in normal control tissues similar to our study 
of the conjunctiva. Apart from the nasal mucosa, IL-9 and IL-9R are also highly 
expressed in the mucosa of patients with ulcerative colitis (421). 
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Based on double immunofluorescence staining, my study has found that IL-9R 
is expressed on the surface of mast cells in conjunctival biopsies. This result is 
also in line with a study done by Kearly et al., where they found that IL-9R is 
present on the surface of mast cells in the lung of mice with chronic allergic 
asthma (328).  
 
Immunostaining of IL-9 and IL-9R in the conjunctiva of both normal and 
allergen-challenged SAC biopsies revealed that some of the IL-9+/IL-9R+ cells 
were also positive for tryptase, suggesting that the mast cell secretes IL-9 and 
expresses IL-9R. However, in allergen-challenged conjunctival biopsies, a 
considerable proportion of IL-9 and IL-9R positive cells did not colocalise with 
tryptase (tryptase negative). This suggests that other cells secrete IL-9 and 
express IL-9R during allergen challenge. IL-9R is present on the surface of T 
lymphocytes, eosinophils, mast cells and also epithelial cells. Since in SAC 
there are very few T cells present (72), they are unlikely to be a source of IL-9 in 
these tissues. Eosinophils could be the IL-9-expressing, tryptase-negative cells 
since this cell type was also found to be upregulated in the conjunctiva during 
AC (422) and they have also been reported to secrete high amounts of IL-9 
during inflammation (423). Other cell types that also secrete IL-9 and express 
IL-9R during allergy include CD4+T cells and ILCs, although there is no direct 
evidence of the contribution of these cells and IL-9 secretion during AC.  
 
Another way to confirm the colocalisation of IL-9 and mast cells is through in 
situ hybridisation staining, looking at the expression of IL-9 mRNA and mast 
cells, as previously shown for nasal biopsies of allergic rhinitis patients (276). 
However, I did not perform that technique in my studies. Given more time, and 
sample availability, it would have been an opportunity to be able to explore 
other types of cells including eosinophils, CD4+ T cells and ILCs, which also 
secrete IL-9 in the conjunctiva during AC. 
 
In summary, despite a polyclonal anti-IL-9 Ab being used for staining tissue 
sections we could still postulate that IL-9 was present in both healthy controls 
and challenged biopsy sections and the level was upregulated on cells outside 
the blood vessels, in the stromal tissues, in allergen-challenged biopsies. These 
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IL-9-positive cells colocalised with mast cells but, in the allergen-challenged 
biopsies, other cells were also a source of IL-9. Besides conjunctival tissues, IL-
9 was also found to be increased in the cell-free tear fluids of VKC patients 
relative to healthy control tears, and this level increased with disease severity 
(424). This data may suggest that IL-9 could play an important contribution in 
chronic allergic conjunctivitis and further studies with VKC/AKC tissues will be 
performed to investigate IL-9 expression in more clinically severe forms of AC. 
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CHAPTER 6 
 
 
The Role of IL-9 on Conjunctival Epithelial Cells 
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6.1. INTRODUCTION  
 
IL-9 is a pleiotropic cytokine that exerts a wide spectrum of functions on 
hematopoietic and non-hematopoietic cells. Apart from its role on the survival 
and proliferation of T cells and mast cells (297,425), IL-9 is also important in 
modulating B cell function by upregulating IL-4-mediated IgE and IgG 
production from human B cells (300). IL-9 specifically binds to IL-9Rα to deliver 
its signals into target cells. The IL-9R was reported to be expressed on the 
surface of eosinophils, as shown in a mouse model of allergic airway 
inflammation, where blocking the function of IL-5 in mice overexpressing IL-9 in 
the lungs resulted in reduced eosinophil recruitment (387), suggesting that 
eosinophil functions were affected by IL-9 indirectly via IL-5 secretion.  More 
recently, IL-9 was shown to promote Th2 cytokine expression and to regulate 
the functions of innate lymphoid cells (ILCs) (281). Besides its influences on 
immune cells, IL-9 also  directly affects tissue resident cells including epithelial 
cells. A few studies have investigated the role of IL-9 on lung epithelial cells in 
allergic airway disease and studies in this thesis have demonstrated that IL-9 is 
expressed on epithelial cells in human conjunctival tissues and in mouse 
models of allergic conjunctivitis. Based on these findings, I was interested in 
determining the functional effects of IL-9 on conjunctival epithelial cell function. 
The aim of this chapter was to investigate the effects of IL-9 added exogenously 
to human conjunctival epithelial cells, using a well-known in vitro human 
conjunctival spontaneously transformed epithelial cell line (IOBA-NHC).  
 
Normally, both stratified squamous and stratified columnar epithelial cells play 
important roles by forming a barrier, which is the first line of defence against 
external microorganisms and allergens. However, in the lung, epithelial cells 
play another important role in the regulation of immune cells. During allergic 
airway inflammation, epithelial cells secrete TSLP and IL-33 to enhance 
immune cell recruitment, promoting Th2 and Th9 cells and, in studies involving 
functional blocking of IL-9 in mice with allergic airway inflammation, this 
downregulates TSLP-induced lung inflammation (260).  
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Conjunctival epithelial cells contain goblet cells that secrete mucus in response 
to a range of stimuli. Increased mucus secretion occurs due to the expansion in 
the numbers of goblet cells in the epithelium. IL-9 is known to cause an 
increase in secretion of mucus as well as goblet cell expansion (goblet cell 
hyperplasia), in the lung epithelium. Various studies have shown that in the lung 
and colon of IL-9 transgenic mice, mucus production and mucus-associated 
genes including Muc2, Muc5ac and TFF2 (mucus associated peptide that is 
responsible for mucus viscosity) mediated by IL-13 was upregulated 
(246,314,388,426). Although mucus upregulation by IL-9 was mediated by IL-
13, IL-9 did not synergise with IL-13 and IL-9 alone did not induce goblet cell 
hyperplasia, as observed in paediatric bronchial epithelial cells (427). Absence 
of IL-9 in mice did not affect the level of mucus secretion, suggesting that IL-13 
is probably able to compensate for the effects of IL-9 on lung epithelium (329).   
 
Encoded by MUC genes, mucins are synthesised by both goblet cells and 
submucosal glands. There are 9 different derivations of MUC genes. Both 
MUC2 and MUC5ac (gel forming mucin) are found to be present in human 
conjunctival tissues (350) and are expressed in the epithelium (428).  
 
In this chapter, different cytokines were used to compare their effects on the 
levels of MUC mRNA expressions in the conjunctival epithelial cells in vitro. The 
panel of cytokines consisted of IL-1β, IL-9, IL-13 and IL-17α. IL-1β, IL-13 and 
IL-17α, which are known to upregulate mucins in the epithelium and can be 
used as controls to compare MUC mRNA in cells treated with IL-9. These 
cytokines have also been shown to be present in the tear fluids of AC patients 
(64,424,429), hence these cytokines were considered relevant for this study. 
Since both MUC2 and MUC5ac genes are consistently associated with goblet 
cells, these two MUC genes were used as markers for mucin in this chapter. 
However, only MUC2, and not MUC5ac, gene expression had previously been 
reported in IOBA-NHC cells (367).  
 
The ocular surface is constantly exposed to a myriad of pathogens and 
allergens from the environment. In order to maintain ocular surface protection, 
molecular components that seal the space in between adjacent ocular surface 
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epithelial cells like TJ and a second layer of protection (the transcellular barrier) 
is provided by membrane-associated mucins, which are available at the ocular 
surface. During allergy and inflammation, cells, cytokines, pathogens and 
allergens are known to disrupt these barriers, enabling pathogens and allergens 
to penetrate through the ocular surface and cause further immune-mediated 
tissue responses.   
 
Besides upregulation of mucin production, IL-9 also regulates epithelial barrier 
function. Since the epithelial tight junction is important in ensuring the integrity 
of the epithelium and preventing allergen penetration, studies have investigated 
the role of IL-9 in maintaining epithelial tight junctions. Mutations of the fillagrin 
gene that contribute to barrier function especially in the skin were found to be 
associated with a predisposition to atopic dermatitis (AD) (430). The junctional 
adhesion superfamily of tight junctions including zonula occludens (ZO) 1-3, 
occludin and claudins 1-5, was also shown to be important in regulating the 
lung and nasal mucosa epithelium integrity during allergic asthma and allergic 
rhinitis (431,432). While one study using a mouse model of induced intestinal 
anaphylaxis demonstrated that IL-9 had an indirect effect in altering intestinal 
permeability via mast cell activity (433), another study found that IL-9 exerted a 
direct effect on maintaining intestinal barrier integrity in an oxazolone-induced 
colitis model in mice (375).  
 
All of the aforementioned studies demonstrated functional effects of IL-9 on the 
mucosal epithelium. Despite studies aiming to understand the mechanisms of 
AC at the epithelium, to my knowledge no study has directly investigated the 
functional properties of IL-9 on the conjunctival epithelium. Here, the aim of this 
chapter was to investigate the functions of IL-9 on conjunctival epithelial cells. 
All of our experiments used the fully differentiated and spontaneously 
transformed human conjunctival epithelial cell line (IOBA-NHC) (367) as the in 
vitro model with which to study the effect of IL-9 on the conjunctiva. This cell 
line has previously been used to study immunomodulatory functions within the 
conjunctival epithelium (434,435). The IOBA-NHC cell line has the 
characteristics of primary human conjunctival epithelial cells (367), that is 
characterized by the presence of neutral mucin-like glycoprotein which stained 
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positively with periodic acid Schiff (PAS). These cells also express EFGR, 
ICAM-1 and HLA-DR, secrete mucus and form a barrier with resistance, hence 
making it a good in vitro model for the purpose of this study. Many of the 
functions of IL-9 previously reported include upregulating mucin secretion on 
epithelial cells. In preliminary studies, our group had observed an upregulation 
of MUC2 mRNA following exposure of the IOBA-NHC cells to hrIL-9 (Calder et 
al, unpublished preliminary data).  
 
My hypothesis was that IL-9 upregulates mucus production and supports barrier 
integrity of conjunctival epithelium. This chapter will describe the effects of IL-9 
on human conjunctival epithelial cells. 
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To address this hypothesis, the specific aims were as follows: 
1. To investigate the effects of exogenously added IL-9 and other cytokines 
in MUC gene expression on conjunctival epithelial cells and to compare 
with the effects of these cytokines on human bronchial epithelial cells. 
2. To investigate IL-9R expression on human conjunctival epithelium of AC 
tissue sections and the IOBA-NHC cell line. 
3. To investigate the effects of IL-9 and other cytokines on conjunctival 
epithelial cell tight junctions.  
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6.2. Results 
 
6.2.1. Upregulation of MUC mRNA in conjunctival epithelial cells in 
response to pro-inflammatory cytokines.  
 
Mucin is secreted by goblet cells in the epithelium in response to inflammation 
and its secretion is important to dampen down inflammatory responses. There 
are different mucin subtypes (MUC) and the ones that are commonly found in 
the conjunctiva are MUC1, 2, 4, 5ac and 16. However, since MUC2 was known 
to be expressed in IOBA-NHC cells (367), we first assayed the effects of IL-9 as 
well as other cytokines on the level of MUC2 mRNA expression using 80% 
confluent IOBA-NHC cells plated in 6-well plates with triplicate wells per 
condition. The cytokines (IL-1β, IL-9, IL-13 and IL-17α) were first titrated in 
order to observe the optimal concentration for upregulating MUC2 expression in 
IOBA-NHC cells with an exposure time of 24 hours (based on unpublished work 
previously done in the lab). (Figure 46) illustrates the experimental design, 
including the different concentrations of cytokines that were assayed and fold 
change calculated for MUC2 mRNA expression at different cytokine 
concentrations relative to untreated controls cells. Data were analysed 
statistically using the student’s t test. MUC2 mRNA expression was upregulated 
in a dose-dependent manner in response to treatment with IL-1β, IL-9 or IL-13. 
However, only a very low concentration of IL-17A (0.2ng/ml) was required to 
upregulate MUC2 gene expression (p<0.005). In subsequent experiments, 20, 
10, 40 and 0.2 ng/ml of IL-1β, IL-9, IL-13 and IL-17α respectively, were added 
to IOBA cells.  
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Figure 46: Fold change of MUC2 mRNA expression upon exposure to IL-1β, IL-
9, IL-13 and IL-17α stimulation at different concentration relative to unstimulated 
cells. Data were plotted as mean±SEM from three independent experiments, 
*p<0.05, **p<0.005, and analysed by student’s T test. 
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Having demonstrated which concentrations of cytokines were able to 
upregulate MUC2 expression, the next study involved determining the time 
course of MUC2 upregulation. In this study, each cytokine was added to 80% 
confluent wells of IOBA cells and left for 2, 6 and 24 hours in culture. In this 
experiment, the mRNA expression levels in both MUC2 and MUC5ac were 
assayed. Relative to untreated cells, MUC2 mRNA expression was not 
upregulated at 2 hours’ post cytokine exposure in IOBA-NHC cells treated with 
all cytokines (Figure 47) However, MUC2 mRNA expression was significantly 
downregulated at 6 hours post IL-13 exposure (P<0.05). The effects of all 
cytokines on MUC2 mRNA expression by IOBA cells were detected at 24 hours’ 
treatment. At this timepoint, all cytokines in the panel induced an increase in 
MUC2 mRNA expression, especially in those cells exposed to IL-9, where 
MUC2 mRNA expression was significantly increased by more than 2-fold 
relative to untreated cells (P<0.05).   
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Figure 47: Fold change of MUC2 mRNA expression level (relative to 
unstimulated cells) in IOBA-NHC cells normalized to β-actin upon exposure to 
different cytokines at 2, 6 and 24 hours post stimulation. 20, 10, 40, and 0.2 
ng/ml of IL-1β, IL-9, IL-13 and IL-17α respectively, were added to IOBA cells 
Data were plotted as mean±SEM from four independent experiments, *p<0.05 
and analysed by student’s T test. 
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I also investigated the expression of MUC5ac mRNA expression in this model. 
The cytokines induced different levels of MUC5ac mRNA expression as 
compared to MUC2 gene expression (Figure 48). Most cytokines did not affect 
the levels of MUC5ac gene expressions at 2 hours’ post stimulation. However, 
MUC5ac mRNA expression in IOBA-NHC cells was significantly downregulated 
after 6 hours of treatment to IL-9 or IL-13, (p<0.005, p<0.0005, respectively). 
After 24 hours post cytokine exposure, only cells exposed to IL-1 β and IL-17A 
had increased levels of MUC5ac mRNA expression although the levels did not 
reach significance. 
 
To compare results obtained with the IOBA-NHC conjunctival cell line, I also 
investigated the effect of these cytokines on a well-established lung epithelial 
cell line (HBE-16). To investigate the contribution of IL-9 and other cytokines 
(IL-1β, IL-3 and IL-17A) on MUC2 mRNA expression on human lung epithelial 
cells, these cytokines were added to the HBE-16 cell line in culture and left for 2 
and 6 hours. IL-9 had no effect on MUC2 expression even at 6 hours post 
stimulation.  In contrast, at 2 hours’ exposure MUC2 expression upregulated in 
cells treated with IL-13 and IL-17A (Figure 49). IL-13 also consistently 
upregulated MUC2 expression level even at 6 hours post IL-13 stimulation.  
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Figure 48: Fold change of MUC5ac mRNA expression level (relative to 
unstimulated cells) in IOBA-NHC cells normalized to β-actin upon exposure to 
different cytokines at 2, 6 and 24 hours post stimulation. 20, 10, 40 and 0.2 
ng/ml of IL-1β, IL-9, IL-13 and IL-17α respectively, were added to IOBA cells 
Data were plotted as mean±SEM from 4 independent experiments, **p<0.005, 
***p<0.0005 and analysed by student’s T test. 
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Figure 49: Fold change of MUC2 mRNA expression level (relative to 
unstimulated cells) in HBE-16 cells normalized to β-actin upon exposure to 
different cytokines at 2 and 6 hours post stimulation. 20, 10, 40, and 0.2 ng/ml 
of IL-1β, IL-9, IL-13 and IL-17α respectively, were added to IOBA cells Data 
were plotted as mean±SD from a single experiment and analysed by student’s 
T test. 
 
 
6.2.2. IL-9R expression on the surface of a human conjunctival epithelial cell line.  
 
IL-9R is expressed on different cell types including T helper cells, mast cells 
and on the surface of epithelium (as previously discussed in chapter 4). So far, 
it was already reported that IL-9R is expressed on the surface of human lung 
epithelium (363,436) but the presence of IL-9R on the surface of conjunctival 
epithelium was still unknown. In order to investigate the presence of IL-9R on 
the conjunctival epithelium, IOBA-NHC cells were stained with anti-IL-9R 
antibody. As seen in (Figure 50) IL-9R (green) is highly expressed on the 
surface of IOBA-NHC cells, whilst MUC2 expression (red) was localised to the 
cyotoplasm.  
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Figure 50: Immunofluorescent staining of IOBA-NHC cell line with IL-9R (green, 
pink arrows), MUC2 (red) in a. 200x magnification and b. at 400x magnification 
c. negative control staining x200 without primary antibodies. 
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6.2.3. Effects of cytokines on conjunctival epithelial cell tight junctions. 
 
Besides upregulation of mucins, we also investigated the effects of IL-9 on the 
epithelial cell tight junctions of IOBA-NHC cell monolayers. Tight junctions (TJ) 
that maintain the intracellular junctional complexes of an epithelial cell layer are 
composed of transmembrane proteins occludin, claudins and junctional 
adhesion molecules (refer to Chapter 1, section I.6.1.2.). Integral TJ protein, 
occludin and TJ plaque proteins which express PZD domains, zonal occludin 1 
(ZO-1) that serve as the links between integral TJ proteins and actin 
cytoskeleton, functioning as adapters for the recruitment of cytosolic molecules 
implicated in cell signalling, are the components of the TJ complex.  
 
 
In order to investigate the effects of cytokines on conjunctival epithelium TJ, 
IOBA-NHC cells were stained with anti-occludin and anti-ZO-1 antibodies after 
24 hours treatment with cytokines, based on a previous time course study done 
in the lab. For each slide, cells were visualised using ZEISS 710 Confocal 
microscopy. From the immunofluorescence staining, all cells stained positively 
for both ZO-1 and occludin. Differences in overall changes observed were 
based on differences in intensity and localisation of the staining rather than the 
positivity of the staining (Figures 50 to 53). Hence, these images were analysed 
based on the intensity of expression by the cells and the values were measured 
as the number of pixels. These images were analysed using Fiji Image J 
software as this software can detect the moderate effect that the cytokine has 
on cells.  Images were analysed as follows: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 192 
 
 
1) Single colour images were dragged into the Fiji window and displayed as 
below. 
 
 
 
 
 
 
 
 
 
2) For each image, click IMAGE tab followed by ADJUST tab and then 
select COLOR THRESHOLD. 
 
 
 
 
 
 
 
 
 
 
No treatment +IL-1β 40ng/ml 
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3) Adjust the colour by moving the saturation and brightness tab. Click 
original button at the bottom of the screen in order to view the original 
image. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4) Choose SELECT, then go to ANALYSE tab and click MEASURE.  
 
 
 
 
 
 
 
 
 
 
Colour threshold 
Original 
image 
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5) Values are shown as pixels of the area from the whole image. Each 
image was analysed using the same method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
No treatment 
+IL-1β 40ng/ml 
 195 
 
 
Pixel values obtained from analysis of the confocal images were translated into 
the intensity of TJ in IOBA-NHC cells. The intensity of expression by treated 
cells was calculated as the percentage of intensity relative to cells without 
treatment. The intensity of ZO-1 (Figure 51) and occludin (Figure 52) on IOBA-
NHC cells that were treated with different concentrations of IL-9, TNF-α, IL-1β, 
IL-4, IL-13 and IL-17A was recorded. TNF-α was selected as the positive 
control, since it was already demonstrated that TNF-α downregulates epithelial 
barrier functions (437). TNF-α was titrated and 40ng/ml was found to be the 
optimal concentration to use for subsequent experiments. Although adding 
higher concentrations of TNF-α further downregulated both ZO-1 and occludin, 
there was also a decrease in cell viability at these higher concentrations.  
 
TNF-α was added in each experiment as the positive control. IL-1β 
downregulated ZO-1 (Figure 51b) and the greatest decrease of occludin (Figure 
52b) was observed after treating the cells with 40ng/ml of IL-1β. Treating cells 
with IL-4 (Figure 51c and 52c), IL-13 (Figure 51e and 52e) and IL-17A (Figure 
60f and 61f) also downregulated TJ intensity, where increasing concentrations 
of cytokines downregulated the intensity of both ZO-1 and occludin. Similar 
effects were observed when IOBA-NHC cells were treated with IL-9. IL-9 
(Figure 51d and 52d) decreased molecules associated with barrier functions (as 
measured by decreases in ZO-1 and/or occludin expression) where the intensity 
of expression of the TJ-associated molecules were downregulated to that 
detected in untreated cells. This experiment was repeated three times by 
treating IOBA-NHC cells with cytokines at their optimal concentration; IL-9: 
30ng/ml, TNF-α: 40ng/ml, IL-4: 40ng/ml, IL13: 40ng/ml and IL-17A: 80ng/ml. 
Figure 62 summarises ZO-1 and occludin staining (pixel intensity). The levels of 
ZO-1 pixel intensity were significantly downregulated as compared to 
unstimulated cell after treating cells with TNF-α, IL-9 and IL-4, p<0.01. 
However, only TNF-α caused a significant downregulation in occludin intensity, 
p<0.01. This way of measuring tight junction intensity using pixels could be one 
way to detect a general overview of TJ intensity on confocal photos, but is not 
suitable for quantitative measurements, given that the purpose of 
immunostaining is to analyse in detail the quality and distribution of cells during 
staining, rather than measuring photos using quantitative measures. In order to 
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obtain more quantitative data in the future, this experiment could be repeated 
and analysed by qPCR and western blot 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51: ZO-1 intensity (pixels) from confocal images (n=1) of IOBA-NHC 
cells after treatments with different concentrations of a. TNF-α, b. IL-1β, c.IL-4, 
d. IL-9, e. IL-13 and f. IL-17A. Data shown were from a single experiment 
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Figure 52: Occludin intensity (pixels) from confocal images of IOBA-NHC cells 
after treatment with different concentrations of a. TNF-α, b. IL-1β, c. IL-4, d. IL-
9, e. IL-13 and f. IL-17A. Data shown were from a single experiment 
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Figure 53: Summary of ZO-1 and occludin intensity (pixels) from confocal 
images of IOBA-NHC cells after treatments with TNF-α, IL-1β, IL-4, IL-9, IL-13 
and IL-17. Data shows mean mean±SEM from 3 independent experiments. 
*p<0.05, **p<0.01by Student’s t test. 
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Interestingly, based on immunofluorescence staining photomicrographs (Figure 
54), in some cells, the distribution of ZO-1 and occludin revealed a remarkable 
difference in the localization pattern as compared to unstimulated cells. In 
unstimulated cells, both ZO-1 and occludin showed a diffuse staining and were 
always expressed in the plasma membrane in cell-to-cell contact points. Cells 
treated with TNF had marked changes in the distribution and intensity of both 
ZO-1 and occludin expression, as predicted from the literature. Both ZO-1 and 
occludin disappear from the adjacent conjunctival cells and the distribution 
becomes more localized within the cytoplasm. In cells treated with all other 
cytokines, the ZO-1 staining showed a more predominant cystolic localization 
with disappearance of cell-to-cell contact points. More irregular distribution of 
the staining was also observed. IL-9 treatment did not affect occludin 
distribution where occludin was observed localized within the plasma 
membrane and had a diffuse staining pattern where cell-to-cell contact points 
were still visible. A similar effect was observed with IL-4 treatment. Although the 
intensity of the protein expression was similar to unstimulated cells, some 
occludin was observed localized within the cytoplasm in cells stimulated with IL-
17. 
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Figure 54: ZO-1 and occludin intensity (pixels) from confocal images 
(representative from 3 independent experiments) of IOBA-NHC cells after 
treatments with TNF-α, IL-1β, IL-4, IL-9, IL-13 and IL-17. 
 
IL-4 
IL-9 
IL-17 
IL-1𝛃 
TNFα 
IL-13 
unstimulated 
ZO-1 Occludin Merged 
 201 
 
 
 
6.3. DISCUSSION 
 
In this chapter, I have detected some effects of IL-9 on human conjunctival 
epithelial cells using the IOBA-NHC cell line as the in vitro model. The design of 
the study was to compare a range of relevant cytokines with IL-9, and to use 
TNF-α as a positive control. Generally, data in this chapter did not focus on the 
effect of IL-9 in particular as these are preliminary works comparing the effect of 
IL-9 and different cytokines on epithelial cells. Given more time, further 
experiments focusing on IL-9 in combination with different cytokines could 
conclude the effects of IL-9 on epithelial cells. 
 
There are a few technical issues I would like to address in regard to the 
experiments performed in this chapter. Firstly, besides using IOBA-NHC cell 
line, I also tried to investigate the expression levels of MUC2 and MUC5ac on 
primary human corneal epithelial cells (HCEC). However, after several 
attempts, I failed to grow these cells to the required amount to perform 
experiments, perhaps due to these cells being more delicate to handle and not 
being as robust as the transformed IOBA-NHC cell line. Also, as I did not have 
access to fresh human conjunctival biopsies at the time I was performing the 
MUC expression studies, I was unable to compare MUC2 staining in the cell 
line with conjunctival tissue sections.   
 
Given more time, it would have been preferable to repeat TJ barrier staining 
with different TJ proteins including Claudin 1 and Claudin 2 in light of a study 
done by Gerlach and colleagues which reported that the protein Claudin 1 
showed lower expression levels in IL-9 knockout mice (370). They managed to 
show this analysis by performing qPCR and western blot to obtain quantitative 
data and immunostaining tissue sections for qualitative analysis- some 
experiments which I would like to do to bring this study forward. 
 
Immunostaining of ZO-1 and occludin was not optimised as the staining was not 
localised within the cell membrane. This study could have been improved if the 
staining was optimised properly with correct concentration of antibodies and 
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techniques plus optimised microscopy technique. Hence, the effects of 
cytokines on tight junction could not be concluded concretely until the 
immunostaining has been optimised. 
 
In response to inflammatory cytokines, both MUC2 and MUC5ac mRNA 
expression was upregulated in IOBA cells. Similarly MUC5ac expression in 
HBE cells was found to be upregulated in cells treated by IL-1β and IL-17 via 
NFκβ activation (438). This finding was also supported by Enss et al, who found 
that IL-1β upregulated both MUC2 and MUC5ac expression in an intestinal 
human colon cell line (439). IL-13 was reported to have a direct stimulatory 
effect on conjunctival goblet cell proliferation but did not affect their mucin 
secretion (440). In contrast, Tukler Henriksson et al demonstrated that IL-13 
stimulated mucin gene expression in cultured conjunctival goblet cells obtained 
from mouse conjunctival explants (353). Addition of IL-13 also induced the 
increase of MUC2 mRNA expression in a human colonic cell line (441).  
 
IL-9 was also found to upregulate MUC2 gene expression. In the colon of IL-9 
transgenic mice, MUC2 expression was upregulated (426). Similarly, both 
MUC2 and MUC5AC expression was elevated in airway epithelial cells of IL-9 
transgenic mice (324). Study by Temann and colleague found that IL-9 
promotes IL-13-mediated effects on mucus production in mice but IL-9 alone 
was not essential for mucus production in the lung (442). However, Louahed 
and colleagues reported that IL-9 alone can induce expression of both MUC2 
and MUC5AC both in human primary lung culture and in IL-9 transgenic mice 
suggesting that IL-9 has important role in mucus production (324). This 
controversy in findings is likely due to the different cell lines and mouse models 
used, and further studies are required in this area. 
 
The conjunctival surface area is formed by an extensive network of epithelial 
cells that form an intact barrier to prevent inflammatory diseases. In allergic 
diseases, allergens, irritants and pollutants to varying degrees can weaken the 
integrity of the epithelial barrier, allowing allergens and pollutants to cross the 
barrier, facilitating easy entry of allergens to cause inflammatory responses by 
immune cells. TJ complexes form a seal between the epithelial cells, and 
 203 
 
 
impairment in TJ complexes contributes to barrier dysfunction, as observed in 
atopic dermatitis patients (443), ulcerative colitis (444), asthmatic patients (445). 
By immunofluorescence staining of asthmatic tissue biopsies, it was revealed 
that both ZO-1 and occludin in the TJs of asthmatic epithelium was poorly 
developed as compared to normal epithelium (431).   
 
TJ permeability can be affected by many different stimuli including cytokines, 
chemokines and growth factors. During allergy, several cytokines including IL-4, 
IL-5 and IL-9 are known to be involved in mediating the response, and these 
cytokines are known to affect the permeability of epithelial TJ’s. In this chapter, 
these classical allergy-associated cytokines (IL-4, IL-9 and IL-13) alongside 
other cytokines (TNFα, IL-1β and IL-17A) were added to IOBA-NHC cells and 
the intensity of ZO-1 and occludin was visualised by immunofluorescence 
staining and the level of intensity was analysed by Image J.  
 
Based on in vitro studies with different cell lines, TNFα has been shown to 
directly impair TJ functions by downregulating occludin and e-cadherin, hence, 
lowering the complexity of TJ (446). Others have found that TNFα induces a 
drop in transepithelial resistance (TER) and that effect was dose-dependent 
(447). TJ junction disruption by TNFα treatment was associated with 
transmembrane protein internalisation (448). This is consistent with our results 
where the intensity and distribution of ZO-1 and occludin in IOBA cells after 
TNFα treatment was dowregulated in a dose-dependent manner and 
associated with a change in pattern of staining. In all experiments, TNFα was 
used as the positive control for barrier dysfunction.  
 
IL-1β, which is released by immune cells such as macrophages, was reported 
to cause an increase in intestinal epithelial TJ permeability at physiologically 
relevant concentrations (1-10ng/ml) (449). In this experiment, IL-4 and IL-13 
also decreased TJ integrity by downregulating ZO-1 and occludin. IL-4 and IL-
13 treatments decreased barrier functions in Calu-3 airway epithelial cells, as 
assessed by electrophysiological and [14C]mannitol flux measurements (450). 
Further analysis of TJ-associated proteins ZO-1 and occludin revealed that IL-4 
and IL-13 treatment caused a significant decrease in ZO-1 protein expression 
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and slowly decreased occludin expression as compared to control cells, hence 
diminishing the capacity of Calu-3 cells to maintain barrier function and repair 
wounds (450).  Another study has also confirmed that TNFα and IL-13 induced 
structural and functional disruption of human corneal epithelial barrier (451)  
 
Following IL-9 treatment, the levels of ZO-1 were significantly downregulated as 
compared to untreated cells, suggesting that IL-9 also affects TJ permeability. 
However, the levels of occludin were only slightly downregulated after IL-9 
treatment. This is the first time that IL-9 has been found to selectively 
downregulate ZO-1 expression in human conjunctival epithelial cells, although 
the data is preliminary and requires further investigation. Another study has 
explored the relationship between IL-9 and tight junction integrity using a model 
of IL-9-deficient experimentally-induced colitis in mice. In that study, the levels 
of pore-forming factor claudin-2, sealing factor claudin-3 and TJ protein occludin 
in IL-9-deficient colitis mice were supressed as compared to wild type mice, 
suggesting that IL-9 controlled barrier functions of the intestine (375). Parker 
and colleagues have found that IL-9 alone or in combination with IL-13 has a 
significant role in reducing ciliated cell numbers and transepithelial electrical 
resistance due to degradation of tight junction in normal epithelium, suggesting 
the role of IL-9 in inhibiting mucociliary clearance in asthmatic lung via 
degradation of tight junction (427). 
 
In this current study, IL-17 was found to have no effect on the TJ proteins ZO-1 
and occludin. Another study found that IL-17A promoted, instead of 
downregulated the development of TJ barriers in intestinal epithelial cells 
(452,453). According to Kinugase et al, the enhancing effect by IL-17 of 
epithelial TJ barrier may be mediated by ERK activation.   
 
In conclusion, this chapter describes preliminary experiments on the general 
effects of cytokines including IL-9 on MUC expressions and barrier functions. 
Further experiments as previously discussed in these chapter could be done in 
the future in order to solidify these preliminary conclusions which will also 
focussing on IL-9 functions on epithelial cells. 
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In summary, this thesis has focussed on the role of cytokines secreted by mast 
cells and T cells, in particular IL-9, in allergic conjunctivitis. Firstly, Chapter 3 
described experiments that demonstrated that IL-9 intracellular expression was 
upregulated in conjunctival mast cells of EAC mice, as compared to control 
mice. There were also increased levels of CD4+IL-9+ T cells, CD4+PU.1+ T cells 
and CD4+IL-4+GATA2+ T cells in the conjunctiva of EAC mice compared to 
control mice. Significant increases in CD4+PU.1+IL-9+ T cells were observed in 
the draining lymph nodes of EAC mice as compared to naïve mice, suggesting 
that IL-9 is upregulated within the Th9 T cell population. Since we know that IL-
9 was expressed by mast cells in the conjunctiva in EAC mice, further in vitro 
experiments were done to investigate the role of IL-9 secreted by mast cells on 
mast cell functions. As demonstrated in chapter 4 blocking IL-9R function, either 
by applying an IL-9R blocking antibody or by silencing IL-9R function at the 
gene level, downregulated histamine and cytokine secretion by mast cells. 
Interestingly, neutralising IL-9 functions did not significantly affect mast cell 
function.  In addition to investigating the effects of IL-9 secreted by mast cells in 
vitro, the next aim was to investigate the presence of IL-9 in human conjunctival 
tissue sections. In chapter 5, IL-9 expression was found to be upregulated in 
the conjunctival tissue sections from allergen-challenged SAC donors as 
compared to normals. These IL-9-expressing cells were also colocalised with a 
mast cell marker, suggesting that mast cells were the source of IL-9 during AC, 
although some IL-9 positive cells were clearly not mast cells. Lastly, Chapter 6 
describes the effect of IL-9 on conjunctival epithelial cell responses. Based on 
the preliminary in vitro studies using the human conjunctival epithelial cell line, 
IOBA-NHC cells, data in Chapter 6 suggests that IL-9 upregulated Muc2 and 
Muc5ac mRNA expression and, to a lesser extent than other cytokines, IL-9 
also downregulated ZO-1, a TJ protein on the epithelial cell surface. However, 
upon IL-9 treatment, occludin expression was slightly upregulated as compared 
to the non-treated cells.  
 
Based on the hypothesis of this study, which is that conjunctival IL-9 is 
upregulated during allergic conjunctivitis and contributes to the 
immunopathogenesis of the disease, overall, this thesis managed to 
demonstrate an upregulation of IL-9 during allergic conjunctivitis and IL-9 
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secreted by mast cells and T cells correlated with the pathogenesis of the 
disease, which also affected the conjunctival epithelium.  
 
As has previously been discussed in each results chapter, there are several 
limitations in this study. In chapter 3, there were no FMOs as the control to set 
the FACS gates hence, gates drawn in the FACS plots might not be accurate. 
However, based on the results, there are clear differences in the levels of IL-9 
from CD4+ T cells and mast cells in the conjunctiva and CD4+ T cells in the 
lymph nodes. In chapter 4, IL-9 and IL-9R blocking antibodies were not 
adequately titrated hence this might have resulted in an insufficient block of IL-9 
function. However, IL-9 levels were dampened down in mast cells upon IL-9R 
antibody blocking suggesting that IL-9 secreted by mast cells affects mast cell 
functions. Immunostaining on human conjunctival biopsies in chapter 5 might 
not be convincing due to the polyclonal IL-9 antibody used for staining. Based 
on IL-9R staining (of which antibody used was monoclonal antibody), significant 
increases in the levels of IL-9R were observed in allergen-challenged biopsies 
and these IL-9R positive cells were identified as mast cells. Lastly, chapter 6 
was primarily preliminary data and solid conclusions cannot be drawn from this 
chapter. In order to be able to conclude IL-9 functions on conjunctival epithelial 
cells, further functional experiments like Western blotting or blocking IL-9R 
function on human conjunctival epithelial cells to observe an effect on mucus 
production and tight junction formation will enable further understanding of the 
effects of IL-9 on epithelial cells. 
 
This study has raised more research questions and there are several areas 
which could be done in the future in order to bring the research forward. Since 
current data in this thesis managed to show that blocking IL-9R in mast cells in 
vitro affects mast cell functions, further studies using anti-IL-9R blocking 
antibody in mouse models of AC will be one way to confirm in vivo the mast cell 
in vitro data. In order to fully determine the functional properties of IL-9/IL-9R in 
vivo, AC could also be induced in IL-9R knockout mice (322). The present study 
demonstrated that IL-9 expression was upregulated in the conjunctivae and 
draining lymph nodes of mice with AC. Further in vivo studies with the 
application of anti-IL-9R blocking antibody and IL-9R knockout mice would be 
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ideal in order to confirm the functionality of IL-9R activation during AC. The 
present study has also demonstrated that there were significant levels of CD4+ 
T cells expressing IL-9 in the conjunctivae of EAC mice. It will be very 
interesting to further explore the role of IL-9 and CD4+T cells in allergic 
conjunctivitis. In order to translate these in vitro and in vivo findings into human 
disease, further immunostaining of IL-9 on CD4+ T cells and other cell types, 
and analysis of tear samples could confirm the findings in human disease. Once 
the role of IL-9 in allergic conjunctivitis has been establish, further studies could 
also investigate possible therapeutic intervention using IL-9 blockade in allergic 
conjunctivitis. 
 
Cytokines are small protein molecules that are important in cell signalling and 
are secreted by pro-inflammatory cells during inflammation. Targeting cytokines 
in order to dampen immune response can be a good therapeutic target since 
certain cytokines are upregulated during inflammation. Anti-cytokine treatment 
has been used in treating autoimmune diseases like rheumatoid arthritis and 
allergic diseases including allergic asthma. However, to date, anti-cytokine 
treatment has not yet been used as the choice of treatments for severe AC.  
 
A number of different anti-cytokine therapies have already been used in human 
trials for clinical targets. Targeting key cytokines that drive type 2 inflammation 
in allergic diseases have been the areas that interest clinicians and researchers 
in these past years. To date, efforts have been put into researching key Th2 
type cytokines, IL-4, IL-5 and IL-13 as prime targets to supress allergic 
inflammation and have shown to be promising and achieved therapeutic 
benefits across diseases. 
 
IL-4 receptor (IL-4R) can be found on most haematopoietic and non-
haematopoietic cells. Type 1 IL-4R, which consists of heterodimeric chains of 
IL-4Rα and common γc chain can be found exclusively on haematopoietic cells 
whereas type 2 receptor which consists of IL-4Rα and IL-13Rα1 chain can be 
found mostly on non-haematopoietic cells including epithelial cells and 
fibroblasts. IL-4R can have distinct and overlapping functions with IL-13 partly 
due to the shared receptor moiety in which IL-13 receptor functions through 
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activation of specific IL-13α1 receptor. Having understood IL-4R structure in 
more details, several molecules targeting IL-4 and IL-13 were developed, with 
the idea that once these key cytokines are blocked, further inflammation will be 
dampened. 
 
In a preclinical study, the attenuation of allergic airway disease in IL-4-/- mice 
resulted in the reduction of eosinophil recruitment into the airways and 
increased epithelial hypertrophy and allergic hyperresponsiveness (AHR) (454). 
Another study on IL-4 in mouse model of allergic airway disease demonstrated 
beneficial effects of suppressing IL-4 activities, resulted in suppression of 
eosinophil infiltration into the airways and inhibit IL-5 release from T cells (455).  
 
Besides IL-4, there have been significant experimental studies to support IL-13 
as a potential target in asthma. IL-13-/- mice induced for allergic asthma showed 
attenuation of mucus hypersecretion despite the persistence AHR (456). 
Neutralisation of IL-5 in these mice inhibits AHR suggesting that tissue 
eosinophilia accumulation is linked to the mechanism underlying AHR only in 
the absence of IL-13. This study shows the pro-inflammatory role of IL-13 when 
challenged. Administration of humanized anti-IL-13 suppressed AHR and 
eosinophil influx in broncheoalveolar lavage from models of allergic airway 
disease (AAD) (457,458). These studies indicate a good potential for anti-IL-13 
to be used as therapy for allergic asthma.  
 
After gathering information from mouse studies, two IL-4 inhibitors have been 
developed. Altrakincept, administered by a nebuliser, is a recombinant soluble 
IL-4Rα which competitively binds to IL-4 has shown to have positive outcome 
on asthma symptoms (459). Another IL-4 inhibitor is paslizumab, which is a 
humanized IL-4 specific antibody. Several IL-13 inhibitors, including 
anruknizumab, IMA-026 and Lebrikizumab, a humanized monoclonal antibody 
which bind to soluble IL-13 with high affinity, have shown to be promising in 
improving asthma symptoms during preclinical and early clinical study. 
However, all of these inhibitors failed to show efficacy and inconsistent results 
during larger Phase II and Phase III clinical study (460–463). Besides asthma, 
lebrikizumab is also currently being evaluated in atopic dermatitis and has 
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entered phase II clinical study. There are several reasons why a single cytokine 
target may not be effective in allergic disease. Among the reasons are the fact 
that many of these diseases utilise a range of inflammatory cytokines, and that 
the disease may be heterogeneous. 
 
Although several attempts failed in targeting cytokines IL-4 and lL-13 
individually, blocking dual cytokines by targeting the shared IL-4Rα is a novel 
approach to modulate type 2 inflammation. A few inhibitors targeting both 
IL4/IL-13 have shown some promising data. Pitrakinra, a mutated recombinant 
human interleukin 4 which competitively inhibits IL-4Rα receptor complex to 
interfere with the actions of both IL-4 and IL-13 significantly improved FEV1 
upon allergen challenge and reduced spontaneous asthma attacks (464). 
Aeroderm, a modified version of pitrakinra with added polyethylene glycol 
(PEG), has also been tested in atopic dermatitis. Even though Aeroderm shows 
improvement in clinical symptoms, results from clinical studies failed to show 
statistical significance on disease end points. Dupilumab on the other hand has 
very recently received FDA approval for use as injection for the treatment of 
uncontrolled, moderate-severe atopic dermatitis. Previous clinical studies 
showed marked and rapid improvement in all evaluated measures for atopic 
dermatitis (52). In asthma, dupilumab has demonstrated several improvements 
by significantly downregulated several biomarkers related to type 2 diseases 
and also downregulates asthma exacerbation and FEV1 in Phase IIb of clinical 
studies (465,466).  
 
Besides studies on IL-4 and IL-13, studies on mice showed that pre-treatment 
of a single dose of anti-IL-5 neutralizing antibodies (TRFK-5) was able to inhibit 
eosinophil influx into the airways of the challenged mice (467). Treating mice 
with allergic asthma has been shown to effectively suppress eosinophil 
recruitment and accumulation of inflammatory cells in the airways but failed to 
inhibit airway hyperresponsiveness (AHR) (468). Several IL-5 inhibitors have 
been developed such as IL-5-specific monoclonal antibodies, mepolizumab and 
reslizumab and IL-5 receptor α (IL-5R α)-specific monoclonal antibody, 
benralizumab, primarily targeting eosinophils during allergic airway disease. 
Administration of mepolizumab during a clinical trial in moderate asthma has 
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been shown to have similar effects as observed in the models of asthma in mice 
(469). It is safe to use and has been shown to reduce the number of eosinophils 
in the airways and blood (470), but did not improve asthma symptoms (471). A 
similar study on reslizumab has reported a decrease in the number of 
eosinophils in patients with severe eosinophilic asthma but modest 
improvement in airway symptoms (472). However, more recent clinical studies 
demonstrated that mepolizumab significantly reduced exacerbation in subset of 
asthma with high eosinophil count (473,474). Renewed interest in mepolizumab 
and reslizumab has led to FDA approval for both of these inhibitors for the 
treatment of severe asthma. Benralizumab is currently in Phase III clinical trial 
and has already demonstrated an ability to reduce the use of oral steroids in 
asthma patients and significantly decrease the frequency of asthma 
exacerbations in two trials (475,476). 
 
Recently, many researchers have been focusing on IL-9 functions in allergy. 
Based on different evidence of IL-9 in the pathogenesis of allergic diseases 
especially in asthma, MEDI-528 (MedImmune), an antibody to IL-9, has been 
developed and studied in an early phase clinical trial for patients with asthma. 
Although it was shown to be safe for mild, moderate to severe asthma 
(335,477), a large phase 2b study with 329 subjects with moderate to severe 
persistent asthma failed to demonstrate improvement in Asthma Control 
Questionnaire 6 (ACQ-6) score, asthma exacerbation rates or FEV1 values 
(478). 
 
Despite convincing preclinical studies providing strong evidence that IL-9 
expression was upregulated in the airways of patients with asthma and that IL-9 
functions to regulate mucus production, airway responsiveness and 
subepithelial fibrosis (479), the application of anti-IL-9 therapy in asthmatic 
subjects failed to achieve a clinically important effect on related quality of life 
and lung function (478). However, a previous study with a smaller sample size 
had observed a potential improvement in asthma exacerbation rates in subjects 
with mild asthma where fewer subjects experienced ≥ 1 asthma exacerbation in 
group treated with MEDI-528 as compared to placebo control group (335).  
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IL-9 is believed to play important roles in the trafficking and functions of mast 
cells. IL-9 is responsible for the development and recruitment of mast cells from 
the bone marrow to the lung in allergic asthma (236,480). Hence, it is also 
possible that therapeutic blocking of IL-9 would not expect to have a direct 
immediate clinical effect in asthma but could possibly affect mast cell functions 
at a later stage, and will have effects on other immune cells during disease and 
this will take a longer time to take effect. This explains why, in the clinical trials 
mentioned above, it did not result in short term improvements in asthma 
symptoms. 
 
It is apparent that the heterogeneous nature of asthma makes it difficult to treat 
and is challenging for developing a single targeted therapy with monoclonal 
antibodies. Targeting mono cytokine in a non-selected asthma population might 
be hard to observe significant beneficial improvements in this cohort. 
Identification of single cytokine could be a great help in determining the disease 
marker, leading to a more accurate diagnosis and treatment as observed by 
Corren and colleagues, where subjects were grouped according to baseline 
type 2 helper T-cell (Th2) status which then led to a greater improvement on 
lung function after treatment with Lebrikizumab (anti-IL-13 mAb) (481). 
Unfortunately, a marker of the IL-9 pathway has not yet been identified although 
recent studies on IL-9 pathways in allergic diseases (276,340,363) are leading 
in this direction, making IL-9 a promising disease marker. 
  
Targeting IL-9 could be an effective treatment for allergic conjunctivitis, since 
my data suggests that IL-9 is important for upregulating the Th2 cytokine 
response by mast cells. AC is classified as either mild, moderate or severe 
forms of disease and typically is more localized to the eye area. Based on a 
preliminary study by Bonini et al (unpublished observations), in cell-free tear 
specimens of VKC patients treated with cyclosporine, lower IL-9 expression 
levels were observed in comparison with untreated, active VKC, suggesting that 
the level of IL-9 increased in the active form of the disease.  
 
Other studies on monoclonal anti-cytokine targets have also focused on 
targeting cytokine receptor functions. One mouse study revealed the 
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attenuation of allergic airway disease in mice in IL-4R-/- mice and by co-
administration of a murine IL-4R antagonist (215,482). These are due to the 
inhibition of both IL-4 and IL-13 functions as compared to studies done in IL-4-/- 
mice (483). A soluble anti-IL-4Rα Ab seems to have beneficial effects in 
preserving FEV1 and asthma symptoms score of participants with moderate 
asthma compared to placebo (459).  
 
Since current anti-IL-9 antibody has shown inconsistent results in treating 
asthma patients, it might be worth considering using an anti-IL-9R antibody as 
an alternative treatment. The data presented in this thesis are the first to show 
that blocking IL-9R affects mast cell function, suggesting that targeting IL-9R 
rather than the cytokine itself might be more effective in regulating mast cell 
functions. It is possible that IL-9R-directed blocking could potentially be a good 
therapeutic target for AC treatment.  A study used IL-9R knockout mice to show 
that IL-9, as an autocrine amplifier, mediated the survival of ILC2 via activation 
of IL-9R (322).  
 
 
In conclusion, based on the work in this thesis, IL-9 that is secreted by different 
cell types could be a proinflammatory cytokine that contributes to AC. The 
discovery of the increased expression of IL-9 during AC makes targeting the IL-
9/IL-9R axis an attractive new target for anti-inflammatory therapy in allergic 
diseases and further studies are needed to confirm my findings in this thesis. 
Since the role of IL-9 has been extensively studied in asthma, it might also play 
important roles in AC. Inhibition of IL-9R activation could be promising in mast 
cell-mediated diseases such as allergic asthma as demonstrated by Kearly et 
al. where they demonstrated that IL-9R was mainly expressed by mast cells in 
human asthmatic lung tissue (328). Additionally, they have also demonstrated 
that mice treated with anti-IL-9 antibody showed protection from airway 
remodeling, characterized by reduction in the number of active mast cells, plus, 
decreased expression of profibrotic factors; TGFβ, vascular endothelial growth 
factor (VEGF) and fibroblast growth factor 2 (FGF-2) in the lung.  
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